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ABSTRACT
This dissertation pursues a paradigm shift from traditionally recorded censored
time-to-event and time-to-recurrent event data and corresponding analyses. Instead
these data are repurposed into censored short-term outcomes measured longitudi-
nally over potentially overlapping follow-up periods of length τ . Previous work by
Tayob and Murray (2014, 2016, 2017) exploited this framework, with univariable and
multivariable methods for estimating behavior of τ -restricted outcomes drawn from
a single time-to-event and with a two-sample test developed for comparing censored
longitudinal outcomes drawn from the recurrent events setting. This thesis consid-
ers three practical settings that can benefit statistically from repurposing traditional
data into this censored longitudinal data structure.
Chapter II addresses the first research setting. This chapter develops a two-
sample test and corresponding group sequential methodology for comparing overall
τ -restricted means between treatment groups, where each patient contributes many
overlapping τ -length follow-up windows of information during the course of the clin-
ical trial. Operating characteristics explored through simulation compare favorably
with existing nonparametric methods for group sequentially monitored test statis-
tics in this setting, including the traditional restricted mean test and the logrank
test. The proposed method performs especially well in cases where there is a delayed
treatment effect and/or a subset of cured patients. This chapter considers symmetric
and asymmetric error spending approaches and makes recommendations for how to
choose appropriate group sequential stopping boundaries in a variety of settings.
xii
Chapter III addresses the second research setting. Very few methods are currently
available for group sequential analysis of recurrent events data subject to a terminal
event in the clinical trial setting. Chapter 3 helps fill this gap by developing methods
for sequentially monitoring the nonparametric, two-sample Tayob and Murray (2014)
(TM) statistic. This chapter briefly reviews the TM statistic, develops and describes
how to use the proposed group sequential analysis methods, and through simulation
compares its operating characteristics with those of Cook and Lawless (1996), as well
as a time-to-first-event analysis based on the logrank test. Our advantages include
high power to detect treatment differences when there is correlation between event
times in an individual and elegantly avoiding dependent censoring bias.
One important component of using the TM statistic, as well as Chapter III
methodology for group sequential monitoring, is to wisely construct the censored
longitudinal data framework for the recurrent events. Chapter IV formalizes the cor-
responding guidance. A useful metric, the expected proportion of recurrent events
captured as the first event in at least one follow-up window, is derived, and oper-
ating characteristics of the TM statistic are summarized. For design and analysis
purposes, we formulate recommendations based on the special case with independent
exponentially distributed gap times.
Chapter V develops multivariable restricted time models appropriate for analysis
of recurrent events data, where data is repurposed into censored longitudinal outcomes
in τ -length follow-up windows. This chapter develops two approaches for addressing
the censored nature of the outcomes: a pseudo-observations (PO) approach and a
multiple imputations (MI) approach. Each of these approaches allows for complete
data methods, such as generalized estimating equations, to be used for the analysis of
the newly constructed correlated outcomes. Through simulation, this chapter assesses
the performance of the proposed PO and MI methods. Both PO and MI approaches
show attractive results with either correlated or independent gap times.
xiii
CHAPTER I
Introduction
Restricted mean survival time methodology for censored survival data has grown
in popularity as an alternative to hazard-oriented methods. It has advantages of free
from assumption of proportionality and clinically meaningful interpretation. This dis-
sertation work evaluates the restricted time after repurposing the traditional recorded
time-to-event or recurrent event data into censored longitudinal outcomes from over-
lapping follow-up windows. Previous work by Tayob and Murray explored the use
of repeated and overlapping follow-up windows to supplement restricted mean esti-
mation (Tayob and Murray , 2016) and regression analysis (Tayob and Murray , 2017)
in single time-to-event setting, as well as two-sample testing in recurrent event set-
ting subject to terminal events and censoring (Tayob and Murray , 2014). However,
these methods are only ready for single time analysis. In this dissertation, we develop
group sequential methods for two-sample tests with a similar technique for construct-
ing follow-up windows in (Chapter II) the standard censored survival endpoint setting
as well as (Chapter III-IV) the recurrent events setting. In these chapters, group is
the only covariate. For the setting with multiple, possibly time-dependent covariates
and recurrent event outcomes, we develop multivariable restricted time regression
methodology using multiple follow-up windows (Chapter V).
Throughout this dissertation, we use repeated and overlapping follow-up windows
1
to improve the restricted mean survival time estimation and to extend the restricted
time methodology to recurrent event setting. The idea is to repurpose the data into
a regularly spaced longitudinal form. The endpoints are based on τ -length follow-up
windows that start at evenly spaced times. In each of these follow-up windows, the
observed endpoint is the time from the beginning of the window to the first event
that occurs in that window, or τ if no event occurs during that window. These
endpoints are subject to the usual independent right censoring that occurs in the
clinical trial setting. The restricted time estimated from the longitudinal censored
survival endpoints can be readily interpreted as the survival time or time free from
recurrent events over the next τ -length period. The follow-up windows are constructed
upon each patient’s entry and are universal across all enrolled patients. Specification
of the follow-up windows is predetermined by investigators at the phase of study
design: the length of windows, τ , is usually decided by the clinical interest and the
spaced time between adjacent windows is determined by testing/modeling efficiency
which will be discussed more in Chapter IV.
In Chapter II, we take a fresh look at group sequential methods applied to two-
sample tests of standard censored survival data and proposes an alternative method
of defining and evaluating treatment benefit. Our method repurposes traditional
censored event time data into a sequence of short-term outcomes taken from the (po-
tentially overlapping) follow-up windows. A new two-sample restricted means test
based on this restructured follow-up data is proposed along with group sequential
methods for its use in the clinical trial setting. This method compares favorably
with existing methods for group sequential monitoring of time-to-event outcomes, in-
cluding methods for monitoring the restricted means test and the logrank test. Our
method performs particularly well in cases where there is a delayed treatment effect
and/or a subset of cured patients. As part of developing group sequential methods for
these analyses, we consider asymmetric error spending approaches that differentially
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limit the chances of stopping incorrectly for perceived efficacy versus perceived harm
attributed to the investigational arm of the trial, to ensure an attractive safety pro-
file while allowing for additional follow-up of auxiliary data for future research use.
Recommendations for how to choose proper group sequential stopping boundaries
are given, with supporting simulations and an example from the AIDS Clinical Trial
Group.
In Chapter III, we generalize the group sequential testing procedure to recurrent
event setting. Very few methods are currently available for group sequential analy-
sis of recurrent events data subject to a terminal event in the clinical trial setting.
Our research helps fill this gap by developing methods for sequentially monitoring
the nonparametric, two-sample Tayob and Murray (2014) statistic. Advantages of
the Tayob and Murray statistic include a high power to detect treatment differences
when there is a correlation between recurrent event times or between recurrent and
terminal events in an individual. This statistic does not suffer bias from dependent
censoring potentially caused by the terminal events, regardless of the correlation be-
tween event times in an individual. Nor does the statistic assume the proportionality
between groups of the cumulative mean number of events over time. This chapter
briefly reviews the Tayob and Murray statistic, develops and describes how to use
methods for its group sequential analysis, and through simulation compares its oper-
ating characteristics with those of Cook and Lawless (1996), which is currently in use,
as well as a time-to-first-event analysis using the logrank test. We further illustrate
our method using data from the Azithromycin in COPD Trial.
As described previously, how to wisely place the τ -length follow-up windows is
predetermined by the investigators and is related to the testing efficiency. Chapter II
uses follow-up windows initiated every τ/2 suggested for the special case with a single
time-to-event. In terms of the recurrent event setting in Chapter III, we will prefer,
intuitively, smaller values of spaced time which will create more follow-up windows
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that capture more recurrent events, however, at the cost of computational efficiency.
In Chapter IV, we give improved guidance on the choice of the spaced time between
adjacent windows. Our recommendation is framed in terms of the average proportion
of recurrent events captured in at least one follow-up window for individuals. We
study how the average proportion influences our choice of spaced time and therefore
power through simulations.
Following the recurrent event setting as Chapter III, the nonparametric two-
sample test may not be adequate in the analysis of data where more than one factors
are interested and potentially associated with the recurrent event times. In Chap-
ter V, we target on predicting the time free from recurrent events over a prespeci-
fied follow-up period with multivariable regression model. We embrace the similar
philosophy of transforming the recurrent event data structure into censored longi-
tudinal time-to-first-event outcomes via repeated τ -length follow-up windows. Two
approaches are developed to account for censoring issue: pseudo-observations (PO)
and multiple imputations (MI). Generalized estimating equation can be then utilized
to illustrate the mean structure with complete data and correlated outcomes. We
assess the performances of PO and MI methods against the uncensored case by sim-
ulation under scenarios of independent gap times or correlated gap times. Both PO
and MI approaches show attractive results. We also demonstrate how to apply the
proposed methods in the data from Azithromycin in COPD Trial.
Before we start the next chapter, to make sure that all readers are on the same
page, we briefly review some concepts and related context for future use.
1.1 Restricted Mean Survival Time
The restricted mean survival time (RMST) was first proposed by Irwin (1949)
since the mean survival time is not estimable in the presence of censoring. Under
the standard survival setting where we use T as the time to an event, a τ -restricted
4
mean survival time, denoted by µ(τ), is the mean of time to events truncated by a
prespecified time τ , i.e. µ(τ) = E[min(T, τ)]. Let S(t) indicate the survival function
of T . The RMST is also the area under the survival curve of T up to time τ , thus µ(τ)
can be estimated well with the area under the corresponding Kaplan-Meier estimator
or Nelson-Aalen estimator from time zero to τ :
µˆ(τ) =
τ∫
0
Sˆ(t)dt.
Analysis based on the RMST includes two-sample tests of the difference in RMST
between two groups (Pepe and Fleming , 1989; Karrison, 1997; Zhao et al., 2016) and
modified two-sample tests to be adjusted by covariates (Karrison, 1987, 1997; Zucker ,
1998), to be applied in group sequential design (Murray and Tsiatis , 1999; Li , 1999b)
or to fulfill other particular requirements (Zhao and Tsiatis , 1997; Chen and Tsiatis ,
2001; Schaubel and Wei , 2011). Regression model based on pseudo-observations is
proposed by Andersen et al. (2004) and then generalized to be applied in more sce-
narios with special data structures (Klein and Andersen, 2005; Andersen and Klein,
2007; Andrei and Murray , 2007; Graw et al., 2009; Xiang and Murray , 2012; Nicolaie
et al., 2013; Tayob and Murray , 2017). Besides the pseudo-observations approach,
multivariable regression analysis on RMST are also developed with other strategies
accounting for censoring, for example, with multiple imputations (Liu et al., 2011; Xi-
ang et al., 2014; Tayob and Murray , 2017), with inverse probability weighting (Zhang
and Schaubel , 2011, 2012; Tian et al., 2013; Wang and Schaubel , 2018), parametric
modeling (Royston and Parmar , 2011), etc.
The RMST analysis has many attractive properties. First, the estimation and
comparison of RMST is valid under any distribution of time to event and does not
require any assumption of proportionality between treatment groups in the clinical
trial setting. It can summarize the difference in survival when the difference between
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groups is not constant over time, for example cases where there is a delayed treatment
effect or a crossing hazard. Besides, we think this measure has a relatively meaningful
interpretation for both clinicians and patients. It directly illustrates the gain or loss
of life expectancy. A certain hazard ratio reflects no information about the actual
progression status of the patient cohort, while the RMST can provide both absolute
and relative measures of risk. Therefore, more and more literature suggest moving
beyond the hazard ratio in quantifying the survival difference and recommend RMST
methodology as a default alternative option in the clinical trial design and analysis
(Royston and Parmar , 2013; Uno et al., 2014; Kim et al., 2017; Calkins et al., 2018).
In this dissertation, we take advantage of the appealing properties of RMST anal-
ysis and add to the field a new two-sample test with favored operating characteristics
and a modified version for group sequentially monitoring. We also extend the re-
stricted time analysis to the setting with recurrent events and work on the restricted
time free from recurrent events. Besides providing a group sequential test for monitor-
ing the recurrent event data subject to terminal events and censoring, we generalize
the regression with pseudo-observation and multiple imputation techniques for single
time-to-event data into the setting with recurrent events.
1.2 Group Sequential Design
Group sequential monitoring has a long and respected history in clinical trial
design. It is a study design where data are evaluated as they are collected. Further
sampling is stopped in accordance with pre-defined stopping rules. Multiple reasons
can cause an early stop: 1) significant efficacy has been detected at an interim analysis,
in which case the investigators would like to stop the current trial and move to the
next stage so that the new treatment can be put into market and help the patients
as soon as possible; 2) perceived harm of the investigational treatment goes out of
tolerance, in which case it is morally unacceptable to keep the assigned patients in
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high risk or to keep recruiting more patients to the harmful treatment group; 3)
evidence has shown that there is barely any chance of getting a significantly superior
results by the end of the study, in which case financial and human resources can be
saved by stopping the trial early.
Based on the many obvious benefits, group sequential design becomes popular in
clinical trials, which is also why we think it is worthwhile to develop methods that
can be implemented in group sequential context. However, a statistical price must be
paid for this monitoring process. By repeatedly looking at the data and conducting
significance testing, we inflate the type I error probability beyond the desired level.
As a remedy, statistical methods controlling type I error throughout a trial have
been developed by many classic group sequential researches (Pocock , 1977; Lan and
DeMets , 1983; Tsiatis , 1981, 1982). To maintain the overall type I error despite the
repeated significance tests, we have to adjust the critical values c1, . . . , cK of the K
number of planned analysis such that
Pr{|T1| < c1, . . . , |TK | < cK} = 1− α
under the null hypothesis, where Tk is the test statistic based on data cumulated up
to the kth interim analysis. Given the critical values, the exit probability is defined
as
Pr{|T1| < c1, . . . , |Tk−1| < ck−1, |Tk| > ck} = pik
with the restriction
∑K
k=1 pik = α (Harrington, 2012). Under this guidance, Lan and
DeMets (1983) proposed alpha spending function, which is one of the most commonly
used approaches, to provide options of how to spend the type I error, namely, how to
distribute α to pi1, . . . , piK . Given the pre-specified pi1, . . . , piK and joint distribution of
T1, . . . ,TK under the null hypothesis, we are able to determine the critical values to
maintain the type I error probability at the level of α. More application based on the
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alpha spending function to determine symmetric or asymmetric stopping boundaries
will be discussed in this dissertation.
1.3 Recurrent Event Data
In clinical trial and medical research, investigators are often interested in studying
processes which generate events repeatedly over time. Such processes are referred to
as recurrent event processes and the data they provide is called recurrent event data
(Cook and Lawless , 2007). Examples include recurrence of acute exacerbation of
patients with chronic obstructive pulmonary disease (Albert et al., 2011), recurrent
ischemic cardiovascular events after acute coronary syndrome (Schwartz et al., 2018),
recurrent clostridium difficile infection (Wilcox et al., 2017), repetitive head injuries
in high-contact sports (DeKosky et al., 2010), etc.
Poisson and negative binomial count models have been used to analyze recurrent
event data per time at risk (Frome et al., 1973; Lawless , 1987; Lambert , 1992; Greene,
1994). Besides, analysis strategies based on event times instead of event counts are
favored and developed. The most commonly used methods are those based on the
Cox proportional hazards model. Andersen and Gill (1982) proposed an extension of
the original Cox model, assuming independence between the event gap times within
the same patient. Prentice et al. (1981) proposed two stratified proportional hazard
model considering the order of event and include intensity based on either the time
from the beginning of study or gap times. Wei et al. (1989) formulated the marginal
distribution of event times by Cox model based on time from the beginning of study.
Pepe and Cai (1993) advocated the use of rate function of recurrence after the first
event and Lawless and Nadeau (1995); Lin et al. (2000) later developed models for
the cumulative mean number of events, assuming proportionality on the cumulative
means over time. In terms of more complex recurrent event setting, frailty or random
effect models were introduced to describe individual patients’ heterogeneity or the
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correlation between event times (Aalen and Husebye, 1991; Hougaard , 1995; Rondeau
et al., 2007; Mazroui et al., 2013; Rogers et al., 2016).
Another data structure of recurrent event in the presence of terminal events are
also commonly seen in clinical research. For example in pulmonary disease studies,
clinicians are interested in multiple progression endpoints including recurrent events of
acute exacerbation, 10% decline in forced vital capacity and 15% decline in diffusing
capacity of the lung for carbon monoxide; as well as terminal events of death and
lung transplant. This type of data will be more and more common in future studies
because treatments are continually improving and trials are becoming more dependent
on surrogate outcomes or combined endpoints rather than mortality alone. This
trend is likely to continue as lifetimes are successfully extended and as time pressure
for faster drug approval increases. Primary methods are based on the analysis of
marginal mean/rate function for the cumulative number of recurrent events with
non-parametric (Cook and Lawless , 1997; Ghosh and Lin, 2000) or semi-parametric
approaches (Cook and Lawless , 1997; Ghosh and Lin, 2002; Schaubel and Zhang ,
2010).
Although many advanced tools have been developed to deal with the recurrent
events in an appropriate manner, time-to-first-event analysis with traditional logrank
test or Cox model are still very popular in clinical researches as those we cite at
the beginning of the section (Albert et al., 2011; Schwartz et al., 2018; Wilcox et al.,
2017). To cater the taste of clinical researchers while making use of data more effi-
ciently, in this dissertation we borrow the philosophy of time-to-first-event analysis
but incorporate more than one event by constructing multiple follow-up windows. We
believe our work will help the design and analysis in clinical studies, as well as better
understanding the patients’ disease burden.
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CHAPTER II
Nonparametric Group Sequential Methods for
Evaluating Survival Benefit from Multiple
Short-Term Follow-up Windows
2.1 Introduction
Traditionally in the censored time-to-event setting, with or without group se-
quential monitoring, two-sample treatment comparisons are based on restricted mean
event times or integrated weighted hazard differences estimated over many follow-
up years (Mantel , 1963; Gehan, 1965; Mantel , 1966; Breslow , 1970; Peto and Peto,
1972; Prentice, 1978; Harrington and Fleming , 1982; Tsiatis , 1982; Pepe and Flem-
ing , 1989; Li , 1999b; Murray and Tsiatis , 1999). Investigators and biostatisticians
alike hope that treatment differences will emerge throughout the trial, anticipating
Kaplan-Meier curves that snake farther and farther apart as the end of follow-up
draws near.
In this chapter we embrace the philosophy that for each patient in a clinical trial,
short-term survival over repeated, overlapping intervals are observed, and that each
of these has value in assessing treatment benefit. In short, time-to-event data can be
reformulated as repeated short-term longitudinal outcomes subject to censoring, and
then analyzed using methodology that takes into account both the censored nature
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of the data as well as the correlation between short-term events measured from the
same individual.
Tayob and Murray (2016) followed this train of thought when they evaluated
the behavior of an overall τ -restricted mean estimated from multiple, overlapping τ -
length follow-up windows. Their overall estimated τ -restricted mean integrates area
under an estimated survival curve, but instead of using time-to-event data in its
original form, Tayob and Murray estimate the curve from a massive censored lon-
gitudinal repeated measures dataset with multiple overlapping short-term outcomes
taken from each individual’s observed follow-up. Corresponding confidence intervals
nonparametrically take into account the correlation between outcomes taken from
the same individual. The choice of τ is typically taken from the context in which the
method is applied. For instance, in pulmonary literature a 1-year restricted mean
is common, and fairly stable over time as seen in Tayob and Murray. In scenarios
where τ -restricted means are not stable over time, the overall τ -restricted mean is an
estimate from a mixture distribution that results from combining information from
overlapping follow-up windows.
In this chapter we propose a new two-sample test comparing τ -year restricted
means estimated in the manner proposed by Tayob and Murray. As with existing
two-sample tests, this test is valid under the null hypothesis of no treatment difference
regardless of the distributions under study. We also develop group sequential methods
for monitoring a clinical trial via the proposed statistic, along with graphics displaying
the estimated overall years of life gained per τ time units when assigned the superior
treatment.
Group sequential monitoring via nonparametric two-sample tests has a long and
respected history in clinical trial design. Classic group sequential analysis literature
gives stopping rules for statistically significant treatment benefit or harm (Pocock ,
1977; O’Brien and Fleming , 1979). The most common approach for controlling type
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I error throughout a trial is to use error spending functions proposed by Lan and
DeMets (1983), which allow for both symmetric and asymmetric stopping rules. Sym-
metric stopping rules imply that stopping early for statistically significant treatment
differences have the same cost, whether benefit or harm is attributed to the experi-
mental therapy. Asymmetric bounds are useful when consequences of stopping early
are different according to the treatment difference that is emerging (Tsiatis , 1981;
DeMets and Ware, 1982). Futility bounds have become increasingly popular as a
mechanism for stopping a trial that is unlikely to end in a new treatment recommen-
dation (Friedman et al., 2015; Harrington, 2012). These types of bounds also avoid
the ethically uncomfortable scenario of trial termination only after statistical proof
of increased mortality from the new treatment.
This chapter proceeds with a description of notation in Section 2.2. In Section
2.3 we describe the proposed test statistic in the case where a single analysis is
performed, with an extension to the group sequential setting given in Section 2.4;
Derivations behind methods in Sections 2.3 and 2.4 are relegated to Appendix A.
In Section 2.4, we also review symmetric versus asymmetric stopping boundaries,
with a modified recommendation for safety monitoring. Section 2.5 summarizes finite
sampling behavior of our group sequential monitoring procedure in a variety of clinical
trial settings. An example from the AIDS Clinical Trial Group is given in Section 2.6
and followed by discussion in Section 2.7.
2.2 Notation
Our ultimate goal is to group sequentially monitor two-sample tests that compare
estimates of τ -restricted mean lifetimes, µg(s, τ), with group subscript g = 1, 2, in-
corporating information from multiple, potentially overlapping, short-term follow-up
windows of length τ . For simplicity, we first describe notation for the one-sample
case, submerging the g subscript.
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2.2.1 Description of Random Variables
Suppose i = 1, . . . , N patients participate in a clinical trial. Patient-specific ran-
dom variables are measured against two different time scales in the group sequential
setting: calendar time, s, and study time, t. Study time, t, indexes time from a
patient’s clinical trial entry; length of life, length of follow-up and other clinical trial
endpoints are described on this time-scale. Calendar time, s, indexes time from the
initiation of the overall study; patient entry times and interim analysis times are
described on this time scale.
In particular, study time indexed random variables include failure times, Ti and
potential loss-to-follow-up times Vi, i = 1, . . . , N . On the calendar time scale, we
define random study entry times, Ei, for participant i = 1, . . . , N, as well as interim
analysis times, s = s1, s2, . . ., which are (non-random) study design parameters. At
interim analysis time s, n(s) =
∑N
i=1 I(Ei ≤ s) individuals have entered the trial
with n(s) = N for s ≥ max(E1, . . . , EN). An individual’s maximum follow-up time
at analysis time s is administratively capped at s−Ei. Hence, the censoring random
variable, Ci(s) = min(Vi, s − Ei), for individual i can potentially change at each
analysis time s, depending on the censoring mechanism. We assume that Ti is in-
dependent of Ci(s), i = 1, . . . , N . For patients who have entered the trial, observed
event times at analysis time s are Xi(s) = min {Ti, Ci(s)}, with corresponding failure
indicator variables δi(s) = I{Ti ≤ Ci(s)}, i = 1, . . . , n(s).
Notation for residual lifetime random variables are needed to define short-term
outcomes during several, potentially overlapping, τ -length follow-up windows of in-
terest. The starting times of these follow-up windows, t ∈ {t1, t2, . . . , tb}, are non-
random design parameters measured on the study time scale with t1 = 0, and b
indicating the total number of windows. We define the residual lifetime from study
time t observed at analysis time s as Xi(s, t) = (Xi(s) − t)I{Xi(s) ≥ t} with cor-
responding failure indicator δi(s, t) = δi(s)I{Xi(s) ≥ t}. A third time-scale metric,
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window time u, indexes time from the beginning of each follow-up window. We use the
window time metric as a common time-scale for residual lifetime random variables,
Xi(s, t1), Xi(s, t2), . . . Xi(s, tb).
Figure 2.1 displays data for 3 example individuals, with random variables specific
to subject A given in detail. Patient entry times EA, EB, EC and interim analysis
times s1, s2 are given on the calendar time scale. Death, loss to follow-up, adminis-
trative censoring and window start times are given on the study time scale. At the
second interim analysis conducted on January 1, 2016, n(s2) = 3 individuals have
entered the study. Subject A contributes information from three windows starting
at t1 = 0, t2 = 6 months and t3 = 12 months. Observed residual lifetime and cen-
soring indicator data pairs contributed by Subject A at the second analysis time are
(17, 1), (11, 1) and (5, 1). In terms of short-term follow-up windows of length τ = 12
months, Subject A contributes uncensored information from three windows: in the
first window, Subject A lives 12 of 12 months, in the second Subject A lives 11 of 12
months, and in the third window Subject A lives 5 of 12 months. Any test statistic
incorporating multiple short-term outcomes taken from an individual as laid out in
Figure 2.1 will need to account for potential correlation between these outcomes.
2.2.2 Counting Process Notation and Estimation
For an individual i who has entered the trial by interim analysis time s, Ni(s, t, u) =
I{Xi(s, t) ≤ u, δi(s, t) = 1} and Yi(s, t, u) = I{Xi(s, t) ≥ u} are the counting and
at risk processes for the number of events occurring no later than window time u
within the follow-up window starting at study time t. From Figure 2.1, consider
Subject A’s data at the 2nd interim analysis time, s2, from the follow-up window
starting at t2 = 6 months. Subject A’s corresponding counting process data at win-
dow times u = 11−, 11, and 11+ months are {NA(s2, t2, 11−) = 0, YA(s2, t2, 11−) = 1},
{NA(s2, t2, 11) = 1, YA(s2, t2, 11) = 1} and {NA(s2, t2, 11+) = 1, YA(s2, t2, 11+) = 0}.
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D: Death
L: Lost to Follow-up
A: Administrative 
Censoring
Calendar time s
Study time t    Subj. A
Subj. B
Subj. C
D
D
L
s1: 1/1/2015 s2: 1/1/2016
t=0
t=0
t=0
EA: 2/1/2014 
EB: 5/1/2014 EC: 3/1/2015 
TA=17m
TB=6m
VC=9m
N=3
At Analysis Time s1 (n(s1)=2)
t
Subj. A
DSubj. B
A
6m 11m
t1=0
t2=6m
t3=12m
XA(s1)=11m        δA(s1)=0
XA(s1,t1)=11m    δA(s1,t1)=0
XA(s1,t2)=5m      δA(s1,t2)=0
XA(s1,t3)=0m      δA(s1,t3)=0  ……
At Analysis Time s2 (n(s2)=3)
t
Subj. A
DSubj. B
6m 9m
t1=0
t2=6m
t3=12m
D
LSubj. C
17m
t4=18mXA(s2)=17m        δA(s2)=1
XA(s2,t1)=17m    δA(s2,t1)=1
XA(s2,t2)=11m    δA(s2,t2)=1
XA(s2,t3)=5m      δA(s2,t3)=1
XA(s2,t4)=0m      δA(s2,t4)=0  ……
Figure 2.1: Notation for 3 Example Individuals, with Random Variables Specific to
Subject A Given in Detail.
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Let N(s, t, u) =
∑n(s)
i=1 Ni(s, t, u) and Y (s, t, u) =
∑n(s)
i=1 Yi(s, t, u) represent pro-
cesses summed across individuals entered by interim analysis time s. For individual
i at interim analysis s, let Ni(s, u) =
∑b
j=1 Ni(s, tj, u) count the observed resid-
ual lifetime events across the b follow-up windows attributed to individual i that
are seen prior to window time u; the corresponding at risk process is Yi(s, u) =∑b
j=1 Yi(s, tj, u). Ni(s, u) has the potential to count the same event more than once,
since this event may be contained in more than one follow-up window. Likewise,
Yi(s, u), includes at-risk processes from the same individual more than once from
follow-up windows that overlap. Combining all information available at interim anal-
ysis time s regarding event and at-risk information for window time u we define
N(s, u) =
∑n(s)
i=1 Ni(s, u) and Y (s, u) =
∑n(s)
i=1 Yi(s, u).
At analysis time s, let hazard function λ(s, t, u) = lim∆u→0[Pr{u ≤ Xi(s, t) ≤
u+ ∆u, δi(s, t) = 1|Xi(s, t) ≥ u}/∆u] and
λW (s, u) =
∑b
j=1 λ(s, tj, u)Pr{Xi(s, tj) ≥ u}∑b
l=1 Pr{Xi(s, tl) ≥ u}
.
As in standard group sequential methods, we assume that analysis time does not
affect the true event-time hazard, so that the superfluous s notation in λ(s, t, u) can
be dropped to become λ(t, u). However, because λW (s, u) corresponds to a mixture
distribution of residual lifetimes contributed from individuals at time s, and is a
function of Pr{Xi(s, t) ≥ u} that depends on follow-up, analysis time s can influence
this term.
2.3 Two-sample Test at a Single Analysis Time, s
In this section, we propose a two-sample test that compares average lifetime per τ
follow-up years. The test is inspired by overall τ -restricted mean estimates developed
by Tayob and Murray (2016) that incorporate information from repeated, overlapping
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follow-up windows of length τ , subject to censoring. Additional subscripts g, g = 1, 2,
indicate treatment group when used with notation from the last section; random
variables from different treatment groups are assumed independent. We assume a
single analysis at calendar time s.
For treatment g at analysis time s, following results from Tayob and Murray,
µˆg(s, τ) =
τ∫
0
exp
−
u2∫
0
dNg(s, u1)
Yg(s, u1)
 du2
consistently estimates µg(s, τ) =
∫ τ
0
exp
{− ∫ u2
0
λWg (s, u1)du1
}
du2, the average life-
time per τ time units as measured from the mixture distribution of short-term,
overlapping τ -length follow-up windows starting at times t1, . . . , tb. Our proposed
two-sample test becomes
T (s) =
√
n1(s)n2(s)
n1(s) + n2(s)
{µˆ1(s, τ)− µˆ2(s, τ)}. (2.1)
Let pˆig(s) = ng(s)/{n1(s) + n2(s)}, g = 1, 2. As shown in Appendix A.1, under
the null hypothesis of µ1(s, τ) = µ2(s, τ), the asymptotic limiting distribution of
T (s) has a mean 0 Normal distribution with variance that can be estimated by
pˆi2(s)σˆ
2
1(s) + pˆi1(s)σˆ
2
2(s), where σˆ
2
g(s) =
∑ng(s)
i=1 [zi{µˆg(s, τ)}− z¯{µˆg(s, τ)}]2/[ng(s)−1],
with zi{µˆg(s, τ)} =
∑b
j=1 zij{µˆg(s, τ)}; z¯{µˆg(s, τ)} =
∑ng(s)
i=1 zi{µˆg(s, τ)}/ng(s) and
zij{µˆg(s, τ)} =
τ∫
0
exp
−
u2∫
0
dNg(s, u1)
Yg(s, u1)


u2∫
0
dNgi(s, tj, u1)− Ygi(s, tj, u1)dNg(s,u1)Yg(s,u1)
Yg(s, u1)/ng(s)
 du2
An approximate 1 − α level confidence interval for the average difference in life-
time per τ time units, µ1(s, τ) − µ2(s, τ), becomes {µˆ1(s, τ) − µˆ2(s, τ)} ± Z1−α/2 ×√
σˆ21(s)/n1(s) + σˆ
2
2(s)/n2(s), where Z1−α/2 is the 100 × (1 − α/2)% quantile of the
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standard Normal distribution. A standard Normal(0,1) version of the test statistic
can be calculated using
T˜ (s) =
T (s)√
pˆi2(s)σˆ21(s) + pˆi1(s)σˆ
2
2(s)
=
√
n1(s)n2(s)
n2(s)σˆ21(s) + n1(s)σˆ
2
2(s)
{µˆ1(s, τ)− µˆ2(s, τ)}.
In describing efficiency of their estimation procedure, Tayob and Murray (2016)
give guidance on selection of follow-up window start times t1, t2, . . . , tb based on the
special case where event-times follow an exponential distribution. In this case, an
analysis of their closed form asymptotic variance showed that, for a fixed number b of
incorporated windows, equal spacing of t1, t2, . . . , tb gave the smallest possible vari-
ability. For any fixed duration follow-up period, simulations also indicated increased
efficiency in estimation with increasing b, even though increases in b create increasing
amounts of overlap between a patient’s incorporated short-term follow-up windows.
However, Tayob and Murray (2016) found that increasing b beyond approximately
(2s−τ)/τ gave diminishing returns in efficiency; they ultimately recommended incor-
porating outcomes from follow-up windows starting after every τ
2
units of follow-up
time, i.e., t = {0, τ
2
, τ, . . . , s−τ}. For instance, with τ = 1 year and an interim analysis
3 years into the trial, we would incorporate information from 1-year duration follow-
up windows starting at t1 = 0, t2 = 0.5 years, t3 = 1 year, t4 = 1.5 years and t5 =
2 years.
2.4 More Than One Analysis at Calendar Times, s1, . . . , sK
At analysis time s, a decision to continue or end the clinical trial is based on
the standardized test statistic, T˜ (s), exceeding predetermined lower or upper critical
values (CVs), cL(s) and cU(s), respectively. When K > 1 analyses are planned, group
sequential methodology tells us that CVs, {cL(s1), cU(s1)} , . . . , {cL(sK), cU(sK)} ,
corresponding to test statistics, T˜K =
{
T˜ (s1), . . . , T˜ (sK)
}
, must be carefully chosen
18
to preserve an overall type I error of α (Pocock , 1977; O’Brien and Fleming , 1979;
Demets and Lan, 1994).
CVs, {cL(sk), cU(sk)} , for the kth analysis (k = 1, . . . , K) can be calculated
from the multivariate distribution of T˜k. As shown in Appendices A.1 and A.2,
T˜k has a mean zero multivariate Normal distribution with k × k covariance ma-
trix Σ, where the diagonal elements are equal to one and the off-diagonal elements,
σk1k2 = σk2k1 , k1 < k2, can be estimated by
σˆk1k2 ={pˆi2(sk1)σ˜21(sk1) + pˆi1(sk1)σ˜22(sk1)}−
1
2{pˆi2(sk2)σˆ21(sk2) + pˆi1(sk2)σˆ22(sk2)}−
1
2
×
2∑
g=1
√
pˆi3−g(sk1)pˆi3−g(sk2)ψˆg(sk1 , sk2)
( ng(sk1 )∑
i=1
{ng(sk1)− 1}−1
× [z˜i{µˆg(sk1 , τ)} − ¯˜z{µˆg(sk1 , τ)}] [zi{µˆg(sk2 , τ)} − z¯{µˆg(sk2 , τ)}]
)
(2.2)
where pˆig, σˆ
2
g(sk2), zi{µˆg(sk2 , τ)} and z¯{µˆg(sk2 , τ)} have been defined in Section 2.3
with s = sk2 and ψˆg(sk1 , sk2) = ng(sk1)/ng(sk2). The zij{µˆg(sk1 , τ)} terms in σˆ2g(sk1),
zi{µˆg(sk1 , τ)} and z¯{µˆg(sk1 , τ)} are replaced with
z˜ij{µˆg(sk1 , τ)} =
τ∫
0
exp{−
u2∫
0
dNg(sk1 , u1)
Yg(sk1 , u1)
}
[ u2∫
0
b∑
l=1
ng(sk2 )∑
i=1
I{Tgi ≥ u1 + tl}
ng(sk1 )∑
i′=1
I{Cgi′(sk1) ≥ u1 + tl}

−1
× ng(sk1)ng(sk2)Ygi(sk1 , tj, u1)
{
dNgi(sk2 , tj, u1)
Ygi(sk2 , tj, u1)
− dNg(sk1 , u1)
Yg(sk1 , u1)
}]
du2
when calculating σ˜2g(sk1), z˜i{µˆg(sk1 , τ)} and ¯˜z{µˆg(sk1 , τ)}.
Examples of calculating CVs based on the joint distribution of T˜k are described
further in Sections 2.4.1 and 2.4.2. Section 2.4.1 reviews how to calculate CVs based
on symmetric type I error spending functions that are in common use. In Section 2.4.2
we describe calculation of CVs based on asymmetric error spending approaches that
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differentially limit the chances of stopping incorrectly for perceived efficacy versus
harm attributed to the investigational arm.
2.4.1 Symmetric Spending Functions
Interim analysis CVs are often based on a monotonically increasing spending func-
tion, α(γ), 0 ≤ γ ≤ 1, with α(0) = 0 and α(1) = α, the desired overall type I
error. A valuable advantage of spending functions is increased flexibility in schedul-
ing interim analyses, for instance as prespecified accrual and follow-up targets are
met. Spending functions that approximate the Pocock (P) and the O’Brien-Fleming
(OF) approaches to type I error control are αOF (γ) = 2 − 2Φ(Z1−α/2/√γ) and
αP (γ) = α ln{1 + (e − 1)γ}, respectively. At interim analysis time s, γ is often
taken to be the proportion of available statistical information relative to the informa-
tion anticipated at the final analysis. Another common choice for γ is the proportion
of expired calendar time relative to the planned trial duration.
As a simple example of the OF spending function with α = 0.05, suppose K = 2
analyses are planned at s1 and s2. We choose to use symmetric bounds so that
cL(s1) = −cU(s1) and cL(s2) = −cU(s2). Further suppose that at s1, γ = 23 , giving
αOF (
2
3
) = 0.016; at the final analysis time γ = 1 and αOF (1) = 0.05 by design. Since
under the null hypothesis T˜ (s1) has an approximate Normal(0,1) distribution, and
no type I error has been spent prior to s1, {cL(s1), cU(s1)} =
{Z0.016/2,Z1−0.016/2} .
Calculation of {cL(s2), cU(s2)} is not as straightforward due to stochastic dependence
between T˜ (s1) and T˜ (s2). The symmetric OF spending function allows 0.05−0.016 =
0.034 type I error to be spent at the 2nd analysis, with 0.017 error allocated towards
incorrectly claiming a statistically significant treatment benefit and 0.017 error to-
wards incorrectly claiming statistically significant treatment harm.
Calculations for {cL(s2), cU(s2)} are only relevant when the trial continues beyond
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the first interim analysis (Z0.016/2 < T˜ (s1) < Z1−0.016/2) and need to satisfy:
Pr
{
T˜ (s2) /∈ (cL(s2), cU(s2)) | Z0.016/2 < T˜ (s1) < Z1−0.016/2, H0
}
=
Pr
{
Z0.016/2 < T˜ (s1) < Z1−0.016/2, T˜ (s2) /∈ (cL(s2), cU(s2))|H0
}
Pr
{
Z0.016/2 < T˜ (s1) < Z1−0.016/2|H0
}
=
0.034
1− 0.016 ≈ 0.035.
Suppose the estimated correlation between T˜ (s1) and T˜ (s2), i.e. σ12, is 0.5.
Modern software packages can easily generate a large number of mean zero bivari-
ate normal iterates with correlation 0.5, {Zm(s1), Zm(s2)} ,m = 1, . . . ,M ; in sim-
ulation we used M=10 million. The desired CVs, cL(s2) = −cU(s2), satisfying
Pr{T˜ (s2) /∈ (cL(s2), cU(s2)) | Z0.016/2 < T˜ (s1) < Z1−0.016/2, H0} = 0.035 are cal-
culated by first subsetting the iterates who failed to reject at s1, i.e., the set S(s1) ={
m ∈ 1, . . . ,M : Z0.016/2 < Zm(s1) < Z1−0.016/2
}
. Then cU(s2) = −cL(s2) is the 1-
0.035=0.965 percentile of |Zm(s2)| iterates taken from S(s1).
The calculation of CVs in the general case with an arbitrary spending function
α(γ) is similar. At analysis time sk with γk, estimate Σk and generate M mean
zero multivariate normal iterates, {Zm(s1), . . . , Zm(sk)}, with correlation (covariance)
matrix Σk,m = 1, . . . ,M . Calculate the subset of iterates S(sk−1) that fail to reject
the null hypothesis at all previous interim analyses 1, . . . , k − 1. Then cU(sk) is
the 1 − α(γk)−α(γk−1)
1−α(γk−1) percentile of |Zm(sk)| iterates taken from the set S(sk−1), and
cL(sk) = −cU(sk).
2.4.2 Asymmetric Type I Error Control and Patient Protection
Symmetric stopping boundaries make it equally difficult to reject the null hy-
pothesis due to treatment benefit or harm. These bounds are appropriate when trial
monitors are blinded to the identity of the superior treatment arm at each analysis.
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Modern Data and Safety Monitoring Committees are rarely blinded, however, and
in cases where the control is a viable therapeutic choice, there is additional motiva-
tion to end a trial where the investigational arm is trending towards harm. For the
remainder of this section we consider asymmetric stopping boundaries, classified as
efficacy, safety or futility bounds.
The priority of the efficacy stopping bound is to limit the clinical trial false positive
rate to α/2, where a false positive clinical trial is defined as a trial that incorrectly
stops in favor of the investigational arm. Typically we choose α/2 = 2.5% and
use a traditional spending function approach for this bound. This bound is tightly
linked to overall study power. When triggered, futility and safety bounds stop the
trial without favoring the investigational arm, but are motivated by different desired
operating characteristics of the trial.
The goal of a futility boundary is to terminate the trial once it seems unlikely
to end with statistical evidence favoring the investigational arm (Ware et al., 1985).
Criteria for defining a futility boundary are variable, chosen to have simulated op-
erating characteristics attractive to the trial sponsor and investigative team in the
trial’s design phase. Such boundaries are much more aggressive at ending an un-
promising trial than when compared to a symmetric stopping rule; trial sponsors
using a futility boundary avoid spending resources that prove their latest offering is
significantly worse than the current standard of care. Although this logic suggests
a cost-benefit motivation, such boundaries have the added attraction of stopping a
trial before even weak statistical evidence of harm attributed to the clinical trial has
been obtained. Further discussion of futility stopping boundaries with examples can
be found in Friedman et al. (2015); Harrington (2012). If the only goal of a clinical
trial is to move forward with a new therapeutic, the financial and ethical protection
afforded by futility boundaries are quite attractive.
The distinction we place between a safety boundary and a futility boundary is
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that safety boundaries never recommend ending a trial early if the investigational
arm is performing at the level of or superior to the control arm. Symmetric OF
and Pocock stopping rules include a boundary that can be classified as a safety
boundary, the boundary that ends the trial in favor of the control when crossed.
Hereafter, we refer to these as OF or Pocock safety boundaries. It is possible to mix
and match efficacy and safety boundaries using commercial software, for instance
an OF efficacy boundary may be paired with a Pocock safety boundary (Proschan
et al., 2006). Traditional type I error is maintained at level α, with α/2 type I error
generated from efficacy and safety boundaries, respectively. The OF efficacy bound
encourages additional follow-up time for collecting data on secondary endpoints when
the investigative arm is favored, while the Pocock safety boundary allows for an earlier
average stopping time when the treatment arm reflecting current medical practice is
favored.
In updating our own thoughts on safety boundaries, we note that (1) in the era
of big data (proteomics, genetics. microbiome, etc.), clinical trial auxiliary data is
tremendously valuable. Clean prospective longitudinal follow-up can generate pre-
liminary data on disease mechanism, therapeutics and personalized medicine, for a
start. For this reason, futility boundaries with very early termination of unpromising
therapies seem less appealing. However, (2) we feel uncomfortable with current OF
and Pocock safety boundaries that require statistically significant harm attributed to
the investigational therapy before stopping a trial.
For our own clinical trials, we have sought solutions via asymmetric boundaries in-
spired by Jennison and Turnbull with ideas incorporated from Proschan et al. as well
as DeMets and Lan (Jennison and Turnbull , 2000; Proschan et al., 2006; Demets and
Lan, 1994). In particular, we recommend a safety bound modified from a Jennison
and Turnbull (JT) spending function, αJT (γ) = γ
ωαsafety, where γ is the propor-
tion of information at the interim analysis, ω > 0 is a user-defined shape parameter
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and αsafety > 0 is a user-specified overall error rate for exceeding the safety bound-
ary and stopping the trial under the null hypothesis. Our recommendation for ω
is log
{
α−1safetyα/2
}
/log(γ1) with γ1 being the proportion of information at the first
analysis, which allows the trial to terminate at the first interim analysis time if the
test statistic indicates harm from the investigational therapy at the α/2 significance
level; hereafter we call this the JT safety boundary.
Figure 2.2 displays symmetric, futility and safety boundaries for a trial planning 5
interim analyses using a standardized test statistic; an OF efficacy bound with a 2.5%
false positive clinical trial rate is also shown. OF and Pocock safety boundaries are
also shown, where the overall probability of ending the trial incorrectly due to safety
is taken to be 2.5% for each of these boundaries. The displayed JT safety boundary
assumes αsafety = 0.20 and α/2 = 0.025, so that ω ≈ 1.29. The displayed Pampallona
and Tsiatis (PT) futility bound (Pampallona and Tsiatis , 1994) is the only bound
with potential to stop the trial while the investigational arm is performing at or above
the level of the control.
2.5 Simulation Study
In this section we summarize finite sample operating characteristics of our test
statistic, with τ = 1 year, against the most popular group sequentially monitored
tests: the logrank test and the restricted mean survival test (RMS). In Appendix
A.4 we summarize results for our test statistic (2.1) using alternative choices of τ =
0.25, 0.50 and 0.75 years as well as results for weighted logrank tests that use Peto
& Peto’s weight favoring early treatment differences and Fleming and Harrington’s
(0.5, 0.5) weight favoring late differences.
In each setting we use an OF efficacy bound with a 2.5% false positive clinical
trial rate. For safety, we consider (1) an OF safety boundary and (2) a Pocock safety
boundary, where each of these assume an overall 2.5% chance of ending the trial
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(OF:O’Brien and Fleming; PT: Pampallona and Tsiatis; JT: Jennison and Turnbull)
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incorrectly due to safety. And finally, we consider (3) a JT safety boundary assuming
αsafety = 0.20 and α/2 = 0.025.
Each scenario assumes a 5 year study with 100 participants per treatment arm; 50
participants per group are accrued at baseline with the remainder accrued uniformly
over 4 years. Interim analysis are conducted annually (K = 5). In addition to admin-
istrative censoring at each analysis time, we assume a loss-to-follow-up mechanism,
Vi = 5Bi + E˜i × (1 − Bi), where Bi and E˜i are distributed as Bernoulli(0.3) and
Exponential with hazard 0.3, respectively.
Event times are generated from exponential or piecewise exponential distributions.
In Scenario 1, both intervention and control arms have hazards of 0.5 throughout
follow-up (null hypothesis scenario). Scenarios 2-9, shown in Figure 2.3 with piece-
wise hazards superimposed over the various survival curves, consider proportional
hazard alternatives (Scenarios 2-3), delayed treatment effect alternatives (Scenarios
4-5), early treatment differences that attenuate over time (Scenarios 6-7) and alter-
natives subject to a cure pattern (Scenarios 8-9). Left and right panels of Figure 2.3
show scenarios where the investigational arm is beneficial or harmful, respectively;
asymmetric stopping rules have different operating characteristics depending on the
benefit/harm profile of the investigational arm.
Tables 2.1 and 2.2 summarize group sequential operating characterics in Scenarios
1 though 9. Table 2.1 shows rates of stopping for perceived efficacy, i.e. study power,
(column 3) or a perceived safety signal (columns 4-6). Table 2.2 shows the average
study time (AST), the average sample number (ASN) and the average number of
events (ANE) for each scenario. For improved precision, scenario 1 includes 10,000
iterations; scenarios 2-9 include 1,000 iterations.
Table 2.1, Scenario 1, shows that under the null hypothesis, all of the estimated
efficacy and safety stopping rates meet their corresponding design targets within our
tolerance for simulation error, where these targets were 0.025 for the OF Efficacy
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Figure 2.3: Survival Probabilities of the Efficacy and Safety Scenarios with Piecewise
Hazards Superimposed over the Curves.
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Scenario Test Statistic OF Efficacy JT Safety P Safety OF Safety
Proposed 0.022 0.198 0.026 0.025
1 RMS 0.023 0.198 0.027 0.027
Logrank 0.022 0.193 0.022 0.024
Proposed 0.807 0.002 0 0
2 RMS 0.816 0.001 0 0
Logrank 0.820 0.001 0 0
Proposed 0 0.982 0.790 0.838
3 RMS 0 0.980 0.786 0.852
Logrank 0 0.987 0.799 0.849
Proposed 0.855-0.863 † 0.021 0.007 0.001
4 RMS 0.715-0.722 † 0.034 0.010 0
Logrank 0.745-0.749 † 0.026 0.007 0
Proposed 0 0.979 0.787 0.860
5 RMS 0 0.939 0.619 0.731
Logrank 0 0.959 0.642 0.765
Proposed 0.761 0 0 0
6 RMS 0.802 0 0 0
Logrank 0.781 0 0 0
Proposed 0 0.960 0.709 0.738
7 RMS 0 0.965 0.736 0.786
Logrank 0 0.971 0.730 0.764
Proposed 0.884 0 0 0
8 RMS 0.771 0.001 0 0
Logrank 0.863 0 0 0
Proposed 0 0.989 0.847 0.885
9 RMS 0 0.955 0.727 0.770
Logrank 0 0.983 0.826 0.871
Table 2.1: Rates of Stopping for Efficacy (OF Efficacy), i.e. Study Power, or for Safety
(JT Safety, P Safety, OF Safety)
† There is potential for OF efficacy rates to be affected by the safety boundary used, for
instance when an efficacy boundary would have been crossed if not for an earlier safety
boundary being crossed. This was only observed in Scenario 4 of our simulations. In this
scenario we give a range of observed OF efficacy stopping rates for each test statistic, where
the lower OF efficacy stopping rate shown corresponds to use of the JT safety boundary
(most strict safety boundary) and the higher OF efficacy stopping rate shown corresponds
to the OF safety boundary (least strict safety boundary).
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AST ASN ANE
Scenario Test Statistic JT P OF JT P OF JT P OF
Proposed 4.7 4.9 5.0 195 199 200 156 163 164
1 RMS 4.6 4.9 5.0 195 199 200 156 163 164
Logrank 4.7 4.9 5.0 195 199 200 156 164 165
Proposed 3.7 3.7 3.7 185 185 185 143 143 143
2 RMS 3.7 3.7 3.7 184 184 184 142 142 142
Logrank 3.7 3.7 3.7 185 185 185 143 143 143
Proposed 2.1 3.0 3.6 151 169 184 93 121 142
3 RMS 2.1 3.1 3.6 151 170 183 93 123 141
Logrank 2.0 3.0 3.6 149 169 184 90 121 141
Proposed 3.7 3.8 3.8 187 188 188 132 134 134
4 RMS 4.2 4.3 4.3 193 195 196 143 146 147
Logrank 4.0 4.1 4.1 191 192 193 140 142 143
Proposed 2.8 3.8 3.9 169 185 189 108 132 137
5 RMS 3.4 4.3 4.3 180 193 195 123 146 147
Logrank 3.0 4.1 4.2 173 189 193 113 140 144
Proposed 3.7 3.7 3.7 184 184 184 143 143 143
6 RMS 3.6 3.6 3.6 183 183 183 141 141 141
Logrank 3.7 3.7 3.7 184 184 184 143 143 143
Proposed 2.2 3.2 3.8 153 171 185 96 126 145
7 RMS 2.2 3.2 3.6 153 171 183 96 126 142
Logrank 2.1 3.1 3.7 150 170 184 92 124 143
Proposed 3.4 3.4 3.4 181 181 181 128 128 128
8 RMS 3.7 3.7 3.7 183 183 183 132 132 132
Logrank 3.5 3.5 3.5 182 182 182 130 130 130
Proposed 2.1 3.0 3.5 152 169 182 92 113 130
9 RMS 2.2 3.2 3.7 154 172 184 94 118 133
Logrank 2.0 3.0 3.6 150 169 183 90 113 131
Table 2.2: Average Study Time (AST) in Years, Average Sample Number (ASN) and
Average Number of Events (ANE) in Scenarios 1 - 9
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boundary, 0.20 for the JT safety boundary and 0.025 for the OF and Pocock safety
boundaries. The JT safety boundary ends the trial more frequently (Table 2.1) and
earlier (AST in Table 2.2) than either the Pocock or OF safety boundaries in Scenario
1. Regardless of the test statistic used, the JT safety boundary tends to end the trial
0.3-0.4 years earlier with 5 fewer patients enrolled and 7-9 fewer events observed (See
AST, ASN and ANE, respectively in 2.2).
Regardless of test statistic used, in scenarios where the investigational drug is
harmful (Scenarios 3, 5, 7, and 9), the JT safety boundary reaches a safety signal at
a much higher rate than its competitor safety bounds (Table 2.1) and with a much
smaller AST, ASN and ANE (Table 2.2). In scenarios where the investigational drug
is beneficial (scenarios 2, 4, 6 and 8), the additional safety conferred by use of the JT
bound does not reduce study power except very modestly in scenario 4, where the
treatment benefit does not emerge until after the first interim analysis. In this one
case, less than a percentage point of simulated power is lost when using the JT safety
boundary compared to the other safety boundaries.
For proportional hazards scenarios (Table 2.1, Scenarios 2-3), all three test statis-
tics have comparable probabilities of stopping for efficacy (Scenario 2) or safety (Sce-
nario 3), with the logrank test edging out its competitors very slightly. Table 2.2,
likewise, gives very similar AST, ASN and ANE results for the three test statistics.
In Scenarios 4-5, where there is a delayed treatment effect, the proposed statistic
has at least 10% higher power (Scenario 4, Table 2.1) with a better safety profile
(Scenario 5, Table 2.1) compared with both the logrank and RMS tests. Modest
improvements in AST, ASN and ANE are also attributed to use of the proposed test
statistic (Scenarios 4-5, Table 2.2).
In Scenarios 6-7, where an early treatment difference emerges but becomes atten-
uated over time, power increases by approximately 2 percentages points when moving
from the proposed to the logrank test, and from the logrank to the RMS test (Sce-
30
nario 6, Table 2.1). Safety profiles, AST, ASN and ANE likewise slightly favor the
RMS procedure over the logrank and proposed test, respectively (Scenario 7, Tables
2.1 and 2.2).
In Scenarios 8-9, where a cure pattern emerges during the trial, the proposed
test statistic has approximately 2% and 10% higher power than the logrank and
RMS tests, respectively (Scenario 8, Table 2.1). Safety profiles shown for Scenario 9
in Table 2.1 likewise reflect a slight improvement over the logrank test and a large
improvement over the RMS test. AST, ASN and ANE results, however, show only
minimal differences (Scenario 8-9, Table 2.2).
2.6 Example
Fischl et al. (1990), on behalf of the AIDS Clinical Trials Group (ACTG), ran-
domized 524 patients to high-dose (n=262) versus low-dose (n=262) azidothymidine
(AZT). The standard, higher AZT dose succeeded in reducing mortality but came
with substantial toxicity. Investigators hoped that the lower dose would reduce toxic-
ity while maintaining the survival benefit. Figure 2.4(a) displays the average number
of additional days lived per year when taking low versus high dose AZT, estimated
using our methodology with τ = 1 year, at analysis times in 1987, 1988, 1989 and
1990. Although validity of our testing procedure does not require a stable treatment
effect over time, the low-dose AZT benefit appears approximately stable at each anal-
ysis. Using our proposed group sequentially monitored test statistic, the OF efficacy
boundary is crossed at the 1990 analysis with the low dose group living an estimated
10.7 days longer per year than the high dose group. The JT safety boundary ensures
early trial termination if the experimental low-dose trends towards higher mortality,
but this boundary was not crossed. Appendix A.5 summarizes how group sequentially
monitored logrank and RMS tests performed in this case. As seen in Figure 2.4(b),
there was a delayed treatment effect that perhaps favored our methodology as com-
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pared to the logrank and RMS methods. Neither of these competitors recommended
stopping before the 1990 analysis time.
2.7 Discussion
There are a good many nonparametric group sequential monitoring methods avail-
able for censored time-to-event outcomes in clinical trials, the logrank test and the
RMS test among the most popular, and so a natural question is what the proposed
test statistic offers clinical trial researchers that the others do not. We see both
philosophical and operational advantages to this statistic being used in practice. The
philosophical argument hinges on the idea that times-to-event can be repurposed into
a longitudinal data structure, with repeated measures within individual measured reg-
ularly throughout follow-up. Each τ -restricted time-to-event carved from the overall
follow-up time can be thought of as a longitudinal measure in this philosophy. Tayob
and Murray (2016) proposed an improved estimate of τ -restricted means based on this
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idea and showed that τ -length follow-up windows starting every τ/2 time units apart
give attractive efficiency in estimating restricted means without unduly increasing
computational time in creating these longitudinal measures. They extended this idea
to the parametric setting in Tayob and Murray (2017), multiply imputing censored
event times and then using standard generalized estimating equation methods for
analyzing the longitudinal restricted event times. There is great potential in shifting
our thoughts on censored times-to-event towards longitudinal data structures and the
available methodology this shift entails.
In this chapter, we develop a two-sample test statistic based on comparing τ -
restricted means as introduced in Tayob and Murray and we further develop group
sequential monitoring methodology for using the test statistic in standard clinical
trial settings where interim monitoring is common. The validity of the proposed
testing procedure does not hinge upon stability of τ -restricted means in the different
follow-up windows; the type I error is preserved regardless of the true event-time
distribution. In scenarios where τ -restricted means are not stable over time, the test
statistic compares overall τ -restricted means of mixture distributions that result from
combining information from overlapping follow-up windows.
Event rates that shift year-by-year affect the power of all two sample testing
procedures. It is well known that non-proportional hazards plague the power of
the logrank test. Restricted mean differences also change as the period of follow-up
lengthens, with differences becoming larger or smaller as event rates shift over time.
As with all two-sample tests, as data accumulates, so does our interpretation of the
data and the power of the testing procedure. The main concern in choosing any two-
sample test statistic is whether authentic treatment differences can be detected with
high power.
Our proposed method performs well not only in scenarios where short-term differ-
ences are anticipated to be stable, but also in settings that it may be hard to anticipate
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in the design stage of a clinical trial. We find it comforting that our methodology
compares favorably to its competitors in proportional hazards settings, and has a
notably improved performance in settings where treatment differences emerge only
after a certain period of time or in settings where there is potential for cure.
Simulations suggest that shifting towards a longitudinal view of censored survival
outcomes has practical advantages in group sequential monitoring of clinical trials.
The feature of overlapping follow-up windows used in creating repeated τ -restricted
event times subject to censoring is reminiscent of smoothing methods in graphical
displays of longitudinal data.
An additional contribution of this chapter is an updated look at safety boundaries
in the group sequential setting and a new recommendation for the shape parameter
ω used with the JT spending function. Our recommended shape boundary allows
the first interim analysis to reject if the standardized normal test statistic exceeds
the safety boundary of -1.96, which clinical investigators have been hard-wired to
associate with statistical significance. Data and safety monitoring committees are
likely to feel uncomfortable continuing a trial that exceeds this critical value and yet
for many years biostatisticians have taught investigators the consequences of using
traditional significance levels in the group sequential setting in terms of inflated type
I errors. This chapter emphasizes the idea that type I error inflation has different
consequences for the efficacy boundary as opposed to the safety boundary. We argue
that is is possible to maintain an overall false positive trial result to an α/2 level
using an appropriate efficacy boundary and separately strategize a stopping rule that
protects safety without unduly reducing power of the study. Our recommended vari-
ant of the JT safety bound achieves this goal with remarkable effectiveness as seen in
simulation. We ultimately recommend use of our proposed test statistic in the group
sequential setting using OF efficacy and our JT safety boundaries.
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CHAPTER III
Nonparametric Group Sequential Methods for
Recurrent and Terminal Events from Multiple
Follow-up Windows
3.1 Introduction
Consider the typical setting for a two-arm clinical trial of a chronic, slowly pro-
gressing terminal disease. Several lung diseases fall into this category including Inter-
stitial Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD)
and Cystic Fibrosis (CF), among others. Pulmonary exacerbations are a common
recurrent event subject to termination by death in these patients. The Azithromycin
in COPD Trial (NACT) is one of many clinical trials with follow-up of such events.
More generally, patients may experience a mixture distribution of important, poten-
tially recurring, signals of disease progression during follow-up. In IPF studies, for
example, patients are considered progressors if they experience an acute exacerbation,
a 10% decline in forced vital capacity (FVC), a 15% decline in diffusing capacity of
the lung for carbon monoxide (DLCO), lung transplantation or death, where these
latter two events are each considered terminal for lung outcome follow-up. Clinical
research design is often based on time to the first occurrence of a recurrent event or
the first event from a list of potentially recurring progression outcomes.
35
105 days from enrollment 331 days from enrollment298 days from enrollment
Enrollment Acute
Exacerbation
DLCO
Decline
Death
A COMET
Subject
Figure 3.1: An Example IPF Patient from COMET Study.
There are advantages and disadvantages to following only the first time-to-event.
The most obvious advantage is the existence of several methods for group sequential
clinical trial design and analysis of censored survival data that are applicable to
a single time-to-event or time-to-combined-endpoint. (Tsiatis , 1982; Murray and
Tsiatis , 1999; Li , 1999b; Logan and Mo, 2015) An obvious disadvantage, however,
is the loss of information from ignoring progression events after the first that occurs
for each patient. Consider Figure 3.1, which shows progression endpoints from an
IPF patient followed as part of the COMET study (Correlating Outcome Measures
to Estimate Time to progression in IPF) (Ashley et al., 2016). This patient’s first
observed progression endpoint involves a decline in DLCO. An analysis based only
on the first time-to-combined endpoint will ignore information on the subsequent
progression endpoints, acute exacerbation and death.
Although there are several available methods for conducting two-sample tests of
recurrent event data when a single analysis is conducted (based on, for example,
Prentice et al. (1981), Andersen and Gill (1982), Lin et al. (2000), Ghosh and Lin
(2000) or Tayob and Murray (2014)), there is little available methodology for con-
ducting group sequential analysis in this setting. Cook and Lawless (1996) developed
group sequential methods for pseudo-score statistics monitored over time, which are
framed to perform well when the cumulative mean number of events are proportional
over time. Cook et al. (2010) later extended this method to settings with multiple
treatment periods. Jiang (1999) developed group sequential analysis methods for
recurrent events assuming local Poisson processes that allow event rates to change
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over time, and incorporated a frailty parameter to address correlation between event
times rather than accounting for this correlation nonparametrically.
In this chapter, we develop group sequential methods for monitoring the Tayob
and Murray statistic (Tayob and Murray , 2014) for nonparametric analysis of recur-
rent events subject to a terminating event. In framing their statistic, recurrent event
outcomes are restructured into a series of censored longitudinal times-to-first-event in
regularly spaced short-term (length τ) follow-up windows for each patient. Their test
then compares the difference between overall τ -restricted mean event-times between
groups. In the case of a single analysis, Tayob and Murray demonstrated nice operat-
ing characteristics of their statistic in analyzing a mixture of recurrent and terminal
events, with superior performance to methods of Lin et al. (2000) and Ghosh and
Lin (2000) when recurrent and terminal events were correlated. The development of
group sequential methods for this nonparametric statistic will improve the current
arsenal of statistical methods for clinical trial monitoring.
The remainder of this chapter is organized as follows. Section 3.2 defines notation
required to repurpose traditional recurrent events data available at analysis time s
into a series of censored longitudinal times-to-first event in regularly spaced short-
term (length τ) follow-up windows for each patient. Section 3.3 briefly reviews the
Tayob and Murray two-sample testing procedure in the case of a single analysis.
Section 3.4 extends methodology to the group sequential setting. Section 3.5 describes
simulated operating characteristics of our method compared to that of Cook and
Lawless (1996). We demonstrate the method using data from the Azithromycin in
COPD Trial. Discussion follows in Section 3.7.
3.2 Notation
We borrow notation from Tayob and Murray (2014), additionally embedding a
’calendar time’ scale parameter, s, to allow for terms that change according to analysis
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time. For simplicity, we assume that s indexes time from initiation of the overall
study rather than an actual calendar date. Patient entry times and interim analysis
times are both described on this time scale. A separate ’study time’ scale, indexed
by t, denotes time from a participant’s entry to the study. Participants’ time at
risk, duration of follow-up as well as times to recurrent and terminating events are
measured on this time scale.
We temporarily submerge notation corresponding to treatment group g, initially
focusing on the one-sample case. Suppose i = 1, . . . , N patients enter a clinical trial
at calendar times E1, E2, ..., EN . Interim analyses of accumulated data are planned at
calendar times, s = s1, s2, ..., sK . Let n(s) =
∑N
i=1 I(Ei ≤ s) index the number of ac-
crued individuals at interim analysis time, s, with n(s) = N for s ≥ max(E1, . . . , EN).
Recurrent events for individual i occur at times Ti1 < Ti2 < · · · < TiJi−1 on the
study time scale, with a terminating event at time TiJi . For each individual, i, Vi is
a loss-to-follow-up time measured from study entry. The censoring random variable
that also incorporates administrative censoring, Ci(s) = min(Vi, s − Ei), updates at
each analysis time, s. Recurrent and terminal events for participant i are subject
to independent censoring by Ci(s). However, an arbitrary dependence structure is
allowed between all events Tij1 and Tij2 , j1 6= j2, taken from patient i. In particular,
the multivariate distribution of gap times for each patient i, {Ti1, Ti2−Ti1, . . . , TiJi−1−
TiJi−2}, is not constrained to an independent covariance structure.
Traditionally observed data for patients accrued prior to analysis time s is recorded
as Xij(s) = min{Tij, Ci(s)}, j = 1, . . . , J˜i(s) and δij(s) = I{Tij ≤ Ci(s)}, j =
1, . . . , J˜i(s), where J˜i(s) ≤ Ji is the number of observed event times. However,
the Tayob and Murray statistic reorganizes the observed data into τ -length, po-
tentially overlapping, follow-up windows starting at regularly-spaced study times
t ∈ {t1, t2, . . . , tb} with t1 = 0 and b chosen so that tb does not exceed the avail-
able follow-up at analysis time s. Within each τ -length follow-up window, the first
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τ -restricted time-to-event is recorded, along with the corresponding censoring indica-
tor.
For each individual i, a notational bookkeeper that updates at each analysis time
s, ηi(s, t) = min{j = 1, . . . , J˜i(s) : Xij(s) ≥ t}, indexes the time-to-first-event in a
follow-up window starting at t from the original sequence of observed events. Using
this index simplifies notation for the time-to-first event in this window at analysis time
s, Xi(s, t) = Xiηi(s,t)(s)− t and its corresponding failure indicator δi(s, t) = δiηi(s,t)(s).
Tayob and Murray discuss advantages of this data restructuring at length. In
short, a rather complex correlated gaptime data structure that is subject to dependent
censoring by Ci(s) is converted to a well-behaved longitudinal outcomes dataset that is
subject to independent censoring by Ci(s). One feature that emerges as a consequence
of this data restructuring is the possibility that a recurrent event is tagged in more
than one follow-up window for analysis. Hence careful attention to the correlation
structure that takes this additional complexity into account is implemented. There is
also the possibility of a recurrent event being excluded from the analysis, which can
be mitigated by more frequently spaced window start times, t.
In a special case with exponentially distributed gap times between events, Xia
and Murray (2018) quantified the average proportion of recurrent events captured in
at least one follow-up window when traditional recurrent event data is restructured
in the manner of Tayob and Murray. This proportion approaches one as the equal
spacing between follow-up window start times, a = tj − tj−1, j = 2, . . . , b, approaches
zero. However, the computational burden associated with very small a led to their
recommendation that a be a fraction of the anticipated mean recurrent event time
in the control group. In particular, their rule of thumb suggested a = 1/2 or 1/3 of
the control group mean recurrent event time would tend to capture 80% and 90% of
the events, respectively, in the case of exponentially distributed gap times between
events.
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Figure 3.2: An Example IPF Patient from COMET Study with Different Setups of
Follow-up Windows
To solidify some of the notation presented above, consider Figures 3.2 and 3.3. In
Figure 3.2, which is indexed by study time, different spacing of follow-up windows
(a = 50, 100 and 200 days) are shown for the example COMET patient previously
mentioned in the introduction. The choice of a = 200 days results in two observed
events being included in the analysis, the DLCO decline at 105 days and the acute
exacerbation at 298 days. However the death at 331 days is overlooked in the analysis
since it is not the first event to be observed in either of the follow-up windows starting
at zero or 200 days. Both a = 50 and a = 100 days capture all three events in the
analysis.
Moving forward with a = 100 in Figure 3.3, and superimposing calendar time s in
addition to study time t, we see the patient entering the study at Ei = 15 days from
the initiation of the study in calendar time. The first interim analysis is conducted at
s1 = 157 days in calendar time, at which time only a single event has been observed
at Ti1 = 105 days from study entry. The patient’s data is administratively censored
at Ci(157) = 142 days. The traditional version of the recurrent events data at this
analysis time is {[Xi1(157) = 105, δi1(157) = 1]; [Xi2(157) = 142, δi1(157) = 0]}, so
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Figure 3.3: Notation for an Example Individual, with Random Variables Given in
Detail.
that J˜i(157) = 2. At analysis time s1 = 157 days, the longitudinal data structure
imposed by Tayob and Murray has two data triplets from follow-up windows start-
ing at t = 0 and t = 100: {ηi(157, 0) = 1, Xi(157, 0) = 105, δi(157, 0) = 1} and
{ηi(157, 100) = 1, Xi(157, 100) = 5, δi(157, 100) = 1}, so that the Ti1 = 105 event is
captured as the first observed event in each of these two follow-up windows.
At the second analysis time at s2 = 369 days, administrative censoring for pa-
tient i is updated to Ci(369) = 354. The traditional recurrent events data be-
comes {[Xi1(369) = 105, δi1(369) = 1]; [Xi2(369) = 298, δi2(369) = 1]; [Xi3(369) =
331, δi3(369) = 1]}, so that J˜i(369) = 3. The restructured longitudinal dataset in-
cludes data from 4 follow-up windows starting at t = 0, 100, 200 and 300 yielding
the data triplets {[ηi(369, 0) = 1, Xi(369, 0) = 105, δi(369, 0) = 1]; [ηi(369, 100) = 1,
Xi(369, 100) = 5, δi(369, 100) = 1]; [ηi(369, 200) = 2, Xi(369, 200) = 98, δi(369, 200) =
1]; [ηi(369, 300) = 3, Xi(369, 300) = 31, δi(369, 300) = 1]; }.
We now define the counting and at risk processes corresponding to the restructured
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longitudinal dataset at interim analysis time, s. For a follow-up window starting at
time t, u indexes time from t in that window. For any individual i with Ei < s,
Ni(s, t, u) = I{Xi(s, t) ≤ u, δi(s, t) = 1} is the event counting process for the time
to first event in the follow-up window starting at time t. The corresponding at
risk process is Yi(s, t, u) = I{Xi(s, t) ≥ u}. Let N(s, t, u) =
∑n(s)
i=1 Ni(s, t, u) and
Y (s, t, u) =
∑n(s)
i=1 Yi(s, t, u) sum these processes across individuals entered by interim
analysis time s.
At interim analysis s, let Ni(s, u) =
∑b
j=1Ni(s, tj, u) count the observed times-to-
first-event across the b follow-up windows attributed to individual i that are seen prior
to window time u; the corresponding at risk process is Yi(s, u) =
∑b
j=1 Yi(s, tj, u).
Pooling time-to-first event data across all follow-up windows and all individuals ob-
served at interim analysis time s, we define N(s, u) =
∑n(s)
i=1 Ni(s, u) and Y (s, u) =∑n(s)
i=1 Yi(s, u).
It will be convenient to also index hazard functions according to the three time
indices {s, t, u}. At analysis time s, let hazard function
λ(s, t, u) = lim
∆u→0
[Pr{u ≤ Xi(s, t) < u+ ∆u, δi(s, t) = 1|Xi(s, t) ≥ u}/∆u].
The index, s, can be dropped as superfluous in the first term, i.e., λ(s, t, u) = λ(t, u).
This is not true for the hazard function corresponding to the mixture distribution of
times-to-first event contributed from the various follow-up windows from individuals
at analysis time s, λW (s, u).
λW (s, u) =
∑b
j=1 λ(s, tj, u)Pr{Xi(s, tj) ≥ u}∑b
l=1 Pr{Xi(s, tl) ≥ u}
.
Because λW (s, u) is a function of Pr{Xi(s, t) ≥ u}, this term can potentially change
as more follow-up information accumulates at later interim analyses.
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3.3 Nonparametric Two-sample Tests for Recurrent Events
and Terminal Events at Single Analysis Time
In this section, we review the Tayob and Murray test statistic, introducing ad-
ditional notation for when a single analysis is performed at, say, calendar time s.
Subscripts g = 1, 2, indicate treatment group when used with notation from the last
section. Throughout the following, random variables from different treatment groups
are assumed to be independent of one another. Later in section 3.4, we extend these
methods to the case where more than one analysis is performed at calendar times
s1, s2, . . . , sK in the group sequential clinical trial setting.
The estimated overall τ -restricted mean time-to-first-event for treatment group g
based on the restructured longitudinal dataset available at analysis time s is
µˆg(s, τ) =
τ∫
0
exp
−
u2∫
0
dNg(s, u1)
Yg(s, u1)
 du2,
which consistently estimates the mean of this mixture distribution of τ -restricted
times-to-first-event, i.e., µg(s, τ) =
∫ τ
0
exp
{− ∫ u2
0
λWg (s, u1)du1
}
du2.
Let pig(s) be the proportion of individuals in group g at analysis time s, with
consistent estimate pˆig(s) = ng(s)/{n1(s) + n2(s)}. At analysis time, s, the Tayob
and Murray statistic tests the null hypothesis, H0 : µ1(s, τ) = µ2(s, τ), using
T (s) =
√
n1(s)n2(s)
n1(s) + n2(s)
{µˆ1(s, τ)− µˆ2(s, τ)},
which under H0 converges asymptotically to a mean zero Normal distribution with
variance
pi2(s)σ
2
1(s) + pi1(s)σ
2
2(s),
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where
σˆ2g(s) =
ng(s)∑
i=1
[zi{µˆg(s, τ)} − z¯{µˆg(s, τ)}]2/[ng(s)− 1],
zi{µˆg(s, τ)} =
b∑
l=1
zil{µˆg(s, τ)},
z¯{µˆg(s, τ)} =
ng(s)∑
i=1
zi{µˆg(s, τ)}/ng(s)
and zil{µˆg(s, τ)} =
τ∫
0
exp
−
u2∫
0
dNg(s, u1)
Yg(s, u1)


u2∫
0
dNgi(s, tl, u1)− Ygi(s, tl, u1)dNg(s,u1)Yg(s,u1)
Yg(s, u1)/ng(s)
 du2. (3.1)
An approximate 1−α level confidence interval for the average treatment difference
in τ -restricted times-to-first-event, µ1(s, τ)− µ2(s, τ), becomes
{µˆ1(s, τ)− µˆ2(s, τ)} ± Z1−α/2 ×
√
σˆ21(s)/n1(s) + σˆ
2
2(s)/n2(s),
where Z1−α/2 is the 100× (1− α/2)% quantile of the standard Normal distribution.
For finite sample sizes and a single planned analysis at time s, the standardized test
statistic
T˜ (s) =
T (s)√
pˆi2(s)σˆ21(s) + pˆi1(s)σˆ
2
2(s)
=
√
n1(s)n2(s)
n2(s)σˆ21(s) + n1(s)σˆ
2
2(s)
{µˆ1(s, τ)− µˆ2(s, τ)}
follows an approximate Normal(0,1) distribution, with critical values of ± 1.96 con-
ferring an overall type I error of 5%.
3.4 More Than One Analysis at Calendar Times, s1, s2, . . . , sK
In this section, we extend methodology for the Tayob and Murray statistic to the
group sequential setting. At each analysis time s the standardized test statistic, T˜ (s),
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is evaluated and a decision to either end the trial early or continue is made based on
upper and lower critical values, cL(s) and cU(s), respectively. With K > 1 planned
analyses, critical values {cL(s1), cU(s1)} , . . . , {cL(sK), cU(sK)} corresponding to test
statistics, T˜K =
{
T˜ (s1), . . . , T˜ (sK)
}
, must be carefully chosen to preserve an overall
type I error of α (Pocock , 1977; O’Brien and Fleming , 1979). Type I error spending
functions are the most common approach for designating type I error to be used at
interim analyses so that no more than α type I error is used throughout the clinical
trial (Lan and DeMets , 1983; Demets and Lan, 1994). The O’Brien-Fleming (OF)
spending function, αOF (γ) = 2 − 2Φ(Z1−α/2/√γ), proposed by Lan and DeMets is
the most common spending function used in practice, although the only requirement
for a spending function, α(γ), is that it be monotonically increasing over (0, α) as γ
increases from zero to one.
Information-based type I error spending takes the spending function parameter,
γ, to be the proportion of statistical information available at interim analysis time
sk relative to the information that will be available at the final analysis at time sK ,
k = 1, . . . , K. To our knowledge, the two-sample logrank test is the only group
sequentially monitored statistic for time-to-event data where this information pro-
portion reduces to a simple calculation; in this case γ is a ratio of observed events at
sk to the number of events used in powering the study. For the Tayob and Murray
statistic, the proportion of information at analysis time sk is V arT (sK)/V arT (sk),
where V arT (sK) can be estimated via simulation using distributional and design
assumptions used in powering the trial.
A common simplistic surrogate for statistical information is to use the proportion
of calendar time that has passed at analysis time s relative to the planned duration of
the trial. The method for estimating γ at each analysis time may affect study power,
but typically to a less extent than the choice of spending function (Lan and DeMets ,
1989). For simplicity, we use the calendar time surrogate for statistical information
45
in our simulation and example sections. The type I error level is maintained for any
spending function where at the final analysis, γ = 1.
Derivation of critical values for the kth interim analysis also requires knowledge
of the multivariate distribution of T˜k =
{
T˜ (s1), . . . , T˜ (sk)
}
, (k = 1, . . . , K). Let
Σk be the k × k covariance matrix for T˜k, so that the kst1 , knd2 element σk1k2 of this
matrix is Cov
{
T˜ (sk1), T˜ (sk2)
}
, k1, k2 ≤ k. Because each test statistic has already
been standardized to have variance 1.0, Σk is also a correlation matrix for T˜k. In
Appendix B.1 we prove that the multivariate distribution of T˜k is a mean zero Normal
distribution with elements σk1k2 of its covariance matrix Σk that can be estimated
with
σˆk1k2 ={pˆi2(sk1)σ˜21(sk1) + pˆi1(sk1)σ˜22(sk1)}−
1
2{pˆi2(sk2)σˆ21(sk2) + pˆi1(sk2)σˆ22(sk2)}−
1
2
×
2∑
g=1
√
pˆi3−g(sk1)pˆi3−g(sk2)ψˆg(sk1 , sk2)
( ng(sk1 )∑
i=1
{ng(sk1)− 1}−1
× [z˜i{µˆg(sk1 , τ)} − ¯˜z{µˆg(sk1 , τ)}] [zi{µˆg(sk2 , τ)} − z¯{µˆg(sk2 , τ)}]
)
(3.2)
where pˆig, σˆ
2
g(sk2), zi{µˆg(sk2 , τ)} and z¯{µˆg(sk2 , τ)} have been defined in Section 3.3,
and are estimated here using data available at s = sk2 . We also define ψˆg(sk1 , sk2) =
ng(sk1)/ng(sk2) and
z˜ij{µˆg(sk1 , τ)} =
τ∫
0
exp{−
u2∫
0
dNg(sk1 , u1)
Yg(sk1 , u1)
}
[ u2∫
0
b∑
l=1
ng(sk2 )∑
i=1
I{Tgi ≥ u1 + tl}
ng(sk1 )∑
i′=1
I{Cgi′(sk1) ≥ u1 + tl}

−1
× ng(sk1)ng(sk2)Ygi(sk1 , tj, u1)
{
dNgi(sk2 , tj, u1)
Ygi(sk2 , tj, u1)
− dNg(sk1 , u1)
Yg(sk1 , u1)
}]
du2.
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So that we replace the zij{µˆg(sk1 , τ)} terms in σˆ2g(sk1), zi{µˆg(sk1 , τ)} and z¯{µˆg(sk1 , τ)}
with z˜ij{µˆg(sk1 , τ)} to obtain σ˜2g(sk1), z˜i{µˆg(sk1 , τ)} and ¯˜z{µˆg(sk1 , τ)}. The purpose
of these latter substitutions is to estimate quantities that are not parameterized for a
particular analysis time s with the more complete data available at the latter analysis
time, sk2 .
Estimation of null hypothesis percentiles involved in critical value calculations
can be accommodated using either numerical integration techniques applied to the
joint null hypothesis distribution or simulation techniques based on multivariate
replicates from this joint distribution. For instance, suppose an OF spending func-
tion is chosen with spending function parameters (γ1, . . . , γk−1) at analysis times
(s1, . . . , sk−1). At analysis time sk, the upper critical boundary, cU(sk), is based on
the 1 − αOF (γk)−αOF (γk−1)
1−αOF (γk−1) percentile of the null hypothesis conditional distribution
of |T˜ (sk)| given critical boundaries were not crossed at prior interim analyses by
T˜ (s1), . . . , T˜ (sk−1). For symmetric critical boundaries we use cL(sk) = −cU(sk).
In simulation and example sections of this chapter, critical boundaries are simu-
lated. In particular, for critical values at analysis time sk, we generate H = 1 million
mean zero multivariate normal iterates, {Zh(s1), . . . , Zh(sk)} , h = 1, . . . , H, with cor-
relation (covariance) matrix Σk. Among the subset, S(sk−1), of these iterates that
fail to reject the null hypothesis at previous analyses from s1 to sk−1, we estimate
cU(sk) = −cU(sk) with the 1 − αOF (γk)−αOF (γk−1)1−αOF (γk−1) percentile of |Zh(sk)|. In our simu-
lations, H = 1 million successfully estimated the very small percentiles used by the
OF spending function.
3.5 Simulations
Simulations were conducted to compare operating characteristics in the group
sequential setting for (1) the Tayob and Murray (2014) (TM) test using our proposed
methodology with τ = 12 months, (2) the Cook and Lawless (1996) (CL) cumulative
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mean test and (3) a logrank (LR) analysis of the first time-to-event. Each tabulated
result is based on 1000 iterations of the simulation approaches described below.
We assume a 48-month clinical trial with annual interim analyses scheduled at
s = {12, 24, 36, 48} months from the start of the study. One hundred patients per
treatment group are enrolled, half at baseline, with the remainder accrued uniformly
over the first 24 months. Participants are administratively censored according to the
analysis time, with no additional loss-to-follow-up otherwise. An O’Brien-Fleming
(OF) type I error spending function is used to determine group sequential stopping
rules with an overall type I error of 0.05, where the spending function parameter,
γ, was taken to be the proportion of calendar time used by analysis time s of the
planned 48 months.
Within each patient, we generate a dependence structure between events using
a Gaussian copula approach. (Li , 1999a) This approach induces correlation be-
tween gap times Tij − Tij−1 for j = 2, . . . , Ji − 1 as well as correlation between each
gap time and the terminating event TiJi . We first simulate mean zero multivariate
normal random variables {Ui1, Ui2, . . . , Ui200, Vi}, with covariance matrix satisfying
V ar(Vi) = V ar(Uij) = 1 for j = 1, . . . , 200, with ρ1 parameterizing the correlation
between Uij and Uij′, for j 6= j′, and ρ2 parameterizing the correlation between Uij and
Vi for j = 1, . . . , 200. In addition to the setting with independence between all recur-
rent and terminal events (ρ1 = ρ2 = 0), low (0.3), medium (0.5) and high (0.7) values
of ρ1 and ρ2 are explored. We then use the probability integral transform method
to convert the multivariate normal random variables to correlated Uniform(0,1) ran-
dom variables and then to correlated exponential random variables. The simulated
exponentially distributed random variable originating from Vi becomes the terminal
event and the remaining exponentially distributed events become gap times between
recurrent events, with Ji − 1 counting the recurrent events prior to the terminating
event for individual i; simulated events that occur beyond the terminal event for a
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participant are discarded.
For the control group, recurrent events are simulated to occur every 3 months on
average, subject to a terminal event with a mean of 36 months. Following the rule of
thumb from Xia and Murray (2018) for this control group event rate, follow-up win-
dows for the TM method are initiated every 1.5 months so that t1 = 0, t2 = 1.5, t3 =
3, t4 = 4.5, . . . , tb = s− 12 months. The experimental group experiences a treatment
benefit in terms of both the terminal and recurrent event rates, with recurrent events
occurring every 4.3 months on average and a mean time to terminating event of 51.4
months.
Under the null hypothesis, for all group sequentially monitored test statistics and
all correlation structures, simulated overall type I error was within expected simula-
tion error of the desired 0.05 level. With independently generated event times, overall
type I errors were 0.054, 0.054 and 0.041 for the group sequentially monitored TM,
CL and LR statistics, respectively. Table 3.1 displays overall type I error simulation
results assuming different combinations of low, medium and high correlation between
an individual’s event times.
Cumulative power for detecting the alternative hypothesis at each analysis time,
in the special case of independently generated recurrent and terminal event times,
is shown in Appendix B.2. Simulated power for the group sequentially monitored
CL statistic (triangles) was highest in this case, followed closely by the TM statistic
(circles) and distantly by the LR method (+).
For correlated recurrent and terminal event settings simulated assuming the alter-
native hypothesis, Figure 3.4 displays power for group sequentially monitored TM, CL
and LR statistics. Panels moving from top to bottom in this figure correspond to in-
creasing levels of correlation between recurrent events in an individual. Panels moving
from left to right in this figure correspond to increasing levels of correlation between
recurrent and terminal events. For any particular panel, simulated power is displayed
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Correlation between
recurrent and terminal events&
Test Low Medium High
TM 0.053 0.050
Low CL 0.050 0.050 NA†
LR 0.048 0.041
Correlation TM 0.055 0.058 0.044
between Medium CL 0.039 0.045 0.038
recurrent events∗ LR 0.051 0.055 0.057
TM 0.058 0.056 0.051
High CL 0.040 0.048 0.045
LR 0.054 0.048 0.058
Table 3.1: Overall Type I Error by Varying Levels of Correlation between
Recurrent Events (Rows) and Correlation between Recurrent and
Terminal Events (Columns)
† Data is not shown for the case with low ρ1 and high ρ2 since this covariance
structure was difficult to construct. Intuitively, it is difficult to have gap times
weakly correlated with one another and at the same time all highly correlated
with the terminal event time.
∗ Low, medium to high correlations between recurrent events are generated from
ρ1=0.3, 0.5 and 0.7, respectively.
& Low, median to high correlations between recurrent and terminal events are
generated from ρ2=0.3, 0.5 and 0.7, respectively.
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Figure 3.4: Cumulative Power at Each Analysis Time by Varying Levels of Correla-
tion Between Recurrent Events (Rows) and Correlation between Recur-
rent and Terminal Events (Columns)
† Data is not shown for the case with low ρ1 and high ρ2 since this covariance structure was
difficult to construct. Intuitively, it is difficult to have gap times weakly correlated with one
another and at the same time all highly correlated with the terminal event time.
∗ Low, medium to high correlations between recurrent events are generated from ρ1 =0.3,
0.5 and 0.7, respectively.
& Low, median to high correlations between recurrent and terminal events are generated
from ρ2=0.3, 0.5 and 0.7, respectively.
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on the vertical axis; the horizontal axis is interim analysis time (s = 12, 24, 36 or 48
months). For each of these correlation structures, the power of the group sequen-
tially monitored TM statistic approximates or exceeds the power of the CL and LR
methods.
The group sequentially monitored logrank test only uses the first time-to-event in
each individual, and therefore is not affected by correlation between event times as
simulated in the various panels of Figure 3.4. Because the logrank test’s simulated
power dynamic is similar from panel to panel of Figure 3.4, merely reflecting simula-
tion variability across the scenarios, it is helpful in spotting changes in the behavior of
the group sequentially monitored TM and CL methods. The power dynamics of these
latter group sequentially monitored statistics change according to the degree of sta-
tistical information gained from the additionally incorporated recurrent and terminal
events.
For the TM statistic, only modest changes in power dynamics are seen within any
row of Figure 3.4, likely because of the small relative role terminal events (4.6-8.1% of
simulated events) play in these analyses compared to the role of the recurrent events
(91.9-95.4% of simulated events). As correlation between recurrent events increases,
the statistical information in the longitudinally constructed censored event times used
by the TM method decreases. Hence the power of the TM statistic decreases when
moving from top to bottom panels in Figure 3.4.
The power dynamic of the group sequentially monitored CL statistic is strongly
impacted by the correlation structure between events. Whereas in Supplemental
Figure S1 (with all independent events), the CL test statistic has the largest power
of the methods shown, power for the CL statistic erodes substantially as correlation
between recurrent events increases. In the bottom row panels of Figure 3.4, the
LR test outperforms the CL test even though the LR test is only using the first
observed event-time per individual. Upon further exploration of the simulated CL test
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statistics, the explanation for this power dynamic rests in the variability of the number
of events per individual that the CL test statistic is built from. The patient to patient
variability in the observed number of events increases as the correlation between
recurrent events increases, causing the variance of the mean number of cumulative
events to increase, and the CL test to lose power. Intuitively, increasing correlation
drives the total number of observed events higher in patients with a tendency for short
times-to-event. Similarly, increasing correlation drives the total number of observed
events lower for individuals with a tendency towards long times-to-event. Taking both
of these patterns into account, the range of the observed number of events widens as
correlation between events increases.
Panels in the middle row of Figure 3.4 show power for the CL test improving
from the worst of the three methods (in the case with medium correlation between
recurrent events and low correlation between recurrent and terminal events) to power
nearly identical to the TM method (in the case with medium correlation between
recurrent events and high correlation between recurrent and terminal events). Mov-
ing left to right the variability in the number of observed events per individual is
stabilizing in this row of figures. Those with a tendency towards short times-to-event
are experiencing a terminal event before their total count gets very high. Similarly,
those with a tendency towards longer times-to-event are experiencing longer times to
accumulate these event counts before a terminal event. A similar pattern is observed,
to a lesser extent, in the lower right panel of Figure 3.4, where the power of the CL
method increases a bit compared to its power dynamics as shown in panels to its left.
3.6 Example
The Azithromycin in COPD Trial (Albert et al., 2011) randomized 1117 patients
with a history of acute exacerbations to 250 mg daily of azithromycin or placebo.
The original group sequential monitoring plan for this study was based on a logrank
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analysis of the time-to-first acute exacerbation or death. Interim analyses were con-
ducted every 6 months with overall type I error for the trial controlled via an O’Brien-
Fleming spending function. Conditional power analyses were additionally provided to
the Data and Safety Monitoring Committee. To make this example more interesting,
we restrict attention to 381 patients accrued during the first year of follow-up. In
constructing the TM statistic, we use τ = 6 months and, following Xia and Murray
(2018), initiate follow-up windows every 2 months (approximately one third of the
historic mean time to exacerbation in this population).
Figure 3.5 shows the estimated days free of acute exacerbation or death per
6-months of follow-up, based on the TM statistic, at each of the interim analysis
times. Group sequential boundaries based on the O’Brien-Fleming spending func-
tion are superimposed with an overall type I error of 5%. These boundaries are
presented on the scale of the observed effect size needed for the trial to stop early,
which can be calculated as cU(s)
√
σˆ21(s)/n1(s) + σˆ
2
2(s)/n2(s) for upper bound and
for cL(s)
√
σˆ21(s)/n1(s) + σˆ
2
2(s)/n2(s) lower bound, where cU(s) and cL(s) are critical
values for the standardized test statistics as described in Section 3.4. A recommended
stopping boundary for safety with spending function, αJT (γ) = 0.2γ
1.5, is superim-
posed in Figure 3.5. This boundary is a special case of a Jennison and Turnbull
(Jennison and Turnbull , 2000) boundary that we have personalized to stop at the
first interim analysis if the standardized test statistic exceeds a 1.96 critical bound-
ary in favor of the placebo group. The overall probability of stopping for a safety
signal based on this boundary is 20% under the null hypothesis of no treatment effect.
The TM test statistic recommends stopping the trial in favor of the azithromycin
arm at the 3rd interim analysis (18 months into the study). For comparison, stan-
dardized TM, CL and logrank test statistics and corresponding stopping boundaries
are displayed in Figure 3.6. The CL stops at the 4th interim analysis (2 years into
the study) with 59 additional acute exacerbations and 4 additional deaths observed
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Figure 3.5: Additional Days Free of Acute Exacerbation or Death per 6-months of
Follow-up When Using Azithromycin versus Placebo, Based on the TM
Statistic
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Figure 3.6: Standardized Test Statistics and Critical Boundaries for NACT Example.
Lower (symmetric) O’Brien-Fleming Boundary and JT Boundary Are Not
Displayed.
compared to the TM-based group sequential analysis. The logrank analysis of time-
to-first event does not detect a significant benefit of azithromycin in this subset of
patients from the original study.
3.7 Discussion
In this chapter, we develop a new nonparametric tool for group sequentially mon-
itoring clinical trials based on recurrent event outcomes subject to a terminal event.
Our method is appropriate and robust for events that are correlated within individual
or for completely independent event times. Treatment effects observed across analysis
times are simple to interpret. In addition to plots showing stopping boundaries based
on standardized test statistics, we display observed data and stopping boundaries on
the scale of the needed effect size for the trial to stop.
Statistical literature for nonparametric group sequential monitoring of clinical
trials is currently dominated by single time-to-event analyses. In the recurrent events
setting, many researchers still design their trials using only the first time-to-event
because of the availability of software, or in some cases because of concern that
strong assumptions are required for recurrent event analyses to be valid.
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This, of course, is a shame because (1) there is quite a nice existing nonparametric
method for group sequential monitoring of recurrent events data available from Cook
and Lawless (1996) that is being under-utilized in clinical trial design in our opinion.
This method is also appropriate for correlated events within an individual and per-
forms particularly well when events from the same individual are independent. (2)
Clinical trial designs that do not take advantage of events that occur after the first
observed event are statistically inefficient, which has financial implications for the
overall cost of a clinical trial.
In developing group sequential methodology relating to the Tayob and Murray
statistic, we hope to enrich needed literature in this area. Our method performs
particularly well when events times within an individual are correlated, and is com-
petitive with the Cook and Lawless method when events are independent.
With continually improving treatments for those with chronic disease, trials are
becoming more dependent on surrogate outcomes and combined endpoints rather
than mortality alone. Many of these events are recurrent in nature. This trend
is likely to continue as lifetimes are successfully extended and as time pressure for
faster drug approval increases. We strongly believe that in settings of chronic disease,
clinical trial design and analysis should move towards recurrent events methods that
incorporate a mixture of disease progression events over time; that this should be the
default design choice in understanding a patient’s disease burden.
57
CHAPTER IV
Commentary on Tayob and Murray (2014) with a
Useful Update Pertaining to Study Design
The two-sample tests described in Tayob and Murray (2014) combine information
from recurrent and terminal events in order to detect treatment differences. Instead of
following the standard recurrent events paradigm that uses information on gap times
between events, their work repurposes the data into a regularly spaced longitudinal
form that avoids the usual dependent censoring issues that often plague gap time
analyses. The endpoints are based on τ -length follow-up windows that start at evenly
spaced times {t1, . . . , tb}; b is chosen so that the final τ -length follow-up interval
starting at tb does not exceed the study period. In each of these follow-up windows the
observed endpoint is the time to first event (recurrent event or death) or τ if no event
occurs during that window. These endpoints are subject to the usual independent
right censoring that occurs in the clinical trial setting. The analysis proceeds by
comparing either the overall τ -restricted mean survival estimated from the follow-
up windows from the two treatment groups, or alternatively, the area under the
τ -restricted mean residual lifetime function.
Tayob and Murray (2014) recommended using tk = (k − 1)τ/2, for k = 1, . . . , b,
as the starting points of the incorporated follow-up windows. This recommendation
arose from closed-form variance calculations and accompanying simulations in the
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special case of a single time-to-event. For our purposes it is convenient to describe
these starting points as being initiated every a units starting at time 0 and ending at
time tb, with Tayob and Murray’s recommendation equivalent to setting a = τ/2.
In the recurrent events setting, if a is large relative to the mean of the recur-
rent event time, there is potential for a few of the recurrent events to be left out of
the analysis, potentially reducing power. Intuitively, smaller values of a will create
more follow-up windows that capture more recurrent events, but at the cost of com-
putational efficiency. Computation burden increases substantially as the number of
follow-up windows incorporated into the Tayob and Murray statistic increases. For
example, in a dataset with 100 patients per group observed over 48 months with
control versus treatment mean recurrent event times of 3 versus 4 months, compu-
tation of the Tayob and Murray statistic took an hour when incorporating follow-up
windows starting every 10 days versus 1.7 minutes when spacing follow-up windows
1.5 months apart; times based on running R version 3.4.1 on a MacBook Pro with a
macOS High Sierra operating system, a 2.9 GHz Intel Core i5 processor and 8 GB of
Memory.
In this chapter we give improved guidance on the choice of a. Our recommendation
is framed in terms of the average proportion, p, of recurrent events captured in at
least one follow-up window for individuals followed s time units. This measure, p, is
a compromise between the special case of a single time-to-event considered by Tayob
and Murray (2014) and the impractical opposite extreme where window start times
are taken along a continuum from time 0. Our calculations assume independent
exponential times between recurrent events, with rate λ.
Let pdfExp(λ)(g) be the exponential(λ) probability density function (pdf) with rate
λ and g > 0. Let pdfGamma(α,λ)(r) be the gamma pdf with shape α, rate λ and r > 0,
with corresponding cumulative distribution function (cdf) denoted as cdfGamma(α,λ)(r).
After some calculation shown in Appendix C, we obtain an expression for p that can
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be numerically evaluated in terms of a, λ, and s, or inverted to solve for a as a function
of p, λ and s. That is,
p =1−
∞∑
k=2
1
k
k∑
j=2
b∑
w=1
[ min(aw,s)∫
0
pdfGamma(j,λ)(r)
{
cdfGamma(k−j,λ)(s− r)
− cdfGamma(k−j+1,λ)(s− r)
}
dr
−
(w−1)a∫
0
min(aw,s)−r∫
0
pdfGamma(j−1,λ)(r)pdfExp(λ)(g)
{
cdfGamma(k−j,λ)(s− r − g)
− cdfGamma(k−j+1,λ)(s− r − g)
}
dgdr
]
As one might expect, larger values of p are monotonically related to smaller values of
a in this expression.
As an example of how p influences our choice of a and therefore study power,
suppose we are designing a 48-month study where n = 100 per group. Thirty percent
of these patients are recruited at the start of the study and observed for the full 48
months; the remaining 70% are uniformly accrued over the first 24 months. We wish
to base the analysis on the Tayob and Murray statistic using τ = 12. Table 4.1 below
summarizes operational study design results for 3 different values of p = 0.7, 0.8 and
0.9 and 4 different recurrent event rates in the control group. In each case, the mean
recurrent event time in the control group is 25% shorter than the mean event time in
the treatment group. Values of a in each tabulated scenario are numerically calculated
based on s = 48, λ corresponding to the control group recurrent event rate and p.
Power shown in Table 4.1 is simulated from 1000 Monte Carlo iterations for both
independent and dependent recurrent events with the correlation between recurrent
event times, ρ, equal to 0, 0.25 or 0.5. Type I error rates are 0.05 in all scenarios.
If we first focus on the recommended values of a shown in Table 4.1, we see a wide
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range of values [0.7 to 12 months] with more closely spaced follow-up window start
times recommended when the control group experiences shorter mean times-to-event,
and additionally when we wish to capture a higher proportion of these events in the
analysis plan. This is as opposed to using a = τ/2 = 6 months as recommended in the
original Tayob and Murray manuscript for all scenarios. Our simulations confirm that
there are diminishing returns in power gain as more follow-up windows are included.
The ’sweet spot’ for clinical trial design seems to be p = 0.8, or 80% of events captured
in the analysis, although for particularly expensive clinical trials even modest gains in
power may be worth the extra computational burden. The simulations also suggest
a convenient rule of thumb of choosing a equal to half of the mean recurrent event
time in the control group, which gave p between 0.8 and 0.9 in all scenarios shown.
Similar to all other clustered data structures, our longitudinal restricted mean
event times contain the most statistical information when event times within an in-
dividual are independent. Hence it is not surprising that power is highest in each
scenario when ρ = 0. In clustered data analyses, ρ is typically described as an intra-
class correlation coefficient, and our simulated power results reflect similar results to
those seen in these settings. Namely, higher correlation between events severely im-
pacts available power for analysis. To the extent that our updated recommendations
for a can recover some of the power lost by using the original recommendation of
Tayob and Murray, we feel this chapter may be quite helpful in conserving clinical
trial resources. It should be noted that even with the original recommendation of
a = τ/2, Tayob and Murray saw gains in power compared to methods recommended
in Ghosh and Lin (2000) and Lin et al. (2000) when times between recurrent events
were correlated.
Our closed-form calculation for p ignores the possibility of a terminal event, which
is allowed by the Tayob and Murray statistic. When terminal events are present, our
calculation provides a lower bound on the estimated proportion of observed events
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captured in at least one follow-up window. The intuitive explanation is that follow-
up windows with a terminating event have an observed follow-up duration less than
the value of s assumed in our equation for p. As can be seen in Figure 4.1, smaller
values of s trend, but not monotonically, towards larger values of p. In additional
simulations introducing terminal events, we’ve observed the proportion of captured
events increase by as much as 5% in scenarios with a high terminal event hazard
relative to the recurrent event rate. When terminal events occur much less frequently
than recurrent events, our calculations continue to give very similar results to those
seen in simulation [data not shown].
There are not straightforward extensions of the closed-form formulas to other
distributions. We’ve performed additional simulations with event rates following the
Weibull distribution that show for similar mean gap-times, our closed form formula
underestimates the proportion of captured events when the shape parameter is greater
than 1 and overestimates this proportion when the shape parameter is less than one.
Hence, as is typically the case, simulations are required when event rates are not
anticipated to follow an exponential distribution. Our work provides a framework
(proportion of captured events) for programmers to use in designing such simulations
to understand operating characteristics in non-standard settings.
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Figure 4.1: Proportion (p) of Events Captured by Follow-up Times (s) in Months.
(Curves vary across mean recurrent event times assumed in columns of Table 1. For
each curve a fixed value of a is assumed that corresponds to the recommendation given
in Table 1 for achieving p = 0.8 over an s = 48 month follow-up period. Values of
p trend higher, but not monotonically, as s decreases. The non-monotonic pattern is
caused by cumulative increases in the number of follow-up windows (b) as s increases.)
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Proportion of Control Group Mean Recurrent
Events Captured Event Time in Months
(p) 3 6 9 12
a 2.4 5.3 8.8 12
Power
0.7 ρ = 0 0.969 0.842 0.690 0.548
ρ = 0.25 0.858 0.736 0.634 0.497
ρ = 0.5 0.700 0.588 0.527 0.416
a 1.5 3.2 5.2 7.7
Power
0.8 ρ = 0 0.975 0.868 0.748 0.639
ρ = 0.25 0.887 0.755 0.670 0.547
ρ = 0.5 0.703 0.602 0.544 0.449
a 0.7 1.5 2.4 3.4
Power
0.9 ρ = 0 0.975 0.881 0.767 0.670
ρ = 0.25 0.887 0.773 0.683 0.594
ρ = 0.5 0.710 0.627 0.558 0.505
Table 4.1: Calculated a Values and Estimated Power
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CHAPTER V
Regression Analysis of Recurrent-Event-Free Time
from Multiple Follow-up Windows
5.1 Introduction
Recurrent events are frequently seen in participants of clinical trials and obser-
vational studies of chronic diseases. For instance, patients in the Azithromycin in
Chronic Obstructive Pulmonary Disease (COPD) Trial (Albert et al., 2011) were
followed for recurrent acute pulmonary exacerbations. Other settings with recurrent
events include recurrent ischemic cardiovascular events after acute coronary syndrome
(Schwartz et al., 2018), recurrent clostridium difficile infection (Wilcox et al., 2017)
and even repetitive head injuries in high-contact sports (DeKosky et al., 2010). Pois-
son and negative binomial count models have been used to analyze recurrent event
data per time at risk (Frome et al., 1973; Lawless , 1987; Lambert , 1992; Greene,
1994). These approaches to not take advantage of the timing of events, however, and
may therefore not provide the most powerful analysis (Ozga et al., 2018).
The most commonly used multivariable regression analysis methods for recurrent
events data are extensions of the Cox proportional hazards model to the recurrent
event setting. The extension proposed by Andersen and Gill (1982) analyzes the time
between recurrent events, called gap times, assuming independence between these gap
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times within an individual. Prentice et al. (1981) considered an extension of the Cox
model that allowed stratification of the baseline hazard to depend on time-dependent
features including previous recurrent event time information; both gap time models
and models of time from beginning of follow-up are considered. Wei et al. (1989) pro-
posed a multivariate proportional hazards model, where the multivariate outcomes
are based on separate recurrent events modeled from the beginning of follow-up. An
arbitrary covariance structure is allowed between the different event-times, fit with a
robust sandwich variance estimate. Pepe and Cai (1993) described several manners
of modeling recurrent event rates based on the number of previous recurrent events,
advocating for a Markov approach that models each recurrent event conditional on
information from the immediately preceding event. Lawless and Nadeau (1995) and
Lin et al. (2000) developed models for the cumulative mean number of events, as-
suming proportionality on the cumulative means over time. A number of authors
introduced random effects or frailties to parameterize the dependence between recur-
rent event times (Aalen and Husebye, 1991; Hougaard , 1995; Rondeau et al., 2007;
Mazroui et al., 2013; Rogers et al., 2016).
In pursuing any new modeling framework for recurrent events, three issues are
paramount to address (1) the potential correlation between times between recurrent
events, (2) the potentially censored nature of the data and (3) the interpretability of
results. In addressing each of these issues in this chapter, we take an entirely different
approach to modeling recurrent event data that provides a natural way to handle
correlation between event times and is highly interpretable. In short, we transform
the recurrent event data structure into a very tractible censored longitudinal data
structure. The longitudinal outcomes are τ -restricted times-to-first-event as captured
in follow-up windows that are reinitiated at regularly-spaced intervals. Instead of
modeling the rate or cumulative number of recurrent events, our model estimates
time free from recurrence over a τ -length follow-up period.
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In Section 5.2, we describe notation required to repurpose traditional recurrent
events data into a series of censored longitudinal endpoints. Section 5.3 describes
differences between this data structure and that of the multivariate distribution of
gap times between recurrent events. In section 5.4, we develop a model framework
that can be fit using generalized estimating equation methods, along with two meth-
ods for handling the censored nature of the data: a pseudo-observation approach
(Section 5.4.1) and a multiple imputation approach (Section 5.4.2). Section 5.5 de-
scribes finite sample properties of our methodology in scenarios where times between
recurrent events are independent (Section 5.5.1) and correlated (Section 5.5.2). We
then reanalyze data from the Azithromycin in COPD Trial using our methodology in
Section 5.6. Discussion follows in Section 5.7.
5.2 Notation
For the most part, notation in this chapter is similar to that used in Chapter
III. Because group sequential analysis are not being performed, the parameter, s, for
analysis time is removed. We also drop use of the group subscript, g, since predictors
of this nature will be absorbed into a covariate vector in this chapter.
Suppose i = 1, . . . , N independent patients are followed for recurrent events.
Without loss of generality, we assume each patient’s follow-up period starts from a
baseline time of 0; hereafter, we refer to baseline and time 0 interchangeably. For each
individual patient, i, let Tij, j = 1, . . . , Ji be the time from baseline to the j
th recurrent
event, so that 0 < Ti1 < Ti2 < · · ·TiJi . Let Ci be the censoring time from baseline for
patient i, where Ci is independent of Tij, for j = 1, . . . , Ji. Correlation between recur-
rent event times in an individual i (or lack thereof) is typically formulated in terms of
gap times between events,
{
Gi1 = Ti1, Gi2 = Ti2 − Ti1, . . . , GiJi = TiJi − TiJi−1
}
. We
allow an arbitrary dependence structure between gap time random variables for pa-
tient i, with independent gap times as a special case. Traditional observed recurrent
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event data for patient i is recorded in data pairs {Xij = min(Tij, Ci), δij = I(Tij ≤ Ci)},
j = 1, . . . , J˜i, where J˜i ≤ Ji; in most cases the J˜ thi data pair corresponds to a censored
event time.
In this chapter, we construct a streamlined censored longitudinal data structure
from the recurrent event times. That is, each longitudinally measured outcome con-
tributed by patient i is a censored time-to-first-event in a follow-up window starting
at time t, where t ∈ {t1, . . . , tb} with t1 = 0 and tk = tk−1 + a, k = 2, . . . , b. As
only one time-to-first-event in each follow-up window is measured, we incorporate
at most b outcomes from each individual, regardless of how many recurrent events
they experience. Hence, for a fixed overall study duration, the choice of spacing,
a = tk − tk−1, k = 2, . . . , b, between initiation of each subsequent follow-up window
increases the proportion of recurrent events captured by the censored longitudinal
data structure. It is theoretically possible to create a censored longitudinal dataset
with follow-up windows initiated every day (a = 1), although the computational bur-
den of working with this extended dataset becomes cumbersome. Xia and Murray
(2018) showed that in the case of exponentially distributed times between events with
common intensity λ, using a = 1/(2λ) captures approximately 80% of the recurrent
events in at least one of the constructed follow-up windows over a fixed follow-up
period.
For patient i and follow-up window starting at t, we index the first recurrent
event occurring after time t with the subscript ηi(t) = min{j = 1, . . . , Ji : Tij ≥ t} so
that Ti(t) = Tiηi(t)− t is the time-to-first-recurrent-event measured from t, sometimes
called the residual event-free time from t. We collect individual i’s newly formatted
longitudinal outcomes, {Ti(t1), Ti(t2), . . . , Ti(tb)}, into a vector, Ti, for i = 1, . . . , N .
The observed data counterpart to ηi(t) is η˜i(t) = min{j = 1, . . . , J˜i : Xij ≥ t}.
For each follow-up window starting at time t where Ci > t, patient i contributes the
observed data triplet
{
η˜i(t), Xi(t) = Xiη˜i(t) − t, δi(t) = δiη˜i(t)
}
. For follow-up windows
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starting at t where Ci ≤ t, we use the convention that η˜i(t) = Xi(t) = δi(t) = 0.
Figure 5.1 displays how censored longitudinal data is created from traditional re-
current event data using a participant from the Azithromycin in COPD Trial. During
353 days of follow-up for this patient, J˜i = 4 traditional recurrent event data pairs
emerge: (Xi1 = 53 days, δi1 = 1), (Xi2 = 111 days, δi2 = 1), (Xi3 = 170 days, δi3 = 1)
and (Xi4 = 353 days, δi4 = 0), where the first three data pairs denote acute exacer-
bation (AE) event times and the last data pair reflects a censored event.
Two examples of converting these data into a censored longitudinal data structure
are given, one based on follow-up windows starting at a = 120 day intervals and one
constructed with a = 60 day intervals. As with all longitudinal data structures, the
additional data triplets included using a = 60 day intervals as opposed to a = 120 day
intervals afford capturing more time-to-first events supplied by the recurrent event
times.
Data triplets based on follow-up windows starting at t = {0, 120, 240} days become
{η˜i(0) = 1, Xi(0) = Xi1 − 0 = 53, δi(0) = 1},
{η˜i(120) = 3, Xi(120) = Xi3 − 120 = 170− 120 = 50, δi(120) = 1}
and
{η˜i(240) = 4, Xi(240) = Xi4 − 240 = 353− 240 = 113, δi(240) = 0}.
Data triplets based on follow-up windows initiated every a = 60 days include the
above data triplets plus those starting at days t = {60, 180, 300} days:
{η˜i(60) = 2, Xi(60) = Xi2 − 60 = 111− 60 = 51, δi(60) = 1},
{η˜i(180) = 4, Xi(180) = Xi4 − 180 = 353− 180 = 173, δi(180) = 0}
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Figure 5.1: Creating Censored Longitudinal Data From Recurrent Event Data for an
Example Participant of the Azithromycin in COPD Trial.
(AE: Acute Exacerbation)
and
{η˜i(300) = 4, Xi(300) = Xi4 − 300 = 353− 300 = 53, δi(300) = 0}.
5.3 Times-to-first-event from t ∈ {t1, . . . , tb} versus Gap Times
The marginal distribution of the time-to-first recurrent event after t, Ti(t), is a
quite different creature from the marginal distribution of a gap time between recurrent
events, Gij, j = 1, . . . , Ji, . On a practical note, the random variable, Ti(t), better
reflects the recurrent event time one might seek advice about at a regularly scheduled
clinic visit at time t or at entry into a clinical trial at t. These patient interactions
rarely coincide exactly with a recurrent event, so that a gap time random variable
measured from an individual’s previous event is not the most appropriate random
variable for these settings. On a statistical note, when gap times within an individual
are correlated there is a well-known dependent censoring bias that must be addressed
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in any analysis of the gap time data (Lin et al., 1999). This dependent censoring issue
is circumvented by our censored longitudinal data structure since times-to-first-event
are measured from pre-specified times {t1, . . . , tb} rather than a correlated time-to-
event.
For these different random variables to coincide with one another, the distributions
of Ti(t) and Gij must both be entirely memoryless. This is formally demonstrated
in the following, where we show that the only case where the marginal distribution
of a gap time, Gij, coincides with that of a time-to-first-recurrent-event, Ti(t), is
the special case with independent and identically distributed exponential gap times
{Gi1, . . . , GiJi} for each patient, i = 1, . . . , N . For settings with gap times that are
not exponentially distributed, or for settings with correlated, but otherwise iden-
tically distributed, exponential gap times, the marginal distribution of Ti(t) shifts
from a memoryless distribution to a distribution very much influenced by the series
of recurrent events with positive probabilistic support for occurring in the follow-up
period after t.
Consider the event-free probability function for Ti(t) that is written in terms of
gap time random variables as follows:
Pr{Ti(t) > u} = Pr{Ti1 > t+ u}+ lim
Ji→∞
Ji∑
j=2
Pr{Tij−1 ≤ t, Tij > t+ u}
= Pr {Gi1 > t+ u}+ lim
Ji→∞
Ji∑
j=2
Pr
{
j−1∑
l=1
Gil ≤ t,
j−1∑
l=1
Gil +Gij > t+ u
}
. (5.1)
For independently and identically distributed exponential gap times with intensity λ,
Appendix D.1 shows that these terms reduce to exp(−λu), so that Ti(t) also has an
exponential distribution with intensity λ.
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However, when the gap times are correlated, the term
Pr
{
j−1∑
l=1
Gil ≤ t,
j−1∑
l=1
Gil +Gij > t+ u
}
(5.2)
from the previous equation does not reduce to a simple expression. Term (5.2) is the
probability that an individual’s jth recurrent event will be the first to occur in the
follow-up window starting at t, but that it has not yet occurred as of time t+ u.
To better appreciate the influence of (5.2) on the expression in (5.1), we consider
special cases with correlated and independent exponential(λi) distributed times be-
tween recurrent events. Figure 5.2 displays term (5.2) as a function of time, u, for
different combinations of recurrent event index, j, and follow-up window start time, t,
with λi = 1/3. The solid blue and dashed red lines show the cases with independent
and correlated event times, respectively. For the independence case, the curves have
a closed-form shown in Appendix D.1 to be (λit)
j−1e−λi(t+u)/Γ(j). For the correlated
case, we first simulated correlated exponential event times using a Gaussian copula
approach described in further detail in Section 5.5; the approximate correlation be-
tween recurrent event times was 0.8. We then empirically estimated and plotted term
(5.2) from a large number (N=10,000) of simulated individuals.
In nearly every panel of Figure 5.2, term (5.2) is smaller when times between
recurrent events are correlated. As j increases relative to t the depicted probability
curves get lower, and the curves generated from the two different correlation structures
also get closer together. Overall these curves indicate that Pr{Ti(t) > u} tends to be
much smaller than the exponential(1/3) survival curve that equation (5.1) reduces to
in the case with independent event times.
Of course, we were immediately curious to know whether the distribution of the
time-to-first-event from t, in this special case with correlated exponential(1/3) gap
times, stabilizes. The intuition behind this thought was that the mixture distribution
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Figure 5.2: Pr{Tij−1 ≤ t, Tij−1 +Gij > t+ u} over u for Specific t and j.
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of gap time histories preceding t and likely to influence the distribution of Ti(t) might
stabilize. As seen in Figure 5.3, where (again using the large simulated dataset of
10,000 individuals) Pr{Ti(t) > u} is plotted for increasing values of t, this does seem
to be the case. The distribution of Ti(t) seems to stabilize for values of t ≥ 3, or
1/λi. Stabilization of the distribution of Ti(t), for t > 1/λi was further explored for
different values of λi and found to be a reliable pattern. This feature will be utilized
later in Section 5.5.2, when we simulate a stable time-to-first-event distribution given
covariates in the setting with correlated exponential gap times.
5.4 Multivariable Regression Model of τ-Restricted Times-
to-first-recurrent-event Measured Across Multiple Over-
lapping Follow-up Periods
To study the association between patient covariates, Z, and τ -restricted times-
to-first-recurrent event across follow-up windows starting at times {t1, . . . , tb}, we
consider the following model:
E(log[min{τ, T }]|Z) = βTZ (5.3)
Two features of our data need to be addressed for successful estimation of model (5.3):
(1) the censored nature of the vector of newly formatted longitudinal outcomes, Ti,
from patient i and (2) the correlated nature of these longitudinal outcomes. We
develop two approaches that address the censoring aspect of the data, a pseudo-
observation approach in section 5.4.1 and a multiple imputation approach in section
5.4.2. Each of these approaches converts the censored longitudinal outcomes into a
format appropriate for complete data methods.
Once this feature of the data is addressed, we tackle the correlated nature of the
longitudinal outcomes Ti from each patient, i = 1, . . . , N using existing methods, such
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Figure 5.3: Pr{Ti(t) > u} by Follow-up Window Start Times, t.
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as generalized estimating equations (GEE). Because our recurrent events data have
been restructured into times-to-first event from regularly spaced follow-up periods and
because we consider τ−restricted times-to-first-events in these periods, the correlation
structure of the outcomes can be modeled via well organized correlation matrices.
Two underlying layers of correlation are at work: the natural correlation between
recurrent events within an individual and the possibility that the same event is cap-
tured as the first-time-to-event in more than one follow-up period. In the most general
case, we assume an b× b unstructured correlation matrix with components:

1 corr{Ti(t1), Ti(t2)} corr{Ti(t1), Ti(t3)} . . . corr{Ti(t1), Ti(tb)}
corr{Ti(t2), Ti(t1)} 1 corr{Ti(t2), Ti(t3)} . . . corr{Ti(t2), Ti(tb)}
. . . . . . . . . . . . . . .
corr{Ti(tb), Ti(t1)} corr{Ti(tb), Ti(t2)} corr{Ti(tb), Ti(t3)} . . . 1

However, for settings with fairly stable time-to-first-event distributions over time,
we consider a (banded) Toeplitz correlation structure that allows for correlation to
decrease as the degree of overlap between τ -restricted follow-up periods decreases.
The degree of overlap in τ -restricted follow-up windows can be determined from a
and τ and follows a regular pattern. For instance with a = τ/3 and b = 4 windows
starting at times t = {0, τ/3, 2τ/3, τ}, the Toeplitz correlation matrix is:

1 ρ1 ρ2 ρ3
ρ1 1 ρ1 ρ2
ρ2 ρ1 1 ρ1
ρ3 ρ2 ρ1 1

where ρ1 is the correlation between times-to-first event in adjacent τ -restricted follow-
up windows that overlap by 2τ/3 follow-up units, ρ2 is the correlation between times-
to-first event in windows that start 2a units apart from one another and overlap by
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τ/3 units. Finally, τ -restricted follow-up windows starting a = 3 units apart from
one another do not overlap and are assumed to have correlation ρ3.
The Toeplitz correlation structure requires fewer parameters than the unstruc-
tured matrix. For very large b, the Toeplitz correlation structure may be more fea-
sible to implement that an entirely unstructured variance matrix. GEE also pro-
vides model results based on robust sandwich variance estimation, which provides
protection against misspecification of the working correlation matrix. The general
recommendation when working with large datasets is to use the sandwich estimator,
regardless of the working correlation matrix assumed by the model. We follow this
recommendation throughout the remainder of the chapter.
5.4.1 Pseudo-Observation (PO) Approach For Censored Recurrent Events
For a single time-to-event, Andersen et al. (2004) introduced the idea of using
pseudo-observations (POs) in lieu of censored times-to-event when estimating regres-
sion parameters for the restricted mean model. This method has been successfully
applied in a variety of settings where a single event time is of interest (Klein and An-
dersen, 2005; Andersen and Klein, 2007; Andrei and Murray , 2007; Graw et al., 2009;
Xiang and Murray , 2012; Tayob and Murray , 2017). The appeal of this method is
its ease of use. That is, once appropriate pseudo-observations are estimated for each
patient, they can be used as if they are uncensored counterparts to the original cen-
sored data in standard regression models. In this section, we describe how to create
pseudo-observations that correspond to our censored longitudinal data structure. In
particular, for each follow-up window starting at t, we define pseudo observations for
the random variables log[min{τ, Ti(t)}], i = 1, . . . , N, using a method similar to that
described in Xiang and Murray (2012).
The general intuition behind pseudo-observation approaches for modeling censored
survival data is similar to that of the jackknife method (Quenouille, 1949, 1956; Tukey ,
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1958). One first defines a consistent nonparametric estimate, θˆ, of the marginal
quantity of interest, θ. In our setting, for each t ∈ {t1, . . . , tb}, we define θ(t) =
E[log{min(τ, T (t))}] with consistent nonparametric estimator
θˆ(t) = −
τ∫
0
log(u)dPˆ (Ti(t) > u) + log(τ)Pˆ (Ti(t) > τ),
where Kaplan-Meier estimation is used for Pˆ (Ti(t) > u).
The form of an appropriate PO for any setting arises from framing θ both as a
marginal mean and a weighted average of θZ , the conditional mean given covariates,
Z. Most readers will recognize this relationship when formally depicted as
θ =
∫
θZdFZ(z),
where dFZ(z) reflects Riemann-Stieltjes integration across the distribution of Z. When
the empirical (discrete) distribution of Z is used in framing the relationship above,
dFZ(z) = 1/N and the right hand side of the expression becomes
1
N
N∑
i=1
θZi .
One can algebraically isolate θZi (individual i’s mean given Zi) from the expression
above via
θZi = N
{
1
N
N∑
j=1
θZj
}
− (N − 1)
{
1
N − 1
N∑
j=1,j 6=i
θZj
}
.
Marginal means corresponding to the terms in curly brackets can be consistently es-
timated using nonparametric estimates θˆ and θˆ(−i), respectively, where θˆ(−i) is the
”leave-one-out” estimator of θ, i.e., estimated without individual i. So, taking ad-
vantage of large sample properties of θˆ and θˆ(−i), a natural pseudo-observation for
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individual i to use in modeling θZ is
Nθˆ − (N − 1)θˆ(−i),
a fully observed random variable that asymptotically shares a conditional mean, θZi ,
with patient i.
In our setting, θZ = E(log[min{τ, T }]|Z). For each t, we define pseudo-observations
POi(t) = Nθˆ(t)− (N − 1)θˆ(−i)(t), i = 1, . . . , N,
where
θˆ(−i)(t) = −
τ∫
0
log(u)dPˆ (−i)(Ti(t) > u) + log(τ)Pˆ (−i)(Ti(t) > τ),
where leave-one-out Kaplan-Meier estimation is used for Pˆ (−i)(Ti(t) > u), i.e., exclud-
ing patient i. We denote the vector of pseudo-observations contributed by individual
i as POi = {POi(t1), POi(t2), . . . , POi(tb)}. Parameter estimates for model (5.3) can
be estimated using the longitudinally created PO data via
E[PO|Z] = βTZ. (5.4)
Hereafter, we refer to estimates from equation (5.4) as estimates using the proposed
PO approach.
5.4.2 Multiple Imputation Approach for Censored Recurrent Events
Another approach for producing a complete dataset when a single time-to-event is
subject to censoring is multiple imputation (MI). This approach has been developed
by many authors (Faucett et al., 2002; Taylor et al., 2002; Hsu et al., 2006; Liu
et al., 2011; Xiang et al., 2014; Tayob and Murray , 2017). For our longitudinal
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data structure, we propose multiply imputing outcomes for observed data pairs with
{Xi(t) > 0, δi(t) = 0} , t ∈ {t1, . . . , tb}.
For our longitudinal data structure, the ith individual requires imputation for
times-to-first-event in the set, Si, of follow-up windows starting at times {t ∈ {t1, . . . , tb} :
Xi(t) > 0, δi(t) = 0}. If Si consists of more than one follow-up window, it suffices to
impute the time-to-first-event corresponding to the window starting at follow-up time
tsup(Si) = max{follow-up window start time t for windows ∈ Si}, which then deter-
mines imputes for all times-to-first-event in the set of follow-up windows, Si, that re-
quire imputation (See Appendix D.2 for further details). For better short-hand termi-
nology, we call the imputed event time corresponding to follow-up window start time
tsup(Si) the ’sup impute’, denoted as T˜i{tsup(Si)}, and the follow-up window starting
at time tsup(Si) the ’sup window’. Then imputed event times for follow-up windows
in Si with start times t∗ < tsup(Si) become T˜i{t∗} = T˜i{tsup(Si)}+ tsup(Si)− t∗.
The gestalt of the imputation strategy is to base the sup impute in the sup window
on model (5.4) using individual i’s covariates, Zi. Random error for the sup impute
is sampled nonparametrically from a set of residuals contributed by individuals in a
risk set, Ri, similar to individual i. Further details are described below.
The first step of the imputation procedure is to obtain parameter estimates, βˆPO,
from model (5.4). For individual i requiring a sup impute, T˜i{tsup(Si)}, in the sup
window, we then define a risk set, Ri, of candidate individuals l = 1, . . . , Ni satisfying
two constraints: (1) Xl{tsup(Si)} > Xi{tsup(Si)}, that is, candidate l is still at risk for
their first event time in the sup window as of the time individual i is censored and (2)
|βˆPOTZi− βˆPOTZl| ≤ , where  is a user-defined parameter that controls how similar
individual l’s linear predictor is to individual i’s linear predictor. Our algorithm used
 = 0.01. In cases where  resulted in a risk set with Ni < 5, our algorithm added
0.001 to  until Ni ≥ 5.
The next step of the imputation procedure is use candidate individuals, l =
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1, . . . , Ni,∈ Ri to estimate the survival function for T{tsup(Si)} given membership
in Ri. Nonparametric Kaplan-Meier estimation is used for this purpose, resulting in
estimate, SˆT{tsup(Si)}(v|Ri). Then an inverse transform imputation algorithm (Taylor
et al., 2002; Hsu et al., 2006; Liu et al., 2011; Xiang et al., 2014; Tayob and Murray ,
2017) is used to select an impute following the distribution of T{tsup(Si)} given mem-
bership in Ri based on SˆT{tsup(Si)}(v|Ri). In particular, the inverse transform imputa-
tion method first generates a uniform(0,1) random variable, u. If SˆT{tsup(Si)}(v|Ri) > u
for all observed event times v, we impute T˜i{tsup(Si)} = τ . Otherwise, we find the
smallest value v where SˆT{tsup(Si)}(v|Ri) ≤ u and identify the observed event time,
Tl{tsup(Si)}, that corresponds to v.
The inverse transform impute for patient i’s time-to-first-event in the sup window
would be Tl{tsup(Si)}. However, our proposed imputation algorithm goes one step
further, by defining residual εl = log(min[τ, Tl{tsup(Si)}])− βˆPOTZl and then defining
our final impute T˜i{tsup(Si)} = exp[βˆPOTZi+εl]. This extra step allows for variability
of the impute to be contributed by individial l, while further targeting the impute
using individual i’s covariate structure. If T˜i{tsup(Si)} < Xi{tsup(Si)}, we sample
another uniform(0,1), u, and repeat the process. This ensures that the impute occurs
beyond the last observed time participant i was at risk for a recurrent event in the
sup window.
We repeat the imputation procedure until we obtain M completed datasets and
then analyze the M imputed datasets with methods guided by Little and Rubin
(1986). For dataset m, we fit model (5.3) using GEE as described at the beginning
of this section and obtain parameter estimates, βˆMIm , and standard error estiamtes,
SˆE(βˆMIm ), for m = 1, . . . ,M . Then the final estimate of β from the multiple impu-
tation procedure becomes βˆMI =
∑M
m=1 βˆ
MI
m /M with corresponding standard error
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estimate,
SˆE(βˆMI) =
√√√√ M∑
m=1
SˆE(βˆMIm )
2/M + (1 +M−1)×
M∑
m=1
(βˆMIm − βˆMI)2/(M − 1).
5.5 Simulation
We now evaluate the finite sample performance of the proposed PO and MI meth-
ods for fitting equation (5.3) with simulated recurrent event data from N = 500
individuals over 5 years of follow-up. All simulation results are based on 10,000 iter-
ations. Details of how recurrent events times are simulated are described in sections
5.5.1 and 5.5.2, where independent and dependent recurrent event distributions are
considered, respectively.
In scenarios where censoring is present, the independent censoring random variable
is Ci = 5×I{Vi > 5}+Vi×I{Vi ≤ 5}, i = 1, . . . , 500, where Vi has an exponential dis-
tribution with hazard 1/14. This censoring mechanism corresponds to approximately
70% of participants having 5 years of follow-up, and 30% of participants being subject
to censoring prior to 5 years. In addition to summarizing Model (5.3) results where
censoring is handled via our customized PO and MI approaches, we report results in
the case where outcomes are fully observed through 5 years for comparison.
In each simulation scenario, we build our longitudinal data structure with follow-
up windows starting every a = 1 years apart at times t = 0, 1, 2 and 3 years with
τ = 2 years. These choices coincide with recommendations from Xia and Murray
(2018) based on the recurrent event distributions used in simulation.
With four follow-up windows generating four longitudinal outcomes, we require a
4× 4 working correlation structure to use with GEE software. We consider both (1)
unstructured and (2) Toeplitz structures, with robust sandwich estimates ultimately
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used in all inference. The Toeplitz structure takes the form

1 ρ1 ρ2 ρ2
ρ1 1 ρ1 ρ2
ρ2 ρ1 1 ρ1
ρ2 ρ2 ρ1 1

Since only adjacent τ -restricted follow-up windows have overlap in our setting with
t = 0, 1, 2, 3 and τ = 2, this structure requires only two parameters, as opposed to
six parameters used with the unstructured working correlation matrix.
5.5.1 Independent Times Between Recurrent Events
We first describe the scenario where times between recurrent events are indepen-
dent. Recall from Section 5.3 and Appendix D.1, that when gap times between events
for individual, i, are independent and identically distributed (i.i.d.) exponential(λi)
random variables, then Ti(t) is also marginally distributed as an exponential(λi) ran-
dom variable for each t ∈ {t1, . . . , tb}. Hence, if we generate times-to-first-event from
i.i.d exponential gap times, the mean structure for Ti(t), t ∈ {t1, . . . , tb}, will follow
the same mean structure as the simulated gap times. This offers some computational
convenience for generating outcomes that follow Model (5.3).
For the ith individual, we allow λi to depend on two covariates, i.e., Zi = {Bi, Ui},
where Bi a Bernoulli(0.5) random variable and Ui is a uniform(0,1) random variable.
We generate mild correlation between Bi and Ui using a Gaussian copula approach
(Li , 1999a). That is, we first generate bivariate normal(0, 1) pairs (Q1i = q1i, Q2i =
q2i) with correlation 0.3. We then define Bi = I(Q1i ≥ 0) and Ui = P (Q2i ≤ q2i); the
uniform(0, 1) distribution of Ui follows from the inverse transform theorem. Finally,
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we generate times-to-first-event for patient i, Ti, that satisfy model
E(log[min{τ, T }]|Z) = −0.7 + 0.5Bi + 0.5Ui.
This is accomplished by first simulating i.i.d. exponential(λi) gap times with λi taken
as the numerical solution to
logτ−∫
−∞
yλie
ye−λie
y
dy + e−λiτ × logτ = β0 + β1Bi + β2Ui
and then converting the resulting recurrent event times into times-to-first event as
described in Section 5.2.
Simulation results for the case with independent times between recurrent events
are shown in Table 5.1. For each method and each coefficient, we present simulation
averages for (1) βˆ, (2) bias βˆ−β and estimated robust standard errors (SEs) assuming
(3) unstructured or (4) Toeplitz working correlation matrices. We also report (5) the
empirical standard deviation (ESD) of βˆ across the 10,000 iterations and empirical
coverage probabilities (CP) for the true coefficient using robust standard errors and
either (6) unstructured or (7) Toeplitz working covariance matrices.
Both PO and MI approaches yield approximately unbiased estimates, with abso-
lute bias <0.003. SE results are suitably close to ESD results to ensure that variability
is being estimated well across all methods. As expected, standard errors are slightly
smaller when GEE is fit in the uncensored case compared to censored cases, since
more statistical information is available in the uncensored setting. However, there
is not a clear winner between the PO and MI methods for handling the censored
longitudinal data analysis. SEs attributed to the MI method are negligibly smaller
than those using the PO method; all coverage probabilities are suitably close to 0.95.
Both proposed PO and MI analysis methods perform well in our setting with 30%
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Coef. Method βˆ Bias ESD SE SE CP CP
Unstr. Toepl. Unstr. Toepl.
Uncen. -0.700 <0.001 0.057 0.057 0.057 0.945 0.944
β0 = −0.7 PO -0.702 -0.002 0.061 0.061 0.061 0.948 0.948
MI -0.698 0.002 0.060 0.060 0.060 0.947 0.948
Uncen. 0.503 0.003 0.054 0.054 0.054 0.945 0.946
β1 = 0.5 PO 0.503 0.003 0.058 0.057 0.057 0.942 0.946
MI 0.502 0.002 0.058 0.057 0.057 0.942 0.944
Uncen. 0.497 -0.003 0.089 0.092 0.092 0.958 0.959
β2 = 0.5 PO 0.498 -0.002 0.096 0.098 0.099 0.951 0.951
MI 0.497 -0.003 0.095 0.098 0.098 0.948 0.948
Table 5.1: Simulated Finite Sample Performance for N = 500 Individuals with Inde-
pendently Generated Times Between Recurrent Events. Results Are Based
on 10,000 Iterates.
(Coef.: True value of the coefficient;
For Methods, Uncen.: standard GEE approach applied to uncensored version of the data,
PO: pseudo observation approach, MI: multiple imputation approach;
For remaining column headings, βˆ: average coefficient estimate; Bias: average βˆ − β; ESD:
empirical standard deviation of βˆ; SE Unstr.: the average estimated robust standard error
using an unstructured working correlation matrix; SE Toepl.: the average estimated
robust standard error using a Toeplitz working correlation matrix; CP Unstr.: empirical
coverage probability for true coefficient based on 95% confidence interval using robust
standard error with an unstructured working correlation matrix; CP Toepl.: empirical
coverage probability for true coefficient based on 95% confidence interval using robust
standard error with an Toeplitz working correlation matrix.)
of patients censored. In practice, the PO method is particularly easy to program
compared to the MI method and runs a bit more quickly, since the PO method is
nested within the MI method. We suspect the PO method will be implemented more
in practice as a result.
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5.5.2 Simulating Distribution of Times-to-First-Event Based on Corre-
lated Times Between Recurrent Events and Comparison of Pro-
posed Methods
Simulating a multivariate time-to-first-event distribution is more complex when
times between events are correlated random variables. Recall from Section 5.3 that
positive correlation between exponential(λi) gap times causes the corresponding dis-
tribution for T to change; that P{Ti(t) > u} tends to be smaller than an exponential(λi)
survival function and stabilizes after approximately t > 1/λi follow-up units of gap-
time history has passed. The intuition behind this phenomenon, described in Section
5.3, also suggests the approach for successfully simulating the desired stable multivari-
able distribution for T to be used in this section. That is, upon simulating correlated
exponential(λi) gap times for individual i, we discard at least the first 1/λi follow-up
units of generated information, starting t1 = 0 for individual i after this ’burn-in’
period has passed.
To verify that our model works correctly for finite sample sizes when exponen-
tially distributed times between event are correlated, we need (1) to generate data
that follows model (5.3) for this setting and (2) have a way to verify that estimated
parameters appropriately represent the data. To address (2), we assume a categorical
predictor, Z = {0, 1, 2}, so that E(log[min{τ, Ti(t)}]|Z) can be consistently estimated
from a large dataset (N=10,000) within each level of Z via an empirical mean. From
this model-free process, we can determine values, β˜, of regression parameters that
should be estimated if model (5.3) is working correctly. In particular, we assume
that individuals with Zi = 0, 1 or 2 have a history of exponential gap times with
λi = 1/2, 1/3 or 1/5, respectively, where correlation between any two gap times from
individual i is approximately 0.8. Stabilization of the resulting multivariate time-to-
first-event process is done by defining t1 = 0 after a burn-in period of 5 follow-up
units has passed for each individual.
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A Gaussian copula approach (Li , 1999a) is used to generate correlated exponen-
tial gap times in this section and section 5.3. This approach first simulates mean zero
multivariate normal random variables {Qi1, Qi2, . . . , Qi500} with variance one and 0.8
correlation between Qij and Qij′, for j 6= j′; 500 was chosen to ensure that individuals
would have at least 10 years of gap time history (5 year burn-in period, followed by
5 years of potential follow-up, subject to the previously described censoring mecha-
nism). We then transform the multivariate normal random variables to multivariate
uniform(0,1) and then multivariate exponential random variables via repeated ap-
plications of the inverse transform theorem. The exponential random variables that
result from this process become the correlated gap times {Gi1, Gi2, . . . , Gi500}, which
are then converted into times-to-first event as described in Section 5.2.
Figure 5.4 shows the empirical average of log[min{2, Ti(t)}] for each value of
Z = {0, 1, 2} based on N = 10, 000 individuals with correlated exponential gap time
histories as generated using the copula approach described above. As expected based
on the stabilization of the survival curves seen in Figure 5.3, the empirical average
of log[min{τ, Ti(t)}] seems to stabilize successfully after the 5 year burn-in period.
Results from t = 5 to t = 8 in this figure are averaged to provide nonparametric large
sample estimates, β˜, of parameters in model 5.3:
E(log[min{τ, T }]|Z) = −0.677 + 0.306I(Z = 1) + 0.637I(Z = 2).
Finite sample properties of our PO and MI methods shown in Table 5.2 are based
on N=500 individuals simulated to have an equal chance of following the simulated
time-to-first-event longitudinal data structure governed by covariate values, Z = 0, 1
or 2. The case where these subjects are not subject to censoring is also presented for
comparison. Results are laid out in a similar manner to that seen in Table 5.1, except
that bias is defined in relation to the nonparametric large sample estimate, β˜ rather
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Figure 5.4: Empirical Average of log[min{2, Ti(t)}], Based on N=10,000 Individuals
with Correlated Exponential Gap Time Histories per Curve; Correlation
is Approximately 0.8; t ∈ {0, . . . , 8}; a= 0.1 Units Apart. Curves Seem
to Stabilize after Shaded Burn-in Period of 5 Years.
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Coef. Method βˆ Bias ESD SE SE CP CP
Unstr. Toepl. Unstr. Toepl.
Uncen. -0.671 0.006 0.076 0.075 0.075 0.940 0.940
β˜0=-0.677 PO -0.669 0.008 0.078 0.078 0.078 0.943 0.944
MI -0.670 0.007 0.078 0.077 0.077 0.943 0.945
Uncen. 0.302 -0.004 0.102 0.102 0.103 0.948 0.950
β˜1=0.306 PO 0.300 -0.006 0.105 0.106 0.106 0.952 0.953
MI 0.302 -0.004 0.105 0.106 0.106 0.951 0.950
Uncen. 0.622 -0.015 0.099 0.097 0.097 0.945 0.946
β˜2=0.637 PO 0.617 -0.020 0.101 0.100 0.101 0.944 0.946
MI 0.621 -0.016 0.101 0.100 0.100 0.944 0.946
Table 5.2: Simulated Finite Sample Performance for N = 500 Individuals with Cor-
related Times Between Recurrent Events. Results Are Based on 10,000
Iterates.
(Coef.: True value of the coefficient;
For Methods, Uncen.: standard GEE approach applied to uncensored version of the data,
PO: pseudo observation approach, MI: multiple imputation approach;
For remaining column headings, βˆ: average coefficient estimate; Bias: average βˆ − β˜; ESD:
empirical standard deviation of βˆ; SE Unstr.: the average estimated robust standard error
using an unstructured working correlation matrix; SE Toepl.: the average estimated
robust standard error using a Toeplitz working correlation matrix; CP Unstr.: empirical
coverage probability for true coefficient based on 95% confidence interval using robust
standard error with an unstructured working correlation matrix; CP Toepl.: empirical
coverage probability for true coefficient based on 95% confidence interval using robust
standard error with an Toeplitz working correlation matrix.)
than a true β, since a closed form value for the true β is unavailable.
Results are generally comforting. Again the MI method has very slightly smaller
SE estimates when compared to the PO method. All coverage probabilities are close
to the desired 95%. Interesting, parameter estimate bias is smallest for the groups
where the burn-in period of 5 years was longer than their respective 1/λi values would
have suggested (βˆ0 and βˆ1). These results verify that both the PO and MI methods
estimate parameters with good finite sample properties in this case, but also verify
that we have successfully simulated this complex data structure.
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5.6 Example
In this section, we use the proposed methods to analyze results from the Azithromycin
in COPD Trial. This study followed 1112 patients with a history of acute exacer-
bations (AEs) for recurrent AEs after randomization to either placebo or 250mg
azithromycin daily. This trial ended with favorable results for the azithromycin arm
(Albert et al., 2011), based on an analysis of the time to first acute exacerbation
using the logrank test. Multivariable Cox proportional hazard analysis modeling
time-to-first-exacerbation confirmed azithromycin benefit after adjustment for forced
expiratory volume in one second (FEV1), age, gender, smoking status and study sites.
In our analysis, we estimate parameters in Model (5.3) for τ = 6 months and a
longitudinal data structure, T , measuring times-to-first-recurrent-event in follow-up
windows starting at times t = 0, 2, 4, 6 months. Our selections of τ=6 and a = 2
months are based on the 6-month historic mean time-to-exacerbation in this patient
population and recommendations from Xia and Murray (2018) that approximately
90% of recurrent events should be captured when spacing windows apart by one-third
of a historic mean.
We present results from a univariate analysis that evaluates azithromycin versus
placebo, a forest plot analysis of treatment effect in subgroups of interest, and a mul-
tivariable analysis of treatment effect that adjusts for age, gender, FEV1, smoking
status and study site. We tested for and found no statistically significant interactions
between follow-up window start times and treatment, indicating relatively stable pat-
terns of treatment effect over time (p > 0.41). The Toeplitz working correlation struc-
ture gave a slightly lower QIC value compared to the unstructured working correlation
structure in our multivariable model and was used in all models of the azithromycin
data. All confidence intervals and p-values are based on robust sandwich estimation
of variability.
Forest plots of univariate treatment effects, overall and by subgroup, are shown in
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Figure 5.5 for the PO (left panel) and MI (right panel) methods. Tabulated versions
of these results are located in Supplemental Table D.1 in Appendix D.3. Treatment ef-
fects are displayed on the scale of eβˆ and can be interpreted as multiplicative increases
(or decreases) on the time to first exacerbation over the next 6 months of follow-up.
Overall, azithromycin is estimated to extend the time to the first exacerbation over a
6 month period by approximately 14% using either the PO or the MI method (95% CI
approximately 5%-24% longer, p=0.002 for PO method and p=0.001 for MI method).
Stated as an absolute difference, there was an estimated 0.43 month increase in time-
to-first-exacerbation for the azithromycin group compared to the placebo group over
a 6-month period (I.e., eβˆ0+βˆ1 − eβˆ0 ≈ 0.43 using either the PO or MI method).
Across the various subgroup analyses shown in Figure 5.5 and Table D.1, the
treatment benefit was most pronounced in COPD patients with better preserved
lung function, that is, FEV1 % of predicted > 50 % (approximately 29% longer time
to first exacerbation in the next 6 months, 95% CI 10%-51% longer using PO method
and 11%-50% longer using MI method). In general, point estimates shown for the
PO and MI methods in Table D.1 are very close to one another and 95% CI results
for the methods are also close, but with slightly narrower CI widths using the MI
approach. P-values for the MI method are also slightly smaller using the MI versus
the PO method.
As seen in Table 5.3, the azythromycin group maintains its estimated treatment
benefit when adjusted for confounders in a multivariable model using either the PO
or MI method (approximately 15% longer time to first exacerbation in the next 6
months, 95% CI 6%-25% longer, p=0.001, using PO method and 6%-24% longer, p
< 0.001, using MI method. Interactions between treatment and FEV1, age, gender,
smoking status other than study sites were tested and no significant interactions were
found.
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Figure 5.5: Forest Plot of Univariate Treatment Effects, Overall and by Subgroups of
Interest.
PO MI
eβˆ 95% CI P eβˆ 95% CI P
Intercept 60.34 41.17 88.43 <0.001 61.28 42.33 88.72 <0.001
Azithromycin (vs. Placebo) 1.153 1.063 1.250 0.001 1.150 1.063 1.244 <0.001
FEV1 (per 10% Predicted) 1.041 1.013 1.068 0.003 1.039 1.013 1.066 0.003
Age (per 10 Years) 1.052 0.999 1.108 0.055 1.052 1.001 1.107 0.046
Male (vs. Female) 1.181 1.084 1.287 <0.001 1.171 1.078 1.272 <0.001
Current Smoker (vs. Ex) 1.074 0.967 1.193 0.184 1.071 0.967 1.186 0.188
Table 5.3: Multivariable Results Using PO and MI Methods. Displayed Estimates
Are Additionally Adjusted for Center [Data Not Shown].
(CI: confidence interval; PO: pseudo-observation; MI: multiple imputation.)
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5.7 Discussion
In this chapter, we take a fresh look at the manner in which recurrent event
data is analyzed. By first restructuring the data into a censored longitudinal form,
and then transforming the data via PO or MI models into a complete data format,
we are able to take advantage of existing software from longitudinal data analysis
literature. Our model estimates time free from recurrence over a τ -length follow-
up period. In our opinion, this model gives a clear manner of assessing clinical and
statistical significance of associations simultaneously. As with most longitudinal data,
our method allows for either time-independent or dependent predictors.
We develop two methods for handling censoring that allow standard GEE methods
to be applied to our censored longitudinal data structure: a PO approach and an MI
approach. Both the methods have attractive performance in simulation, even with
high correlation underlying the multivariate gap time distribution.
Experts in multiple imputation theory often prefer these methods to include a
draw from the parameter space, going as far as to say that imputation must include
this step to be proper. The argument is bolstered by noticeably improved coverage
probabilities when this step is included in some cases. In our own work with in-
verse probability transform imputation methods, we have not observed a sufficient
improvement in coverage probabilities to justify the extra computing time needed to
perform this extra step. Although purists will likely agree to disagree, we feel com-
fortable recommending our imputation algorithm, as is, given the very solid coverage
probability results seen in simulation.
An additional contribution of our research is a better understanding of how times-
to-first-event fit within the context of recurrent events data. In most practical clinical
settings, follow-up begins at a clinic visit that does not coincide with a recurrent
event. When patients are scheduled for their next visit, likewise, this is unlikely to
occur at a recurrent event time. Hence in practice, the information most relevant to a
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patient is what to expect between clinic visits, and this is closer to a time-to-first-event
analysis than a gap time analysis. By constructing a longitudinal data structure built
from times-to-first-event, and evaluating this analysis in the presence of dependent
gap times, we have introduced some needed intuition about how these distributions
behave. The notion that the mixture of gap time histories prior to the moment a
patient walks into a clinic for advice influences the time-to-first-event with correlated
gap times, but not independent gap times, seems obvious in hindsight. However,
simulating a stable time-to-first-event distribution required a better understanding of
this process, and led to our suggestion of a burn-in period for simulating this data.
We are hopeful that other researchers will benefit from this simulation framework
alone.
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CHAPTER VI
Conclusion
The objective of this dissertation is to develop study design and analysis methods
for testing or predicting the τ -restricted survival/event-free time from a repurposed
censored longitudinal data framework. We emphasize the advantage of using the
restricted time as a more interpretable outcome, with less assumptions, and hope to
contribute to methods for analyzing restricted survival/event-free times as alternative
tools to hazard-oriented methods. To this end, we estimate the restricted time-to-first-
event based on a paradigm shift from traditionally recorded censored time-to-event
and recurrent events data. The philosophy hinges on the idea that traditional time
data can be transformed into censored short-term outcomes measured longitudinally
over potentially overlapping follow-up periods of length τ . Further tests and analysis
of the τ -restricted survival/event-free time can benefit from shifting our thoughts on
traditional time data structure towards the longitudinal outcomes.
In Chapter II-V, we consider three practical settings that can benefit statistically
from repurposing traditional data into this censored longitudinal data structure. The
first setting is clinical trial design and analysis where the outcome of interest is a
single time-to-event compared between treatments. Chapter II develops a new two-
sample test based on the restructured censored longitudinal data paradigm along
with corresponding methods for group sequentially monitoring across several planned
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interim analyses. Simulations suggest that shifting towards a longitudinal view of
censored survival outcomes has practical advantages. Our proposed test procedure
performs well not only in scenarios where short-term differences are anticipated to
be stable, but also in settings that it may be hard to anticipate in the design stage
of a clinical trial. When treatment differences emerge only after a certain period of
time or in settings where there is potential for cure, we find our test has a notably
improved performance over its competitors.
The second setting is also based on group sequential monitoring of clinical trial
data, where instead of a single time-to-event endpoint the primary endpoints are re-
current in nature and can be subject to a terminating event. Chapter III develops
group sequential methods for monitoring the Tayob and Murray (2014) statistic in
this case. Our method is appropriate and robust for events that are correlated within
an individual or for completely independent event times. Treatment effects observed
across analysis times are simple to interpret. Besides, the assumption of propor-
tionality between groups of the cumulative mean number of events over time is not
required. Focusing on the time from the pre-specified windows’ start instead of the
previous event avoids dependent censoring issues. Chapter IV also provides a useful
guide to help construct the data frame with more intelligence for the second setting.
The recommendation is framed to seek a balance between the average proportion of
recurrent events captured in at least one window and computational efficiency. We
suggest a convenient rule of thumb of choosing spaced time that ensures at least 80%
events are captured to achieve a decent power.
In our third and final setting, we develop multivariable models of recurrent events
based on the censored longitudinal data framework in Chapter V. Instead of analyzing
recurrent events based on intensity function or gap times, we propose to focus on the
time free from recurrence over a prespecified follow-up period whenever an individual
is at risk. Approaches of pseudo-observations and multiple imputations are utilized
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to account for censoring and result a complete data set for further analysis with GEE
model. We generalize and integrate the existing methods in a new way to analyze
the censored longitudinal data transformed from recurrent events. Thus we provide a
fresh perspective of assessing patients’ progression status based on recurrent events.
We also give a guide on how to implement and present our methods by the example
data from the Azithromycin in COPD Trial.
This dissertation plus the researches from Tayob and Murray (2014, 2016, 2017)
give a road map of the paradigm shifting from the traditionally recorded time data
into a censored longitudinal data framework. To sum up, methods benefit from
the data reconstruction include: (1) the improved estimation of τ -restricted mean
survival time; (2) nonparametric two-sample tests of single time analysis and group
sequentially monitoring for two types of data: the standard censored time-to-event
data and recurrent events data subject to terminal events and censoring; and (3)
multivariable methods for τ -restricted outcomes drawn from single time-to-event data
as well as recurrent events data.
97
APPENDICES
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APPENDIX A
Supplementary Materials for Chapter II
A.1 Derivation of the Asymptotic Joint Distribution of the
Proposed Test Statistic at Interim Analysis Times
In this section, we derive the asymptotic joint distribution of the proposed test
statistics, T (s1), . . . ,T (sK) at interim analysis times, s1, . . . , sK . The overall strat-
egy is to first show that the vector of test statistics, {T (s1), . . . ,T (sK)} , is asymp-
totically equivalent in distribution to the more tractable vector of random variables,
{T ∗(s1), . . . ,T ∗(sK)}, where elements of this latter vector are based on sums of in-
dependent and identically distributed quantities. From there, a standard application
of the multivariate central limit theorem gives the desired result.
Our test statistic at analysis time s,
T (s) =
√
n1(s)n2(s)
n1(s) + n2(s)
{µˆ1(s, τ)− µˆ2(s, τ)},
can be rewritten as
T (s) =
√
n2(s)
n1(s) + n2(s)
√
n1(s)µˆ1(s, τ)−
√
n1(s)
n1(s) + n2(s)
√
n2(s)µˆ2(s, τ), (A.1)
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where ng(s)/{n1(s) + n2(s)} p→ pig(s). Suppose at analysis time s, combining infor-
mation across b follow-up windows of length τ , we record M events {0 ≡ T0 < T1 <
... < TM < TM+1 ≡ τ}. Then, by Taylor series expansion,
√
ng(s)µˆg(s, τ) =
√
ng(s)
M∑
m=0
(Tm+1 − Tm)exp
{
−
m∑
j=0
dNg(s, Tj)
Yg(s, Tj)
}
is asymptotically equivalent in distribution to the following terms:
√
ng(s)
M∑
m=0
(Tm+1 − Tm) exp
{
−
m∑
j=0
λWg (s, Tj)dTj
}
(A.2)
+
√
ng(s)
M∑
m=0
(Tm+1 − Tm)
[ m∑
j=0
−exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
dNg(s, Tj)
Yg(s, Tj)
]
(A.3)
−
√
ng(s)
M∑
m=0
(Tm+1 − Tm)
[ m∑
j=0
−exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
λWg (s, Tj)dTj
]
(A.4)
+
√
ng(s)
M∑
m=0
(Tm+1 − Tm) 1
2!
exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
[ m∑
j=0
{
dNg(s, Tj)
Yg(s, Tj)
− λWg (s, Tj)dTj
}]2 (A.5)
+
√
ng(s)
M∑
m=0
(Tm+1 − Tm)[higher order terms] (A.6)
Using arguments similar to those in Tayob and Murray (2016) Appendix B, terms
(A.5) and (A.6) converge to zero in probability. When there is no treatment effect
(i.e., the null hypothesis is true), terms (A.2) and (A.4) for group g = 1 will cancel the
corresponding terms for group g = 2 in the test statistic T (s). Hence, the asymptotic
distribution of T (s) is based on the behavior of term (A.3) for groups g = 1, 2. Term
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(A.3) can be further rewritten as
√
ng(s)
M∑
m=0
(Tm+1 − Tm)
[ m∑
j=0
−exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
dNg(s, Tj)
Yg(s, Tj)
]
= −
√
ng(s)
M∑
m=0
(Tm+1 − Tm)exp{−
m∑
j′=0
λWg (s, Tj′)dTj′}
m∑
j=0
dNg(s, Tj)
Yg(s, Tj)
,
which is asymptotically equivalent in distribution (via Taylor series) to
−
√
ng(s)
M∑
m=0
(Tm+1 − Tm)exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
×
{
m∑
j=0
EdNg(s, Tj)
EYg(s, Tj)
(A.7)
+
m∑
j=0
[
1
EYg(s, Tj)
[dNg(s, Tj)− EdNg(s, Tj)]− EdNg(s, Tj)
EYg(s, Tj)2
[Yg(s, Tj)− EYg(s, Tj)]
]
(A.8)
+[higher order terms]} . (A.9)
Using arguments similar to those in Tayob and Murray (2016) Appendix B once
again, the higher order terms in (A.9) converge to zero in probability. In addition
when the null hypothesis is true, term (A.7) for group g = 1 will cancel with its coun-
terpart term for g = 2 in the test statistic T (s). Hence, the asymptotic distribution
of T (s) is based on the behavior of term (A.8) for groups g = 1, 2 which upon noting
that EdNg(s, Tj)/EYg(s, Tj) = λ
W
g (s, Tj) and EYg(s, Tj) =
∑b
l=1 Pr(Xgi(s, tl) ≥ Tj)
can be algebraically rearranged as:
−
√
ng(s)
M∑
m=0
(Tm+1−Tm)exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
m∑
j=0
dNg(s, Tj)− Yg(s, Tj)λWg (s, Tj)∑b
l=1 Pr(Xgi(s, tl) ≥ Tj)
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or returning to more standard stochastic integral notation as:
−
√
ng(s)
τ∫
0
exp
−
u2∫
0
λWg (s, u1)du1

u2∫
0
dNg(s, u1)− Yg(s, u1)λWg (s, u1)∑b
l=1 Pr(Xgi(s, tl) ≥ u1)
du2.
(A.10)
Summarizing calculations from equation (A.1) to equation (A.10),
T (s) =
√
n2(s)
n1(s) + n2(s)
√
n1(s)µˆ1(s, τ)−
√
n1(s)
n1(s) + n2(s)
√
n2(s)µˆ2(s, τ)
is asymptotically equivalent in distribution to
√
pi1(s)
√
n2(s)
τ∫
0
exp
−
u2∫
0
λW2 (s, u1)du1

u2∫
0
dN2(s, u1)− Y2(s, u1)λW2 (s, u1)∑b
l=1 Pr(X2i(s, tl) ≥ u1)
du2
−
√
pi2(s)
√
n1(s)
τ∫
0
exp
−
u2∫
0
λW1 (s, u1)du1

u2∫
0
dN1(s, u1)− Y1(s, u1)λW1 (s, u1)∑b
l=1 Pr(X1i(s, tl) ≥ u1)
du2.
From here, we note that the remaining terms above can be written in terms
of independent and identically distributed random variables that lend themselves
to standard limiting distribution results via the multivariate central limit theorem.
Recall that
Ng(s, u) =
ng(s)∑
i=1
Ngi(s, u) =
ng(s)∑
i=1
b∑
j=1
Ngi(s, tj, u)
and
Yg(s, u) =
ng(s)∑
i=1
Ygi(s, u) =
ng(s)∑
i=1
b∑
j=1
Ygi(s, tj, u).
Define:
Zij{µˆg(s, τ)} =
τ∫
0
exp
−
u2∫
0
λWg (s, u1)du1

u2∫
0
dNgi(s, tj , u1)− Ygi(s, tj , u1)λWg (s, u1)du1∑b
l=1 Pr(Xgi(s, tl) ≥ u1)
du2
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and
Zi{µˆg(s, τ)} =
b∑
j=1
Zij{µˆg(s, τ)}.
Note that Zi{µˆg(s, τ)} only depends on patient i and is independent and identically
distributed for i = 1, . . . , ng(s). Using this notation, the above asymptotically equiv-
alent representation of the distribution of T (s) becomes
T ∗(s) =
√
pi1(s)
√
n2(s)
∑n2(s)
i=1 Zi{µˆ2(s, τ)}
n2(s)
−
√
pi2(s)
√
n1(s)
∑n1(s)
i=1 Zi{µˆ1(s, τ)}
n1(s)
.
(A.11)
Application of the multivariate central limit theorem to the vector of test statistics
{T ∗(s1), . . . ,T ∗(sK)} calculated at calendar times, s1, s2, . . . , sK (K finite), gives a
limiting multivariate normal distribution as ng(s1) → ∞, g = 1, 2, with asymptotic
covariance matrix estimated empirically as described in Appendix A.2. A closed-form
version of the asymptotic covariance is described in Appendix A.3.
For convenience, we explicitly describe the special case where only a single analysis
is performed. When the null hypothesis is true, the asymptotic limiting distribution
of T (s) is Normal with mean 0 and variance pi2(s)σ21(s)+pi1(s)σ
2
2(s), where σ
2
g(s), g =
1, 2 is the variance of Zi(µˆg(s, τ)) and can be estimated using the sampling variability
of Zi{µˆg(s, τ)}, that is, σˆ2g(s) =
∑ng(s)
i=1 [zi{µˆg(s, τ)}− z¯{µˆg(s, τ)}]2/[ng(s)− 1], where
zi{µˆg(s, τ)} =
b∑
j=1
zij{µˆg(s, τ)}; z¯{µˆg(s, τ)} =
ng(s)∑
i=1
zi{µˆg(s, τ)}/ng(s)
and zij{µˆg(s, τ)} =
τ∫
0
exp
−
u2∫
0
dNg(s, u1)
Yg(s, u1)


u2∫
0
dNgi(s, tj, u1)− Ygi(s, tj, u1)dNg(s,u1)Yg(s,u1)
Yg(s, u1)/ng(s)
 du2. (A.12)
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For finite sample sizes, we use a standardized version of the test statistic,
T˜ (s) =
T (s)√
pˆi2(s)σˆ21(s) + pˆi1(s)σˆ
2
2(s)
,
which has an approximate Normal(0,1) distribution, with critical values of ± 1.96
conferring an overall type I error of 5% when a single analysis is performed.
A.2 Empirical Covariance Matrix for
{
T˜ (s1), . . . , T˜ (sK)
}
In this appendix, we describe how to estimate the empirical version of the K ×
K asymptotic covariance matrix, Σ, corresponding to standardized test statistics,{
T˜ (s1), . . . , T˜ (sK)
}
. By design, diagonal elements of this matrix are equal to one,
so that this covariance matrix is also a correlation matrix. Off-diagonal elements,
σk1k2 = σk2k1 , k1 < k2, can be estimated based on the more updated dataset at
analysis sk2 .
In Appendix A.1, we show that {T (s1), . . . ,T (sK)} is asymptotically equivalent
in distribution to {T ∗(s1), . . . ,T ∗(sK)}. Similarly, for the standardized version of
each test statistic, T˜ (sk), sk = s1, . . . , sK , we work with the corresponding asymptoti-
cally equivalent in distribution standardized form, T ∗(sk)/
√
pi2(sk)σ21(sk) + pi1(sk)σ
2
2(sk).
Hence, off-diagonal elements σk1k2 = σk2k1 , k1 < k2, of the covariance matrix, Σ, can
be estimated by
σˆk1k2 =
ˆCov {T ∗(sk1),T ∗(sk2)}√
pˆi2(sk1)σ˜
2
1(sk1) + pˆi1(sk1)σ˜
2
2(sk1)
√
pˆi2(sk2)σˆ
2
1(sk2) + pˆi1(sk2)σˆ
2
2(sk2)
(A.13)
We define each component of σˆk1k2 in more detail below.
Estimated terms that use the most up-to-date information at analysis time sk2
have already been described for σˆ2g(sk2), g = 1, 2, in Appendix A.1, captured by terms
in equation (A.12). Appendix A.1 also defines pˆig(sk) = ng(sk)/{n1(sk) + n2(sk)},
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for g = 1, 2 and sk = sk1 , sk2 . Estimates of σ
2
g(sk1), g = 1, 2 used in the covari-
ance estimate are modified to take advantage of additional information available
at sk2 for estimating terms that do not depend on analysis time. In particular,
since both dNgi(sk1 , tj, u1)/Ygi(sk1 , tj, u1) and dNgi(sk2 , tj, u1)/Ygi(sk2 , tj, u1) estimate
λgi(tj, u1)du1, and the latter term uses more data, we replace dNgi(sk1 , tj, u1) in equa-
tion (1) with Ygi(sk1 , tj, u1)× dNgi(sk2 , tj, u1)/Ygi(sk2 , tj, u1). Similarly in equation
(A.12), we replace Yg(sk1 , u1)/ng(sk1), which is an estimate of∑b
l=1 Pr(Tgi(sk1 , tl) ≥ u1)Pr(Cgi(sk1 , tl) ≥ u1), with
[∑ng(sk2 )
i=1 I{Tgi ≥ u1 + tl}/ng(sk2)
]
×
[∑ng(sk1 )
i=1 I{Cgi(sk1) ≥ u1 + tl}/ng(sk1)
]
. Here, terms involving the event time are
estimated using updated data, while terms involving the censoring distribution remain
relevant to analysis time sk1 . Putting these modifications together gives us
z˜ij{µˆg(sk1 , τ)} =
τ∫
0
exp{−
u2∫
0
dNg(sk1 , u1)
Yg(sk1 , u1)
}
[ u2∫
0
b∑
l=1
ng(sk2 )∑
i=1
I{Tgi ≥ u1 + tl}
ng(sk1 )∑
i′=1
I{Cgi′(sk1) ≥ u1 + tl}

−1
× ng(sk1)ng(sk2)Ygi(sk1 , tj, u1)
{
dNgi(sk2 , tj, u1)
Ygi(sk2 , tj, u1)
− dNg(sk1 , u1)
Yg(sk1 , u1)
}]
du2
as an updated version of zij{µˆg(sk1 , τ)} for use in covariance terms. And mimicking
Appendix A.1 notation, σ˜2g(sk1) used in equation (A.13) is calculated by replacing
zij{µˆg(sk1 , τ)} with z˜ij{µˆg(sk1 , τ)} terms in corresponding formulas for σˆ2g(sk1) from
Appendix A.1.
The only remaining undefined term from equation (A.13) is ˆCov {T ∗(sk1),T ∗(sk2)} ,
which is described in the following. From equation (A.11),
Cov {T ∗(sk1),T ∗(sk2)}
=
2∑
g=1
Cov
[√
pi3−g(sk1)
√
ng(sk1)
∑ng(sk1 )
i=1 Zi{µˆg(sk1 , τ)}
ng(sk1)
,
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√
pi3−g(sk2)
√
ng(sk2)
∑ng(sk2 )
i=1 Zi{µˆg(sk2 , τ)}
ng(sk2)
]
.
Without loss of generality, assume k1 ≤ k2 so that ng(sk1) ≤ ng(sk2) and there are
ng(sk1) patients contributing (correlated) data from both analysis times. Then the
previous expression reduces to
=
2∑
g=1
√
pi3−g(sk1)
√
pi3−g(sk2)
ng(sk1)√
ng(sk1)ng(sk2)
Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] ,
which is asymptotically equivalent to
=
2∑
g=1
√
pi3−g(sk1)pi3−g(sk2)ψg(sk1 , sk2)Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}]
where ψg(sk1 , sk2) is the limiting proportion of patients entered at sk1 of those even-
tually entered by sk2 of group g, that is estimated by ng(sk1)/ng(sk2).
In practice, Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] can be estimated based on the em-
pirical covariance of sample realizations of Zi{µˆg(sk1 , τ)} and Zi{µˆg(sk2 , τ)}, that is,
ˆCov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] =
ng(sk1 )∑
i=1
[z˜i{µˆg(sk1 , τ)} − ¯˜z{µˆg(sk1 , τ)}][zi{µˆg(sk2 , τ)} − z¯{µˆg(sk2 , τ)}]
ng(sk1)− 1
, where
z˜i{µˆg(sk1 , τ)} =
∑b
j=1 z˜ij{µˆg(sk1 , τ)}, ¯˜z{µˆg(sk1 , τ)} =
∑ng(sk1 )
i=1 z˜i{µˆg(sk1 , τ)}/ng(sk1).
Putting each described component into equation (A.13), we have the version of σˆk1k2
listed in Chapter 2.4.
A.3 Closed Form Covariance Matrix for
{
T˜ (s1), . . . , T˜ (sK)
}
At times it is convenient to have an asymptotic closed form version of the co-
variance matrix for
{
T˜ (s1), . . . , T˜ (sK)
}
, for instance in assessing whether an inde-
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pendent increments variability structure is present. Working from results in the last
paragraph of Appendix A.2, instead of estimating Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}]
with the empirical covariance, in this section we derive its asymptotic closed-form
formula. Consider Zi{µˆg(sk, τ)} =
∑b
j=1 Zij{µˆg(sk, τ)} at analysis times sk = sk1
and sk2 and recall that group g patients are independent and identically distributed.
Then
Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] =
b∑
j=1
b∑
j′=1
Cov [Zij{µˆg(sk1 , τ)}, Zij′{µˆg(sk2 , τ)}] .
For notational simplicity, we submerge the group indicator g as we work with the
summand term above. That is,
Cov [Zij{µˆg(sk1 , τ)}, Zij′{µˆg(sk2 , τ)}]
=
b∑
j=1
b∑
j′=1
τ∫
0
τ∫
0
exp{−
u2∫
0
λW (sk1 , u1)du1}exp{−
v2∫
0
λW (sk2 , v1)dv1}
×
u2∫
0
v2∫
0
1∑
l Pr(Xi(sk1 , tl) ≥ u1)
∑
l′ Pr(Xi(sk2 , tl′) ≥ v1)
× Cov
{
dNi(sk1 , tj, u1)− Yi(sk1 , tj, u1)λW (sk1 , u1)du1, dNi(sk2 , tj′, v1)
− Yi(sk2 , tj′, v1)λW (sk2 , v1)dv1
}
du2dv2.
Focusing on this last term:
Cov
{
dNi(sk1 , tj, u1)− Yi(sk1 , tj, u1)λW (sk1 , u1)du1,
dNi(sk2 , tj′, v1)− Yi(sk2 , tj′, v1)λW (sk2 , v1)dv1
}
= E[dNi(sk1 , tj, u1)dNi(sk2 , tj′, v1)] (A.14)
−λW (sk1 , u1)E[Yi(sk1 , tj, u1)dNi(sk2 , tj′, v1)]du1 (A.15)
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−λW (sk2 , v1)E[Yi(sk2 , tj′, v1)dNi(sk1 , tj, u1)]dv1 (A.16)
+λW (sk1 , u1)λ
W (sk2 , v1)E[Yi(sk1 , tj, u1)Yi(sk2 , tj′, v1)]du1dv1 (A.17)
−E[dNi(sk1 , tj, u1)− Yi(sk1 , tj, u1)λW (sk1 , u1)du1] (A.18)
×E[dNi(sk2 , tj′, v1)− Yi(sk2 , tj′, v1)λW (sk2 , v1)dv1]. (A.19)
Term (A.14) becomes:
E[dNi(sk1 , tj, u1)dNi(sk2 , tj′, v1)] = lim
∆u1,∆v1→0
Pr{u1 ≤ Xi(sk1 , tj) < u1 + ∆u1,
δi(sk1 , tj) = 1,
v1 ≤ Xi(sk2 , tj′) < v1 + ∆v1,
δi(sk2 , tj′) = 1}
= lim
∆u1→0
Pr{u1 ≤ Xi(sk1 , tj) < u1 + ∆u1, δi(sk1 , tj) = 1}
× I{u1 + tj = v1 + tj′}
= λ(sk1 , tj, u1)Pr{Xi(sk1 , tj) ≥ u1}
× I{u1 + tj = v1 + tj′}du1.
Term (A.15) becomes
E[Yi(sk1 , tj, u1)dNi(sk2 , tj′, v1)] = lim
∆v1→0
Pr{Xi(sk1 , tj) ≥ u1, v1 ≤ Xi(sk2 , tj′) < v1 + ∆v1,
δi(sk2 , tj′) = 1}
= λ(sk2 , tj′, v1)Pr{Xi(sk1 , tj) ≥ u1, Xi(sk2 , tj′) ≥ v1}
[I{u1 + tj ≤ v1 + tj′}+ I{u1 = 0, tj > v1 + tj′}]dv1,
where the expectation is only none-zero when u1 + tj ≤ v1 + tj′. The term I{u1 =
0, tj > v1 + tj′} comes from the case when the failure occurs before calendar time tj,
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namely tj > v1 + tj′, by definition Xi(sk1 , tj) = 0. Therefore the expectation is also
non-zero when u1 = 0.
Term (A.16) becomes
E[Yi(sk2 , tj′, v1)dNi(sk1 , tj, u1)] = lim
∆u1→0
Pr{Xi(sk2 , tj′) ≥ v1, u1 ≤ Xi(sk1 , tj) < u1 + ∆u1,
δi(sk1 , tj) = 1}
= λ(sk1 , tj, u1)Pr{Xi(sk1 , tj) ≥ u1, Xi(sk2 , tj′) ≥ v1}
[I{u1 + tj ≥ v1 + tj′}+ I{v1 = 0, u1 + tj < tj′}]du1,
where the expectation is only none-zero when u1 + tj ≥ v1 + tj′. The term I{v1 =
0, u1 + tj < tj′} comes from the case when the failure occurs before calendar time tj′,
namely u1 + tj < tj′, by definition Xi(sk2 , tj′) = 0. Therefore the expectation is also
non-zero when v1 = 0.
Term (A.17) becomes
E[Yi(sk1 , tj, u1)Yi(sk2 , tj′, v1)] = Pr{Xi(sk1 , tj) ≥ u1, Xi(sk2 , tj′) ≥ v1}.
Term (A.18) becomes
E[dNi(sk1 , tj, u1)− Yi(sk1 , tj, u1)λW (sk1 , u1)du1] =[λ(sk1 , tj, u1)− λW (sk1 , u1)]
× Pr{Xi(sk1 , tj) ≥ u1}du1.
And term (A.19) becomes
E[dNi(sk2 , tj′, v1)− Yi(sk2 , tj′, v1)λW (sk2 , v1)dv1] =[λ(sk2 , tj′, v1)− λW (sk2 , v1)]
× Pr{Xi(sk2 , tj′) ≥ v1}dv1.
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Substituting appropriate terms we now have
Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}]
=
b∑
j=1
b∑
j′=1
τ∫
0
τ∫
0
exp{−
u2∫
0
λWg (sk1 , u1)du1}exp{−
v2∫
0
λWg (sk2 , v1)dv1}
×
u2∫
0
v2∫
0
1∑
l Pr(Xgi(sk1 , tl) ≥ u1)
∑
l′ Pr(Xgi(sk2 , tl′) ≥ v1)
×
{
λg(tj, u1)Pr{Xgi(sk1 , tj) ≥ u1}I{u1 + tj = v1 + tj′}du1
−
[
λWg (sk1 , u1)λ(tj′, v1)[I{u1 + tj ≤ v1 + tj′}+ I{u1 = 0, tj > v1 + tj′}]
+ λWg (sk2 , v1)λ(tj, u1)[I{u1 + tj ≥ v1 + tj′}+ I{v1 = 0, u1 + tj < tj′}]
− λWg (sk1 , u1)λW (sk2 , v1)
]
Pr{Xgi(sk1 , tj) ≥ u1, Xgi(sk2 , tj′) ≥ v1}du1dv1
− {λg(tj, u1)− λWg (sk1 , u1)}{λg(tj′, v1)− λWg (sk2 , v1)}
× Pr{Xgi(sk1 , tj) ≥ u1}Pr{Xgi(sk2 , tj′) ≥ v1}du1dv1
}
du2dv2
Unfortunately, this covariance does not simplify to an independent increments struc-
ture except in special cases such as an exponentially distributed event time. The inde-
pendent increments structure emerges in this special case upon noting that λWg (s, u) =
λ(t, u) = λ for all s, t and u. However, given the advantages of avoiding paramet-
ric assumptions, there is no practical computation savings that can be made from
knowledge of this special case.
We’ve also used this asymptotic closed form variance as a method to double-check
that R code for our empirically calculated covariance is on target. For example, a
covariance matrix estimated from 500 individuals’ data should be relatively close to
the asymptotic closed form. Assuming an Exp(0.5) event time with 2 years of uniform
accrual, and analyses using τ = 1 conducted at 1, 2, 3, 4 and 5 years in calendar time,
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the closed form covariance matrix calculation gives:

0.175 0.085 0.042 0.039 0.035
0.085 0.091 0.052 0.041 0.036
0.042 0.052 0.054 0.042 0.038
0.039 0.041 0.042 0.043 0.038
0.035 0.036 0.038 0.038 0.039

,
whereas the corresponding empirical covariance estimate from the 500 individuals was

0.149 0.082 0.050 0.040 0.034
0.082 0.104 0.056 0.044 0.039
0.050 0.056 0.059 0.045 0.041
0.040 0.044 0.045 0.046 0.042
0.034 0.039 0.041 0.042 0.043

with difference matrix

−0.026 −0.003 0.008 0.001 −0.001
−0.003 0.013 0.004 0.003 0.003
0.008 0.004 0.005 0.003 0.003
0.001 0.003 0.003 0.003 0.004
−0.001 0.003 0.003 0.004 0.004

.
Repeating this exercise for different simulated datasets and sample sizes is a comfort-
ing coding check.
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A.4 Supplementary Simulation Results of Section 2.5
In this section we show supplemental simulation results for our proposed method
using the same simulation scenarios 1-9 described in the Chapter 2.5. In Tables A.1
and A.2, we (1) examine the performance of our method for alternative choices of
τ = 0.25, 0.50 and 0.75 years, (2) show results for the Peto and Peto (WLR-PP)
test that places more weight on hazards at the beginning of the study and (3) show
results for the Fleming-Harrington (WLR-FH) (0.5, 0.5) test that places more weight
on hazards at the end of the study. Table A.1 shows stopping rates based on OF
efficacy, JT safety, Pocock safety and OF safety bounds. Table A.2 shows the average
study time (AST) in years, the average sample number (ASN) and the average number
of events (ANE).
All test statistic boundaries meet their targets within simulation error under Sce-
nario 1, the null hypothesis (Table A.1, Scenario 1).
For the most part, stopping rates do not seem to vary much based on the selection
for τ . The only possible exception is in Scenario 4, the delayed treatment effect
scenario, where power is slightly smaller for smaller values of τ . The WLR-FH test
does well in this setting, with slightly less power than the proposed test using τ = 1
year and slightly more power than the proposed test with smaller values of τ . The
WLR-PP test has much lower power than all other methods in this setting. The WLR-
PP test also performs poorly in Scenario 8, the Scenario with mixed cure distribution
alternatives under consideration.
Note that these extra simulations for τ = 0.25, 0.5 and 0.75 are not intended to
be an exhaustive look at how to choose τ since we believe most applications will have
a natural choice. But these additional simulations verify that the method performs
well for a broader selection of short-term window lengths.
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Scenario Test Statistic OF Efficacy JT Safety P Safety OF Safety
Proposed τ = 0.75 0.024 0.192 0.025 0.024
Proposed τ = 0.5 0.023 0.197 0.024 0.023
1 Proposed τ = 0.25 0.024 0.193 0.024 0.024
WLR-PP 0.023 0.195 0.025 0.026
WLR-FH (0.5, 0.5) 0.023 0.196 0.026 0.026
Proposed τ = 0.75 0.813 0 0 0
Proposed τ = 0.5 0.803-0.804 0.002 0 0
2 Proposed τ = 0.25 0.806-0.807 0.002 0 0
WLR-PP 0.75 0 0 0
WLR-FH (0.5, 0.5) 0.807 0 0 0
Proposed τ = 0.75 0 0.977 0.79 0.847
Proposed τ = 0.5 0 0.979 0.773 0.829
3 Proposed τ = 0.25 0 0.973 0.778 0.839
WLR-PP 0 0.967 0.724 0.76
WLR-FH (0.5, 0.5) 0 0.971 0.773 0.815
Proposed τ = 0.75 0.813-0.825 0.024 0.007 0
Proposed τ = 0.5 0.817-0.824 0.019 0.005 0
4 Proposed τ = 0.25 0.803-0.811 0.025 0.007 0
WLR-PP 0.367 0.029 0.008 0
WLR-FH (0.5, 0.5) 0.823-0.834 0.031 0.008 0
Proposed τ = 0.75 0 0.970 0.742 0.817
Proposed τ = 0.5 0 0.967 0.730 0.819
5 Proposed τ = 0.25 0 0.965 0.718 0.809
WLR-PP 0 0.743 0.325 0.381
WLR-FH (0.5, 0.5) 0 0.970 0.778 0.848
Proposed τ = 0.75 0.764 0 0 0
Proposed τ = 0.5 0.767 0.001 0 0
6 Proposed τ = 0.25 0.761 0 0 0
WLR-PP 0.753 0.001 0 0
WLR-FH (0.5, 0.5) 0.784 0 0 0
Proposed τ = 0.75 0 0.960 0.707 0.744
Proposed τ = 0.5 0 0.961 0.701 0.748
7 Proposed τ = 0.25 0 0.959 0.696 0.743
WLR-PP 0 0.956 0.696 0.736
WLR-FH (0.5, 0.5) 0 0.963 0.725 0.768
Proposed τ = 0.75 0.883 0 0 0
Proposed τ = 0.5 0.876 0 0 0
8 Proposed τ = 0.25 0.879 0 0 0
WLR-PP 0.777 0 0 0
WLR-FH (0.5, 0.5) 0.854 0 0 0
Proposed τ = 0.75 0 0.991 0.849 0.890
Proposed τ = 0.5 0 0.989 0.840 0.881
9 Proposed τ = 0.25 0 0.988 0.843 0.884
WLR-PP 0 0.959 0.735 0.774
WLR-FH (0.5, 0.5) 0 0.982 0.807 0.852
Table A.1: Rates of Stopping for Efficacy or for Safety
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AST ASN ANE
Scenario Test Statistic JT P OF JT P OF JT P OF
Proposed τ = 0.75 4.7 4.9 5.0 195 199 200 156 163 164
Proposed τ = 0.5 4.7 4.9 5.0 195 199 200 156 163 165
1 Proposed τ = 0.25 4.7 4.9 5.0 195 199 200 156 164 165
WLR-PP 4.7 4.9 5.0 195 199 200 156 163 165
WLR-FH (0.5, 0.5) 4.7 4.9 5.0 195 199 200 156 163 164
Proposed τ = 0.75 3.8 3.8 3.8 186 186 186 144 144 144
Proposed τ = 0.5 3.8 3.8 3.8 185 185 185 144 144 144
2 Proposed τ = 0.25 3.8 3.8 3.8 186 186 186 145 145 145
WLR-PP 3.8 3.8 3.8 186 186 186 145 145 145
WLR-FH (0.5, 0.5) 3.7 3.7 3.7 184 184 184 142 142 142
Proposed τ = 0.75 2.1 3.0 3.7 151 169 185 93 120 142
Proposed τ = 0.5 2.1 3.1 3.7 151 170 185 93 123 143
3 Proposed τ = 0.25 2.1 3.1 3.7 152 170 185 94 123 144
WLR-PP 2.1 3.1 3.8 152 170 185 94 123 144
WLR-FH (0.5, 0.5) 2.1 3.0 3.6 152 169 184 94 121 141
Proposed τ = 0.75 3.9 3.9 4.0 189 190 190 135 137 138
Proposed τ = 0.5 3.9 3.9 4.0 189 190 190 136 137 138
4 Proposed τ = 0.25 3.9 4.0 4.0 190 191 191 137 139 140
WLR-PP 4.5 4.6 4.7 195 196 197 152 154 155
WLR-FH (0.5, 0.5) 3.7 3.8 3.8 186 188 188 132 134 135
Proposed τ = 0.75 2.9 3.9 4.0 171 186 191 110 135 140
Proposed τ = 0.5 3.0 3.9 4.0 171 187 191 111 135 140
5 Proposed τ = 0.25 3.0 3.9 4.1 172 187 192 112 136 141
WLR-PP 3.7 4.5 4.6 182 194 197 129 151 154
WLR-FH (0.5, 0.5) 2.8 3.7 3.9 168 184 189 107 132 137
Proposed τ = 0.75 3.7 3.7 3.7 184 184 184 143 143 143
Proposed τ = 0.5 3.7 3.7 3.7 184 184 184 144 144 144
6 Proposed τ = 0.25 3.7 3.7 3.7 185 185 185 145 145 145
WLR-PP 3.7 3.7 3.7 184 184 184 145 145 145
WLR-FH (0.5, 0.5) 3.6 3.6 3.6 183 183 183 142 142 142
Proposed τ = 0.75 2.2 3.1 3.7 152 170 184 95 124 144
Proposed τ = 0.5 2.2 3.2 3.8 153 170 185 96 125 145
7 Proposed τ = 0.25 2.2 3.2 3.8 152 171 185 95 126 146
WLR-PP 2.2 3.2 3.8 152 171 185 95 126 145
WLR-FH (0.5, 0.5) 2.1 3.1 3.7 152 170 184 94 124 144
Proposed τ = 0.75 3.5 3.5 3.5 181 181 181 129 129 129
Proposed τ = 0.5 3.5 3.5 3.5 181 181 181 129 129 129
8 Proposed τ = 0.25 3.5 3.5 3.5 182 182 182 130 130 130
WLR-PP 3.7 3.7 3.7 184 184 184 133 133 133
WLR-FH (0.5, 0.5) 3.5 3.5 3.5 181 181 181 129 129 129
Proposed τ = 0.75 2.1 3.0 3.5 151 169 183 91 114 131
Proposed τ = 0.5 2.1 3.0 3.6 152 170 183 91 114 131
9 Proposed τ = 0.25 2.1 3.0 3.5 151 170 183 91 115 131
WLR-PP 2.2 3.2 3.8 153 171 185 92 116 134
WLR-FH (0.5, 0.5) 2.1 3.0 3.6 152 170 183 91 115 131
Table A.2: AST in Years, ASN and ANE in Scenarios 1 - 9
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Figure A.1: Standardized Test Statistics and Stopping Boundaries
(RMS: Restricted Mean Survival; OF:O’Brien and Fleming; JT: Jennison and
Turnbull)
A.5 Supplementary Example Results of Section 2.6
Figure A.1 shows group sequential OF efficacy boundaries as well as OF, Pocock
and JT safety boundaries for the proposed test statistic (left panel), the RMS statistic
(middle panel) and the logrank statistic (right panel). All test statistics are standard-
ized to ease comparisons between panels of the figure. Boundaries and test statistics
shown in Figure A.1 are enumerated for clarity in Table A.3. Although historically
during that period of clinical trial design symmetric stopping boundaries were typi-
cally used, a more modern safety boundary would make sense in this setting, partic-
ularly since it was not known for certain that the low-dose was sufficient to protect
against mortality in the same way the high dose had up to that time. Observed
values of the test statistics in each panel of Figure A.1 are superimposed as dots with
bold connecting lines. None of the test statistics approached the safety boundaries at
any of the interim analyses. As shown in Table A.3, the standardized proposed test
statistics and the standardized RMS test statistics crossed the OF efficacy boundary
at year 1990. The logrank test did not cross the OF efficacy boundary at any interim
analysis time.
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APPENDIX B
Supplementary Materials for Chapter III
B.1 Asymptotic Multivariate Distribution of T˜k
In this section, we prove that the multivariate distribution of
T˜k =
{
T˜1(s1), . . . , T˜k(sk)
}
is a mean zero Normal distribution with covariance matrix Σk for k = 1, . . . , K as
described in Chapter 3.4.
We start from our unstandardized test statistic at analysis time s:
T (s) =
√
n1(s)n2(s)
n1(s) + n2(s)
{µˆ1(s, τ)− µˆ2(s, τ)},
which can be written as
T (s) =
√
n2(s)
n1(s) + n2(s)
√
n1(s)µˆ1(s, τ)−
√
n1(s)
n1(s) + n2(s)
√
n2(s)µˆ2(s, τ), (B.1)
where ng(s)/{n1(s) + n2(s)} p→ pig(s). Suppose at analysis time s, combining infor-
mation of the time to first event captured in all b follow-up windows of length τ , we
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record M unique event times {0 ≡ T0 < T1 < ... < TM < TM+1 ≡ τ}. Then, by
Taylor series expansion,
√
ng(s)µˆg(s, τ) =
√
ng(s)
M∑
m=0
(Tm+1 − Tm)exp
{
−
m∑
j=0
dNg(s, Tj)
Yg(s, Tj)
}
is asymptotically equivalent in distribution to:
√
ng(s)
M∑
m=0
(Tm+1 − Tm) exp
{
−
m∑
j=0
λWg (s, Tj)dTj
}
(B.2)
+
√
ng(s)
M∑
m=0
(Tm+1 − Tm)
[
m∑
j=0
−exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
dNg(s, Tj)
Yg(s, Tj)
]
(B.3)
−
√
ng(s)
M∑
m=0
(Tm+1 − Tm)
[
m∑
j=0
−exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
λWg (s, Tj)dTj
]
(B.4)
+
√
ng(s)
M∑
m=0
(Tm+1 − Tm) 1
2!
exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
×
[
m∑
j=0
{
dNg(s, Tj)
Yg(s, Tj)
− λWg (s, Tj)dTj
}]2 (B.5)
+
√
ng(s)
M∑
m=0
(Tm+1 − Tm)[higher order terms] (B.6)
Terms (B.5) and (B.6) converge to zero in probability using similar arguments to
those shown in Tayob and Murray (2014) Appendix A. When terms (B.2) and (B.4)
are combined into the test statistic, T (s), under the null hypothesis, they cancel with
terms from the other treatment group. Hence, the asymptotic behavior of T (s) is
based on term (B.3) for groups g = 1, 2, which can be further rewritten as
√
ng(s)
M∑
m=0
(Tm+1 − Tm)
[
m∑
j=0
−exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
dNg(s, Tj)
Yg(s, Tj)
]
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= −
√
ng(s)
M∑
m=0
(Tm+1 − Tm)exp{−
m∑
j′=0
λWg (s, Tj′)dTj′}
m∑
j=0
dNg(s, Tj)
Yg(s, Tj)
,
By Taylor series expansion, this term is asymptotically equivalent in distribution to
−
√
ng(s)
M∑
m=0
(Tm+1 − Tm)exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
×
{
m∑
j=0
EdNg(s, Tj)
EYg(s, Tj)
(B.7)
+
m∑
j=0
[
1
EYg(s, Tj)
[dNg(s, Tj)− EdNg(s, Tj)]− EdNg(s, Tj)
EYg(s, Tj)2
[Yg(s, Tj)− EYg(s, Tj)]
]
(B.8)
+[higher order terms]} . (B.9)
Using arguments similar to those given in Tayob and Murray (2014), the higher or-
der terms in (B.9) converge to zero in probability. When term (B.7) appears in
T (s), it cancels with its corresponding term from the other treatment group un-
der the null hypothesis. Hence, the asymptotic behavior of T (s) is based on term
(B.8) which upon noting that EdNg(s, Tj)/EYg(s, Tj) = λ
W
g (s, Tj) and EYg(s, Tj) =∑b
l=1 Pr(Xgi(s, tl) ≥ Tj) can be algebraically rearranged as:
−
√
ng(s)
M∑
m=0
(Tm+1−Tm)exp
{
−
m∑
j′=0
λWg (s, Tj′)dTj′
}
m∑
j=0
dNg(s, Tj)− Yg(s, Tj)λWg (s, Tj)∑b
l=1 Pr(Xgi(s, tl) ≥ Tj)
or in more standard stochastic integral notation as:
−
√
ng(s)
τ∫
0
exp
−
u2∫
0
λWg (s, u1)du1

u2∫
0
dNg(s, u1)− Yg(s, u1)λWg (s, u1)∑b
l=1 Pr(Xgi(s, tl) ≥ u1)
du2.
(B.10)
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Summarizing the above remarks,
T (s) =
√
n2(s)
n1(s) + n2(s)
√
n1(s)µˆ1(s, τ)−
√
n1(s)
n1(s) + n2(s)
√
n2(s)µˆ2(s, τ)
is asymptotically equivalent in distribution to
√
pi1(s)
√
n2(s)
τ∫
0
exp
−
u2∫
0
λW2 (s, u1)du1

u2∫
0
dN2(s, u1)− Y2(s, u1)λW2 (s, u1)∑b
l=1 Pr(X2i(s, tl) ≥ u1)
du2
−
√
pi2(s)
√
n1(s)
τ∫
0
exp
−
u2∫
0
λW1 (s, u1)du1

u2∫
0
dN1(s, u1)− Y1(s, u1)λW1 (s, u1)∑b
l=1 Pr(X1i(s, tl) ≥ u1)
du2.
(B.11)
Recall that
Ng(s, u) =
ng(s)∑
i=1
Ngi(s, u) =
ng(s)∑
i=1
b∑
j=1
Ngi(s, tj, u)
and
Yg(s, u) =
ng(s)∑
i=1
Ygi(s, u) =
ng(s)∑
i=1
b∑
j=1
Ygi(s, tj, u).
We define:
Zij{µˆg(s, τ)} =
τ∫
0
exp
−
u2∫
0
λWg (s, u1)du1

u2∫
0
dNgi(s, tj, u1)− Ygi(s, tj, u1)λWg (s, u1)du1∑b
l=1 Pr{Xgi(s, tl) ≥ u1}
du2
and
Zi{µˆg(s, τ)} =
b∑
j=1
Zij{µˆg(s, τ)}.
We can write equation (B.11) as
T ∗(s) =
√
pi1(s)
√
n2(s)
∑n2(s)
i=1 Zi{µˆ2(s, τ)}
n2(s)
−
√
pi2(s)
√
n1(s)
∑n1(s)
i=1 Zi{µˆ1(s, τ)}
n1(s)
.
(B.12)
Note that Zi{µˆg(s, τ)} only depends on patient i and is independent and iden-
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tically distributed for i = 1, . . . , ng(s). As a result, the multivariate central limit theo-
rem can be used to determine the asymptotic joint distribution of {T ∗(s1), . . . ,T ∗(sk)},
k = 1, . . . , K, when each statistic is formulated as in equation (B.12). As a result, the
covariance matrix of {T ∗(s1), . . . ,T ∗(sk)} with component Cov {T ∗(sk1),T ∗(sk2)},
can be estimated using empirical covariances of Zi{µˆg(sk1 , τ)} and Zi{µˆg(sk2 , τ)}, for
g = 1, 2, where appropriate, as follows.
First, without loss of generality, assume sk1 ≤ sk2 so that ng(sk1) ≤ ng(sk2) with
ng(sk1) patients contributing (correlated) data from both analysis times. Then
Cov {T ∗(sk1),T ∗(sk2)}
=
2∑
g=1
Cov
[√
pi3−g(sk1)
√
ng(sk1)
∑ng(sk1 )
i=1 Zi{µˆg(sk1 , τ)}
ng(sk1)
,
√
pi3−g(sk2)
√
ng(sk2)
∑ng(sk2 )
i=1 Zi{µˆg(sk2 , τ)}
ng(sk2)
]
=
2∑
g=1
√
pi3−g(sk1)
√
pi3−g(sk2)
ng(sk1)√
ng(sk1)ng(sk2)
Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] ,
which is asymptotically equivalent to
=
2∑
g=1
√
pi3−g(sk1)pi3−g(sk2)ψg(sk1 , sk2)Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] ,
where for group g = 1, 2, ψg(sk1 , sk2) is the limiting proportion of patients entered at
sk1 of those eventually entered by sk2 , that is estimated by ng(sk1)/ng(sk2). Therefore,
we can estimate Cov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] with the empirical covariance of
sample realizations of Zi{µˆg(sk1 , τ)} and Zi{µˆg(sk2 , τ)}, that is,
Ĉov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] =
ng(sk1 )∑
i=1
[zi{µˆg(sk1 , τ)} − z¯{µˆg(sk1 , τ)}][zi{µˆg(sk2 , τ)} − z¯{µˆg(sk2 , τ)}]
ng(sk1)− 1
.
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where zi{µˆg(s, τ)} and z¯{µˆg(s, τ)} are defined in terms of zij{µˆg(s, τ)} in Chapter
3.3. However, this estimation can be improved upon by updating zij{µˆg(sk1 , τ)}
with quantities that that do not depend on analysis time and thus can be estimated
better using the full data at the later analysis time sk2 . In particular, since both
dNgi(sk1 , tj, u1)/Ygi(sk1 , tj, u1) and dNgi(sk2 , tj, u1)/Ygi(sk2 , tj, u1) estimate λgi(tj, u1)du1,
and the latter term uses more data, we replace dNgi(sk1 , tj, u1) with
Ygi(sk1 , tj, u1)
dNgi(sk2 , tj, u1)
Ygi(sk2 , tj, u1)
.
Similarly, we replace Yg(sk1 , u1)/ng(sk1), which is an estimate of
∑b
l=1 Pr{Tgi(sk1 , tl) ≥
u1}Pr{Cgi(sk1 , tl) ≥ u1}, withng(sk2 )∑
i=1
I{Tgi ≥ u1 + tl}
ng(sk2)
ng(sk1 )∑
i=1
I{Cgi(sk1) ≥ u1 + tl}
ng(sk1)
 .
Here, terms involving the event time are estimated using updated data, while terms
involving the censoring distribution remain relevant to analysis time sk1 . Putting these
modifications together gives us
z˜ij{µˆg(sk1 , τ)} =
τ∫
0
exp{−
u2∫
0
dNg(sk1 , u1)
Yg(sk1 , u1)
}
[ u2∫
0
b∑
l=1
ng(sk2 )∑
i=1
I{Tgi ≥ u1 + tl}
ng(sk1 )∑
i′=1
I{Cgi′(sk1) ≥ u1 + tl}

−1
× ng(sk1)ng(sk2)Ygi(sk1 , tj, u1)
{
dNgi(sk2 , tj, u1)
Ygi(sk2 , tj, u1)
− dNg(sk1 , u1)
Yg(sk1 , u1)
}]
du2.
as an updated version of zij{µˆg(sk1 , τ)} for use in covariance terms. So that we replace
the zij{µˆg(sk1 , τ)} terms in zi{µˆg(sk1 , τ)} and z¯{µˆg(sk1 , τ)} with z˜ij{µˆg(sk1 , τ)} to
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obtain z˜i{µˆg(sk1 , τ)} and ¯˜z{µˆg(sk1 , τ)}. And we update the empirical covariance as
Ĉov [Zi{µˆg(sk1 , τ)}, Zi{µˆg(sk2 , τ)}] =
ng(sk1 )∑
i=1
[z˜i{µˆg(sk1 , τ)} − ¯˜z{µˆg(sk1 , τ)}][zi{µˆg(sk2 , τ)} − z¯{µˆg(sk2 , τ)}]
ng(sk1)− 1
.
For the standardized version of test statistic, T˜ (sk), sk = s1, . . . , sK , we work with
the corresponding standardized form of the more tractible random variable that is
asymptotically equivalent in distribution, namely,
T ∗(sk)√
pi2(sk)σ21(sk) + pi1(sk)σ
2
2(sk)
.
which also gives T˜k an asymptotic mean zero multivariate Normal distribution with
covariance matrix Σk. Because the test statistic is standardized to have variance 1.0.
We only need to estimate the off-diagonal elements σk1k2 via
σˆk1k2 =
Ĉov {T ∗(sk1),T ∗(sk2)}√
pˆi2(sk1)σ˜
2
1(sk1) + pˆi1(sk1)σˆ
2
2(sk1)
√
pˆi2(sk2)σ˜
2
1(sk2) + pˆi1(sk2)σˆ
2
2(sk2)
. (B.13)
Chapter 3.3 gives estimates pˆig(sk) for sk = sk1 , sk2 and σˆ
2
g(sk2) using the most up-
to-date information. Estimate σ˜2g(sk1) in equation (B.13) for g = 1, 2 is modified by
replacing zij{µˆg(sk1 , τ)} with z˜ij{µˆg(sk1 , τ)}. Therefore, we have
σˆk1k2 ={pˆi2(sk1)σ˜21(sk1) + pˆi1(sk1)σ˜22(sk1)}−
1
2{pˆi2(sk2)σˆ21(sk2) + pˆi1(sk2)σˆ22(sk2)}−
1
2
×
2∑
g=1
√
pˆi3−g(sk1)pˆi3−g(sk2)ψˆg(sk1 , sk2)
( ng(sk1 )∑
i=1
{ng(sk1)− 1}−1
× [z˜i{µˆg(sk1 , τ)} − ¯˜z{µˆg(sk1 , τ)}] [zi{µˆg(sk2 , τ)} − z¯{µˆg(sk2 , τ)}]
)
.
(B.14)
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B.2 Simulated Cumulative Power in the Special Case with
Independent Recurrent and Terminal Event Distribu-
tions
Figure B.1 shows simulated power for the group sequentially monitored CL, TM
and LR statistics when all events within each individual are statistically independent,
but otherwise have marginal distributions as given in Chapter 3.5. The CL statistic
(triangles) had the highest in this special case, followed closely by the TM statistic
(circles) and distantly by the LR method(+).
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Figure B.1: Simulated Cumulative Power in the Special Case with Independent Re-
current and Terminal Event Distributions
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APPENDIX C
Supplementary Materials for Chapter IV
Derivations are conducted for a typical individual in the study with submerged
subscripts for this individual. Let gap times, Gj, between the j − 1st and the jth
recurrent events independently follow an exponential distribution with rate λ. Then
the total number of observed recurrent events K, occurring during s follow-up units,
follows a Poisson(λs) distribution. Define Rj =
∑j
i=1Gi as the time from the initi-
ation of follow-up to the jth recurrent event; Rj follows a Gamma(j, λ) distribution
with shape j and rate λ. Recall that the Tayob and Murray statistic only includes the
first event in each τ -length follow-up window in the analysis, with follow-up windows
k = 1, . . . , b starting at follow-up times tk = (k− 1)a ≤ s− τ . A recurrent event may
be included in more than follow-up window, particularly if a is small relative to the
mean time between events, 1
λ
.
Conditional on K, it will be convenient to define a random variable, Wj, that
denotes the last follow-up window to overlap the jth observed recurrent event, j =
1, . . . , K. Inclusion of this jth recurrent event in the analysis (at least once), is
satisfied if it is the first such event to occur in window Wj, or equivalently Wj > Wj−1.
Otherwise, if Wj = Wj−1, the j − 1st event precedes the jth event in any follow-up
windows these two events have in common and the jth recurrent event is left out of
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the analysis. By definition, since the follow-up windows are spaced a units apart,
Wj = ceiling
[
Rj
a
]
, so that probability calculations for Wj can be framed in terms of
functions of well understood random variables.
Let Mj be an indicator variable denoting that an individual’s j
th observed event
is left out of the analysis, with Pr{Mj = 1} = Pr{Wj = Wj−1} for j ≥ 2. Then
conditional on the K observed events for the individual, M =
∑K
j=2 Mj is the number
of observed events left out of the analysis, with M = 0 when K ≤ 1. Hence an
expression for p, the average proportion of recurrent events captured in at least one
follow-up window for an individual followed s time units, can be framed as
p = E
(
K −M
K
)
= E
[
E
(
K −M
K
∣∣∣∣K)] = 1− E [E(M |K)K
]
.
For K ≤ 1, E(M |K) = 0. For K ≥ 2,
E(M |K) =
K∑
j=2
E (Mj|K) =
K∑
j=2
b∑
w=1
Pr{Wj = Wj−1 = w|K}.
Let pmfPoisson(λs)(k) be the Poisson(λs) probability mass function (pmf) for k =
0, 1, · · · ,∞. Since K has a Poisson(λs) distribution, the previous expression for p
becomes
p = 1−
∞∑
k=0
[∑k
j=2
∑b
w=1 Pr{Wj = Wj−1 = w|K = k}
k
I{k ≥ 2}
]
pmfPoisson(λs)(k)
The remainder of the appendix details calculations of Pr{Wj = Wj−1 = w|K = k}
for k ≥ 2 in the expression for p. That is,
Pr{Wj = Wj−1 = w|K = k} = Pr{(w−1)a < Rj−1 < Rj ≤ min(aw, s)|Rk ≤ s, Rk+1 > s}
=
Pr {(w − 1)a < Rj−1 < Rj ≤ min(aw, s), Rk ≤ s, Rk+1 > s}
Pr{K = k}
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Random variables in the numerator can be rewritten in terms of components that
are independent, since in general Rk = Rj−1 +
∑k
`=j G` for any j ≤ k. For simplicity
let R(j,k) =
∑k
`=j G`, for j ≤ k, which has a Gamma(k − j + 1, λ) distribution. Then
the numerator becomes
Pr{Rj−1>(w−1)a,Rj−1+Gj≤min(aw, s), Rj−1+Gj+R(j+1,k)≤s,Rj−1+Gj+R(j+1,k)+Gk+1>s}
= Pr{Rj−1 > (w − 1)a,Rj−1 +Gj ≤ min(aw, s), Rj−1 +Gj +R(j+1,k) ≤ s} (C.1)
−Pr{Rj−1 > (w−1)a,Rj−1+Gj ≤ min(aw, s), Rj−1+Gj+R(j+1,k)+Gk+1 ≤ s} (C.2)
Equation (C.1) becomes
=Pr{Rj−1 +Gj ≤ min(aw, s), Rj−1 +Gj +R(j+1,k) ≤ s}
− Pr{Rj−1 ≤ (w − 1)a,Rj−1 +Gj ≤ min(aw, s), Rj−1 +Gj +R(j+1,k) ≤ s}
=Pr{Rj ≤ min(aw, s), Rj +R(j+1,k) ≤ s}
− Pr{Rj−1 ≤ (w − 1)a,Rj−1 +Gj ≤ min(aw, s), Rj−1 +Gj +R(j+1,k) ≤ s}
=
min(aw,s)∫
0
pdfGamma(j,λ)(r) · cdfGamma(k−j,λ)(s− r)dr
−
(w−1)a∫
0
min(aw,s)−r∫
0
pdfGamma(j−1,λ)(r) · pdfExp(λ)(g) · cdfGamma(k−j,λ)(s− r − g)dgdr
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Similarly equation (C.2) becomes
=
min(aw,s)∫
0
pdfGamma(j,λ)(r) · cdfGamma(k−j+1,λ)(s− r)dr
−
(w−1)a∫
0
min(aw,s)−r∫
0
pdfGamma(j−1,λ)(r) · pdfExp(λ)(g) · cdfGamma(k−j+1,λ)(s− r − g)dgdr
So that combining (C.1) and (C.2) we finally have
p = 1−
∞∑
k=2
1
k
k∑
j=2
b∑
w=1[ min(aw,s)∫
0
pdfGamma(j,λ)(r)
{
cdfGamma(k−j,λ)(s− r)− cdfGamma(k−j+1,λ)(s− r)
}
dr
−
(w−1)a∫
0
min(aw,s)−r∫
0
pdfGamma(j−1,λ)(r) · pdfExp(λ)(g){
cdfGamma(k−j,λ)(s− r − g)− cdfGamma(k−j+1,λ)(s− r − g)
}
dgdr
]
,
as given in Chapter IV.
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APPENDIX D
Supplementary Materials for Chapter V
D.1 The Derivation of the Marginal Distribution of Ti(t) With
Independent Recurrent Event Times
In this appendix section we describe that for an individual i, when Gij, j =
1, . . . , Ji are independently and identically distributed as exponential with inten-
sity λi the marginal distribution of Ti(t) for a fixed t is also distributed as ex-
ponential with hazard λi. This result is trivial for the case where t = 0, since
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Ti(t = 0) ≡ Gi1 ∼ Exp(λi). For the case when t > 0,
Pr{Ti(t) > u}
=Pr{Ti1 > t+ u}+ Pr{Ti1 ≤ t, Ti2 > t+ u}+ · · ·+ Pr{TiJi−1 ≤ t, TiJi > t+ u}
=Pr{Ti1 > t+ u}+
Ji∑
j=2
Pr{Tij−1 ≤ t, Tij > t+ u}
=Pr{Gi1 > t+ u}+
Ji∑
j=2
Pr{Tij−1 ≤ t, Tij−1 +Gij > t+ u}
=
∞∫
t+u
λie
−λiydy +
Ji∑
j=2
t∫
0
∞∫
t+u−p
f(Tij−1 = p,Gij = q)dqdp
(D.1)
where Tij−1 ⊥ Gij by assumption. We know that Tij−1 =
∑k=j−1
k=1 Gik. When Gik
iid∼
Exp(λi), Tij−1 ∼ Gamma(j− 1, λi), where j− 1 is the shape parameter and λi is the
rate parameter. Then,
Pr{Ti(t) > u}
=e−λi(t+u) +
Ji∑
j=2
t∫
0
∞∫
t+u−p
pdfGamma(j−1,λi)(Tij−1 = p)pdfExp(λi)(Gij = q)dpdq
where
pdfGamma(j−1,λi)(Tij−1 = p) =
λj−1i
Γ(j − 1)p
j−2e−λip,
pdfExp(λi)(Gij = q) = λie
−λiq.
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So,
Pr{Ti(t) > u}
=e−λi(t+u) +
Ji∑
j=2
t∫
0
λj−1i
Γ(j − 1)p
j−2e−λip
∞∫
t+u−p
λie
−λiqdpdq
=e−λi(t+u) +
Ji∑
j=2
t∫
0
λj−1i
Γ(j − 1)p
j−2e−λi(t+u)dp
=e−λi(t+u) +
Ji∑
j=2
(λit)
j−1
Γ(j)
e−λi(t+u)
=
Ji∑
j=1
(λit)
j−1
Γ(j)
e−λit × e−λiu
When Ji →∞, by Taylor series,
∞∑
j−1=0
(λit)
j−1
(j − 1)! = e
λit.
Therefore, Pr{Ti(t) > u} = e−λiu, namely, Ti(t) ∼ Exp(λi).
D.2 Example Showing the Imputation of Event Times
Figure D.1 shows the same example participant from the Azithromycin in COPD
Trial shown in Figure 5.1. For this example participant, Si = {180, 240, 300} so that
the sup window starts at tsup(Si) = 300. The sup impute becomes T˜i{tsup(Si)} =
T˜i{300} = 65. For the window starting at 240 days, the imputed time-to-first-event
becomes T˜i{240} = T˜i{300} + 300 − 240 = 125, which is greater than the censored
time-to-first-event that was observed for this window, Xi(240) = 113. Similarly for
the window starting at 180 days, T˜i{180} = T˜i{300} + 300 − 180 = 185, which
is greater than the censored time-to-first-event that was observed for this window,
Xi(180) = 173.
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0 60 120 180 240 300
!"# = 353 days'"# = 0
)*+, -" = 300
Sup Impute
./"{)*+, -" } = ./" 300 = 65
./" 240 = ./" 300 + 300 − 240 = 125
./" 180 = ./" 300 + 300 − 180 = 185
Figure D.1: Example Showing the Imputation of Event Times
D.3 Supplementary Table Corresponding to Figure 5.5
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PO MI
eβˆ 95% CI P eβˆ 95% CI P
Overall: 1.143 1.052 1.242 0.002 1.142 1.054 1.238 0.001
Sex:
Male 1.088 0.983 1.204 0.104 1.087 0.984 1.201 0.100
Female 1.234 1.074 1.417 0.003 1.230 1.076 1.406 0.002
Smoking Status:
Former 1.176 1.069 1.294 0.001 1.175 1.071 1.289 0.001
Current 1.032 0.875 1.218 0.707 1.040 0.884 1.223 0.639
Age:
≤ 65 years 1.067 0.949 1.198 0.278 1.069 0.955 1.198 0.246
> 65 years 1.233 1.096 1.387 <0.001 1.226 1.093 1.374 <0.001
FEV1:
≤ 50 % predicted 1.095 0.994 1.208 0.067 1.094 0.995 1.202 0.063
> 50 % predicted 1.291 1.104 1.510 0.001 1.289 1.107 1.502 0.001
Table D.1: Subset Analyses Comparing Azithromycin versus Placebo Using Proposed
PO and MI Approaches with a GEE Model Fit of Equation (5.3)
(CI: Confidence Interval; PO: Pseudo-observation; MI: Multiple Imputation.)
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